,Name_VH,Name_VL,Genbank_protein_id_vh,Genbank_protein_id_vl,Binds_to,Origin,VH,VL,Reference,doi,Description_VH,Description_VL,Date_added
0,FAB14,FAB14,7XXL_A,7XXL_C,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqqsgpglvkpsqtlsltcaisgdsvssnsaawnwirqspsrglewlgrtyyrskwyndyavsvksritinpdtsknqfslqlnsvtpedtavyycareeqqlvhdyyyygmdvwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkth,qavvtqpasvsgspgqsitisctgtssdigaynyiswyqqhpgkapkliiyevsnrpsgisyrfsgsksgntasltisglqaedeanyycssyagsisfgggtkvtvlqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Ku,Z. et al.; Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth; Nat Commun 13 (1), 5552 (2022); 2022.",10.1038/s41467-022-33284-y,"Chain A, Fab14 heavy chain","Chain C, Fab14 light chain",2022-10-12
1,P2B-2F6,P2B-2F6,8DCC_H,8DCC_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslktrvtisvdtsknqfslklssvtaadtavyycaravvgivvvpaagrrafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktggshhhhhh,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dickey,T.H. et al.; Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response; bioRxiv (2021); 2022.",10.1101/2021.05.09.443238,"Chain H, P2B-2F6 Fab heavy chain","Chain L, P2B-2F6 Fab light chain",2022-10-12
3,FAB06,FAB06,7WPH_H,7WPH_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvelqesgpglvkpsgtlsltcavsggsissnnwwtwvrqppgkglewigeihhsggtnynpslksrvtmsvdksknqfslnlysvtaadtavyyctrdraggtysgfdfwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkth,qavvtqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstvvfgggtkvtvlqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Ku,Z. et al.; Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth; bioRxiv (2022); 2022.",10.1101/2022.02.01.478504,"Chain H, Fab06 heavy chain","Chain L, FAB06 light chain",2022-10-12
5,TAU-2212,TAU-2212,7WC0_A,7WC0_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),mgwsciilflvatatgvhsqvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgwvtmtrdtsistaymelsrlrsddtavyycargwatyydiltgyslfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkgs,mgwsciilflvatatgswaqsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstphvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Li,R. et al.; Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies; Commun Biol 5 (1), 789 (2022); 2022.",10.1038/s42003-022-03739-5,"Chain A, TAU-2212 Heavy chain","Chain B, TAU-2212 Light chain",2022-10-12
7,S309,S309,7XCO_O,7XCO_P,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhao,Z. et al.; Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape; Nat Commun 13 (1), 4958 (2022); 2022.",10.1038/s41467-022-32665-7,"Chain O, S309 Fab heavy chain","Chain P, S309 fab light chain",2022-10-12
10,S309,S309,7YAD_C,7YAD_D,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvs,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikr,"Zhao,Z. et al.; Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape; Nat Commun 13 (1), 4958 (2022); 2022.",10.1038/s41467-022-32665-7,"Chain C, S309 neutralizing antibody heavy chain","Chain D, S309 neutralizing antibody light chain",2022-10-12
13,FAB30,FAB30,7ENG_H,7ENG_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssypmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardtedcssttcyvdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,divmtqspdslavslgeratinckssqsvlyrsnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyychqyystpftfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,X. et al.; A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD; Signal Transduct Target Ther 7 (1), 114 (2022); 2022.",10.1038/s41392-022-00954-8,"Chain H, Heavy chain of Fab30","Chain L, Light chain of Fab30",2022-10-12
15,35B5,35B5,7E9N_H,7E9N_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtigyadsvkgrftisrdnaknslylhmrslraedtalyycakavemvrglmglgadpeygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Wang,X. et al.; A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD; Signal Transduct Target Ther 7 (1), 114 (2022); 2022.",10.1038/s41392-022-00954-8,"Chain H, Heavy chain of 35B5 Fab","Chain L, Light chain of 35B5 Fab",2022-10-12
18,35B5,35B5,7F46_H,7F46_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtigyadsvkgrftisrdnaknslylhmrslraedtalyycakavemvrglmglgadpeygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,X. et al.; A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD; Signal Transduct Target Ther 7 (1), 114 (2022); 2022.",10.1038/s41392-022-00954-8,"Chain H, Heavy chain of 35B5 Fab","Chain L, Light chain of 35B5 Fab",2022-10-12
26,CC6.30,CC6.30,7RU8_H,7RU8_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsiyaitwvrqapgqglewmggiipiigtanyaqkfqgrvtitadkststaymelsslrsedtavyycardfrycsstrcyfwfdpwgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasqnissylnwyqqeagkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvdik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; iScience 25 (9), 104914 (2022); 2022.",10.1016/j.isci.2022.104914,"Chain H, CC6.30 Fab heavy chain Fv","Chain L, CC6.30 Fab Kappa chain Fv",2022-10-12
29,CC6.33,CC6.33,7RU4_H,7RU4_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsssaiswvrqapgqglewmggiipilditnyaqkfqgrvtitadkststafmelsslrsedtavyycalrnqwdllvywgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygsslwtfgqgtkleik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; iScience 25 (9), 104914 (2022); 2022.",10.1016/j.isci.2022.104914,"Chain H, CC6.33 IgG heavy chain Fv","Chain L, CC6.33 IgG kappa chain Fv",2022-10-12
32,WS6,WS6,7TCQ_A,7TCQ_B,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),evqfqqsgtvlarpgasvkmsckasgytftnywihwvkqrpgqgleyiggtypgngdttynqkfkgkakvtavtptstaymdlssltnedsavyyctrtgsyfdywgqgttltvssasttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiepr,qivltqspaimsaspgekvtiscsatssvsyiywyqqrpgsspkpwiyrtsnlasgvpvrfsgsgsgtsysltisnmeaedaatyycqqyqsypptfgagtklelkrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrne,"Shi,W. et al.; Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability; Structure 30 (9), 1233-1244 (2022); 2022.",10.1016/j.str.2022.06.004,"Chain A, Anti-SARS-CoV-2 antibody WS6 Fab heavy chain","Chain B, Anti-SARS-CoV-2 antibody WS6 Fab light chain",2022-10-12
33,WS6,WS6,7TCQ_H,7TCQ_L,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),evqfqqsgtvlarpgasvkmsckasgytftnywihwvkqrpgqgleyiggtypgngdttynqkfkgkakvtavtptstaymdlssltnedsavyyctrtgsyfdywgqgttltvssasttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiepr,xivltqspaimsaspgekvtiscsatssvsyiywyqqrpgsspkpwiyrtsnlasgvpvrfsgsgsgtsysltisnmeaedaatyycqqyqsypptfgagtklelkrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrne,"Shi,W. et al.; Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability; Structure 30 (9), 1233-1244 (2022); 2022.",10.1016/j.str.2022.06.004,"Chain H, Anti-SARS-CoV-2 antibody WS6 Fab heavy chain","Chain L, Anti-SARS-CoV-2 antibody WS6 Fab light chain",2022-10-12
34,553-49,553-49,7WOG_A,7WOG_B,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvstisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdssswynyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,divmtqphpvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhvvfgggtkvtvlrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhan,W. et al.; Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer; J Virol 96 (16), e0048022 (2022); 2022.",10.1128/jvi.00480-22,"Chain A, 553-49 VH","Chain B, 553-49 VL",2022-10-12
35,MAB60,MAB60,7WOC_A,7WOC_B,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkrpgssvkvsckasgdtfinyafswvrqapgqglewmgriipildiahyaqkfqgrltitadkstdtaymeltslksddtavyfcarvfrgsqywfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,eivltqspgtlslspgeratlscrasqsinnrhlawyqqkrgqaprfliygaasratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhan,W. et al.; Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer; J Virol 96 (16), e0048022 (2022); 2022.",10.1128/jvi.00480-22,"Chain A, mAb60 VH","Chain B, mAb60 VL",2022-10-12
41,MAB15,MAB15,7WO7_A,7WO7_B,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsggglvqpggslrlscaasgftfssywmswvrqapgkglewvaninqdggekyyvdsvkgrftisrdnaknslflqmnsvraedtavyfcarvwyyygprdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,divmtqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydgsnhnvvfgggteltvlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhan,W. et al.; Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer; J Virol 96 (16), e0048022 (2022); 2022.",10.1128/jvi.00480-22,"Chain A, mAb15 VH","Chain B, mAb15 VL",2022-10-12
51,6M6,6M6,7WK0_D,7WK0_E,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyaihwvrqapgkglewvsgitwnsgtigyadsvkgrftisrdnaknslylqmnslraedtalyycakhhqiavagdaedyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsrsdrvvfgggtkltalgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wang,Y. et al.; A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding; Cell Res. 32, 862 (2022); 2022.",NaN,"Chain D, 6m6 heavy chain","Chain E, 6m6 light chain",2022-10-12
53,6M6,6M6,7WJZ_H,7WJZ_R,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyaihwvrqapgkglewvsgitwnsgtigyadsvkgrftisrdnaknslylqmnslraedtalyycakhhqiavagdaedyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsrsdrvvfgggtkltalgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wang,Y. et al.; A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding; Cell Res. 32, 862 (2022); 2022.",NaN,"Chain H, 6m6 heavy chain","Chain R, 6m6 light chain",2022-10-12
61,P2G3,P2G3,7QTK_B,7QTK_C,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgfrfddyalhwvrqapekglewvsgiswnsnnigyaesvkgrftisrdtakkslylqmndlraedtalyycvkdrhydssgyfvngfdiwgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqltqspsflsasvgdrvtvtcrasqgissyvawyqqkagkaptlliytastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlhsypvtfgqgtrldiertvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Fenwick,C. et al.; Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys; Nat Microbiol 7 (9), 1376-1389 (2022); 2022.",10.1038/s41564-022-01198-6,"Chain B, P2G3 Heavy Chain","Chain C, P2G3 Light Chain",2022-10-12
62,P5C3,P5C3,7QTJ_F,7QTJ_E,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqqfqervtitrdmststaymelsslgsedtavyycaapncsggscydgfdlwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,eivltqspgtlslspgeratlscrgsqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikgtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Fenwick,C. et al.; Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys; Nat Microbiol 7 (9), 1376-1389 (2022); 2022.",10.1038/s41564-022-01198-6,"Chain F, P5C3 Heavy Chain","Chain E, P5C3 Light Chain",2022-10-12
68,MB.02,MB.02,8DZI_G,8DZI_F,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgfsftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarggyedvfdiwgqgtmvtvss,eivltqspgtlslspggratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspptfgqgtkveikr,"Ren,P. et al.; Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages; bioRxiv (2022); 2022.",10.1101/2022.08.09.503414,"Chain G, antibody MB.02 heavy chain","Chain F, antibody MB.02 light chain",2022-10-12
74,K398.22,K398.22,7TP4_H,7TP4_L,['COVID'],Macaca mulatta (Rhesus monkey),evqlaesggglvkpggslrlscvasgftfssnemhwvrqapgkglewvsvisesgftteyadsvkgrftisrdnaknslflqmnslraedtavyyctrvsifgqfivatyfdywgqgvlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qaaltqprsvsgspgqsvtisctgtssdiggynyvswyqqhpgtapklmiyavserpsgvsdrfsgsksgntasltisglqaedeadyyccsyagtvlfgggtrltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"Chain H, K398.22 heavy chain","Chain L, K398.22 light chain",2022-10-12
75,K288.2,K288.2,7TP3_H,7TP3_L,['COVID'],Macaca mulatta (Rhesus monkey),evrlvesggglvkpggslrlscvasgftfssyemhwvrqapgkglewvsvisesgatthytdsvkgrftisrdnaknslflqmnslraedtavyyctrpqsvtvfgvaatsyeafdfwgqglrvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,divmtqspdtlslspgetatlscrasqsvssyvawyqqkpeqpprlliygsssratgmpdrfsgsgsgtdftltisslepddfavyycqqytnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"Chain H, K288.2 heavy chain","Chain L, K288.2 light chain",2022-10-12
76,P008_60,P008_60,7ZBU_H,7ZBU_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrltcaasgfifssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyyctkadyydfwsgyqktyyyymdvwgkgttvtissastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvgrtkhhhhhh,diqltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygtssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Seow,J. et al.; A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination; Cell Rep 40 (8), 111276 (2022); 2022.",10.1016/j.celrep.2022.111276,"Chain H, P008_60 antibody, Heavy chain","Chain L, P008_60 antibody, Light chain",2022-10-12
77,BD55-5840,BD55-5840,7X6A_I,7X6A_K,unknown,Homo sapiens (human),vqlaqsgselrkpgasvkvscdtsghsftsnaihwvrqapgqglewmgwintdtgtptyaqgftgrfvfsldtsartaylqisslkaddtavfycarerdysdyffdywgqgtlvtvss,evvmtqspaslsvspgeratlscraraslgistdlawyqqrpgqaprlliygastratgiparfsgsgsgteftltisslqsedsavyycqqysnwpltfgggtkveik,"Cao,Y. et al.; BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection; Nature 608 (7923), 593-602 (2022); 2022.",10.1038/s41586-022-04980-y,"Chain I, Heavy chain of Fab BD55-5840","Chain K, Light chain of Fab BD55-5840",2022-10-12
80,BD55-5840H,BD55-5840L,7WRZ_H,7WRZ_L,unknown,SARS coronavirus B012,vqlaqsgselrkpgasvkvscdtsghsftsnaihwvrqapgqglewmgwintdtgtptyaqgftgrfvfsldtsartaylqisslkaddtavfycarerdysdyffdywgqgtlvtvss,evvmtqspaslsvspgeratlscraraslgistdlawyqqrpgqaprlliygastratgiparfsgsgsgteftltisslqsedsavyycqqysnwpltfgggtkveik,"Cao,Y. et al.; BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection; Nature 608 (7923), 593-602 (2022); 2022.",10.1038/s41586-022-04980-y,"Chain H, BD55-5840H","Chain L, BD55-5840L",2022-10-12
81,3372H,3372L,7WRO_H,7WRO_L,unknown,Homo sapiens (human),evhlvesggglvkpggslrlscaasgftfsnyamnwvrqapgkglqwvssitgsssfifyadsvkgrftivrdnaqnslylqmnslrdedtavyycarerddydtrldwgqgtlvtvs,pmltqppsvsgapgqtvtiscvgsssnigagyevhwyqqlpgtapkrllsgnsdrpsgvpdrfsgsksgtsaslaitglqaddeadyycqsydsslslsavvfgggtkltv,"Cao,Y. et al.; BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection; Nature 608 (7923), 593-602 (2022); 2022.",10.1038/s41586-022-04980-y,"Chain H, 3372H","Chain L, 3372L",2022-10-12
82,BD55-1239H,BD55-1239L,7WRL_A,7WRL_B,unknown,SARS coronavirus B012,qvqlvqsgaevkkpgssvkvsckasgdiystyasswvrqapgqglewmgriipvsgtvnyadnfqgrvtitadkststaymelrsltsedtavyycardvarggysgtdffdyyygmdvwgqgttvt,saltqpasvsgspgqsitisctgtssdvggynyvswyqqhpdkapklliydvnnrpsgvstrfsgsksgntasltisrlqtddeadyscssytssntwvfgggtk,"Cao,Y. et al.; BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection; Nature 608 (7923), 593-602 (2022); 2022.",10.1038/s41586-022-04980-y,"Chain A, BD55-1239H","Chain B, BD55-1239L",2022-10-12
83,BD55-3152H,BD55-3152L,7WR8_A,7WR8_B,unknown,Homo sapiens (human),mgwslillflvavatrvlsqvqlvqsgaevkkpgasvivsckasgyrfishyihwvrqapgqglewmgkidpsgrgttyaqklqgrvsvtrdtstssvymalsglrsddtavyycardrfplsdpyvwgsplggldvwgqgttvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthhhhhh,mgwsciilflvatatgvhssydltqppsvsvspgqtaritcsgdalpsqyvywyqqrpgqapvlvmykdserppgiperfsgstsgttatltitgvqaedeadyycqsadasttyhvfgggtkvtvvgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Cao,Y. et al.; BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection; Nature 608 (7923), 593-602 (2022); 2022.",10.1038/s41586-022-04980-y,"Chain A, BD55-3152H","Chain B, BD55-3152L",2022-10-12
84,C13C9,C13C9,7U0E_H,7U0E_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgpevkkpgtsarvsckasgftskntalqwvrqargqplewmgwidisnyitnyaqkfrgrltitwdlsasmaymelsslrsedtavyycaavgkdddvltggnkyfdhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviheddkrpsgipgrfsasssgttatltisgaqvedeadyycystdtndnhafgsgtkltvlsqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Low,J.S. et al.; ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies; Science 377 (6607), 735-742 (2022); 2022.",10.1126/science.abq2679,"Chain H, Heavy chain Fab C13C9","Chain L, Light chain Fab C13C9",2022-10-12
86,C77G12,C77G12,7U0A_H,7U0A_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslriscavsgftfgsyamhwvrqapgkglewvgvmssdghneyyadsvkgrftisrdnsrnklylemnnlrvddtavfycargsdyvddspplhywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqltqspsslsasigdrvtitcrasqdianklawfqqapgkapksliyaasrlqsgvpsqfsgsgsgtdftltieslqagdfatyfcqqydsfpftfgpgtkvdvkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Low,J.S. et al.; ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies; Science 377 (6607), 735-742 (2022); 2022.",10.1126/science.abq2679,"Chain H, Heavy chain Fab C77G12","Chain L, Light chain Fab C77G12",2022-10-12
87,C13B8,C13B8,7U09_H,7U09_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvqpsqtltltctvsgdsisnedyhwtwirqhpgkglewmgylqysgntnynpslksrmtisvdtsknqfslrlnsvtaadtavyfcatsivltgmsnkiqpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,syeltqppsvsvspgqmaritcsgealpkkyaywyqqkggqfpvlviykdterpsgiperfsgsssgtivtltisgvqpedeadyyclsadtsgtwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Low,J.S. et al.; ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies; Science 377 (6607), 735-742 (2022); 2022.",10.1126/science.abq2679,"Chain H, Heavy chain Fab C13B8","Chain L, Light chain Fab C13B8",2022-10-12
88,VP12E7,VP12E7,7SL5_J,7SL5_K,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgeslrlscsgsgftfnnyimhwvrqapgqgldyvsgigsdgrntnygdsvkgrftisrdnskdtlylqmtslraedtafyycvkgldvlrfldlstpsgerldafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,divmtqspsflsasvgdrvtitcrasqgisnylawyqqkpgkaphlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyplftfgpgtkvdiertvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Low,J.S. et al.; ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies; Science 377 (6607), 735-742 (2022); 2022.",10.1126/science.abq2679,"Chain J, Heavy chain VP12E7 Fab","Chain K, Light chain VP12E7 Fab",2022-10-12
92,VN01H1,VN01H1,7SKZ_H,7SKZ_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvlpggslrlscsasgftfsdfsmhwvrqspgkgleyvsaitssgsstyypdsvkgrftisrdnskntlylqmgslrvedtavywcvknsdvfrfphlyfdvwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,divmtqspatlsvspgdratlscrasqsvssnlawyqqkpgqaprlliygastraagiparfsgsgsgteftltisslqsedfavyycqqydnwpsitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Low,J.S. et al.; ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies; Science 377 (6607), 735-742 (2022); 2022.",10.1126/science.abq2679,"Chain H, Heavy chain of VN01H1 Fab","Chain L, Light chain of VN01H1 Fab",2022-10-12
93,COV44-79,COV44-79,8DAO_A,8DAO_B,['COVID'],Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgltfsgyamhwvrqapgkglewvavisrdarnkyyadsvkgrftisrdnskktvylemnslrvedtavyycailiipgitepgspdaldiwgqgtmvsvss,diqmtqspssmsasvgdrvtitcrasqdiskwlawyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqassfpwsitfgqgtrleir,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; Science 377 (6607), 728-735 (2022); 2022.",10.1126/science.abq3773,"Chain A, COV44-79 heavy chain variable domain","Chain B, COV44-79 light chain variable domain",2022-10-12
95,COV91-27,COV91-27,8D6Z_G,8D6Z_I,['COVID'],Homo sapiens (human),qvqlvesgggvvhpggslrlscaasgftfsdfamnwvrqapgeglqwvaiisydgrnkhfaasvrgrftisrdnskntmflqmsslraedtaiyycatlggwfeeasptywgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,evvltqspaivslspgeratlscrasqsvgsrlawhqqkpglaprvliydasnratgiparfsgsgsgtdftltissiepedsavyycqqrgdwplitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; Science 377 (6607), 728-735 (2022); 2022.",10.1126/science.abq3773,"Chain G, Neutralizing antibody COV91-27 heavy chain","Chain I, Neutralizing antibody COV91-27 light chain",2022-10-12
99,COV44-62,COV44-62,8D36_H,8D36_L,['COVID'],Homo sapiens (human),qmqlmqsgaevkkpgasvtvsckasgdtfsdyrihwvrqapgqglewmgrmnpksgdtnfaqkfqgrvtmtrdmsintaymtlsgltfddtalyycasllivggfdplddfevwgqgtmvtissastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsaltqppsasgspgqsvtiscsgtssdvggynfvswyqhhpgkapkiliyevtkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyggtnnllfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; Science 377 (6607), 728-735 (2022); 2022.",10.1126/science.abq3773,"Chain H, Neutralizing antibody COV44-62 heavy chain","Chain L, Neutralizing antibody COV44-62 light chain",2022-10-12
100,35B5,35B5,7WM0_H,7WM0_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtigyadsvkgrftisrdnaknslylhmrslraedtalyycakavemvrglmglgadpeygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,X. et al.; 35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope; Cell Host Microbe 30 (6), 887-895 (2022); 2022.",10.1016/j.chom.2022.03.035,"Chain H, Light chain of 35B5 Fab","Chain L, Heavy chain of 35B5 Fab",2022-10-12
104,SW186,SW186,8DT3_H,8DT3_L,"['COVID', 'SARS-COV-2', 'SARS-COV-1', 'Spike protein']",Mus musculus (house mouse),qvqlqqsgaelvkpgasvkisckasgvafssywmnwvkqrpgkglewigqiypgdgdtnyngkfkgkatltadkssstaymqlsslssedsavyfcargfiatveetmdywgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcaa,diqmtqttsslsaslgdrvtiscrasqdisnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgtdysltisnleqediatyfcqqshtlpwtfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgrvlaraspspspslsreac,"Fang,Y. et al.; An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif; Sci Immunol, eabp9962 (2022); 2022.",10.1126/sciimmunol.abp9962,"Chain H, Heavy chain Fab of SW186","Chain L, Light chain Fab of SW186",2022-10-12
105,SP1-77,SP1-77,7UPY_F,7UPY_G,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftgtyihwvrqapgqglewmgwinpnsggtnfaqifqgrvtltrdtsistaymdlnrlksddtavyycardrvlygrsfgwyfdvwgagttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcpscpapeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,diqmtqspsslsasvgdrvtitcqasqdisdylnwyqqqpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedigtyycqqydnlptfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Luo,S. et al.; Humanized antibody potently neutralizes all SARS-CoV-2 variants by a Novel mechanism; Unpublished; 2022.",NaN,"Chain F, SP1-77 Fab heavy chain","Chain G, SP1-77 Fab light chain",2022-10-12
112,002-S21F2,002-S21F2,7UPL_F,7UPL_I,['COVID'],Homo sapiens (human),evqlvqsgaevkkpgeslkisckasgynfayywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargemtavfgdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftltisslqpediatyycqqykilltwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Patel,A. et al.; SARS-Cov2 Omicron variant S protein structure in complex with neutralizing monoclonal antibody 002-S21F2; Unpublished; 2022.",NaN,"Chain F, mAb 002-S21F2 heavy chain","Chain I, mAB 002-S21F2 light chain",2022-10-12
114,ADI-62113,ADI-62113,7T7B_H,7T7B_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgaevkkpgasvklsckasgytfsvfpihwvrqapgqrlewmgwhnagdgdtkysqkfqgrvtiisdtsastaymelsslksedtavyycaraarpyydrrgyffradyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqvtqspsslsasvgdrvtitcqasqdiknslnwyqqkpgkapkllisdasnletgvpsrfsgngsgtdftftisslqpediatyycqqydnlitfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Liu,H. et al.; Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron; Commun Biol 5 (1), 766 (2022); 2022.",10.1038/s42003-022-03700-6,"Chain H, ADI-62113 Fab heavy chain","Chain L, ADI-62113 Fab light chain",2022-10-12
115,10-28,10-28,7SI2_H,7SI2_L,unknown,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssydmhwvrqapgkglewvavisydgsskfyaesvkgrftisrdnskntlylqmnslraeetavyycvkdgeqlvplfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpgvtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Liu,L. et al.; An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses; Sci Transl Med 14 (646), eabn6859 (2022); 2022.",10.1126/scitranslmed.abn6859,"Chain H, 10-28 Heavy Chain","Chain L, 10-28 Light Chain",2022-10-12
118,10-40,10-40,7SD5_H,7SD5_L,unknown,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisssnfywgwirqppgkglewiasitysgrtfynpslksrvaisvdtsknqfslklssvtaadtavyycartfpsyydrsgyhylnygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,nfmltqphsmsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssswvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,L. et al.; An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses; Sci Transl Med 14 (646), eabn6859 (2022); 2022.",10.1126/scitranslmed.abn6859,"Chain H, 10-40 Heavy chain","Chain L, 10-40 Light chain",2022-10-12
119,87G7,87G7,7R40_E,7R40_G,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscvasgftfssyvmswvrqapgkglewvaaisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycakegtyyygsgsfwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,eivltqspatlslspgeratlscrasqsfhnylawyqqkpgraprllifdasnratgiparfsgsgsgtdftltisslepedfavyycqqrfnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,W. et al.; An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern; Sci Immunol 7 (73), eabp9312 (2022); 2022.",10.1126/sciimmunol.abp9312,"Chain E, 87G7 heavy chain variable region","Chain G, 87G7 light chain variable region",2022-10-12
122,2B11,2B11,7E5Y_C,7E5Y_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaaseitvssnymnwvrqapgkglewvsviysggttyyadsvkgrftisrdnsentlylqmnslraedtavyycardlmevggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,lpvltqppsasgtpgqrvtiscsgsssnvendnvnwfqqqvpgstpklviyndrlrpsgvpdrfsgsksgtsaylaisglqsedeadyycvawdaslqsyvfgtgtkvtvlrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Pan,Y. et al.; Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries; Cell Discov 7 (1), 57 (2021); 2021.",10.1038/s41421-021-00295-w,"Chain C, 2B11 Fab Heavy chain","Chain B, 2B11 Fab Light chain",2022-10-12
124,IGG1,IGG1,UUB73689,UUB73690,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscavsgftfssyamhwvrqtpgkglewvavisidgnnnhyadsvkgrftisrdhskntlylqmnslrpedtavyycareldyygsgsypdywgqgtlvtvss,qlvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprflmkvnsdgshnkgdgipdrfsgsssgaeryltisslqsedeavyycqtwgaavwvfgggtrltvl,"Chi,X. et al.; Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination; Signal Transduct Target Ther 7 (1), 139 (2022); 2022.",10.1038/s41392-022-00987-z,"anti-SARS-CoV-2 spike immunoglobulin IgG1 heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike immunoglobulin IgG1 light chain variable region, partial [Homo sapiens]",2022-10-12
125,IGG1,IGG1,UUB73687,UUB73688,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggtlrlscvasgfsfsnywmswvrqapgkglewvanikqdgsethyvdsvkgrftisrdnaknslylqmnslraddtavyfcvkdrtdwelirgyfghwgqgtqitvss,divmtqtpsslslspgdratlscraseniinylawyqqrpgqsprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqriiwppytfgqgtkvdik,"Chi,X. et al.; Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination; Signal Transduct Target Ther 7 (1), 139 (2022); 2022.",10.1038/s41392-022-00987-z,"anti-SARS-CoV-2 spike immunoglobulin IgG1 heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike immunoglobulin IgG1 light chain variable region, partial [Homo sapiens]",2022-10-12
126,IGG1,IGG1,UUB73685,UUB73686,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgaevrkpgasvklsckasgytftsyyihwvrqapgqglewmgiinpsgggtvypqkfqgrvtmtsdtststvsmelsslrsedtavyycardqadyyygsgcivwgqgtlvtvss,diqmtqspatlavslgeratinckssqsvfytsnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysntpltfgggtkvdik,"Chi,X. et al.; Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination; Signal Transduct Target Ther 7 (1), 139 (2022); 2022.",10.1038/s41392-022-00987-z,"anti-SARS-CoV-2 spike immunoglobulin IgG1 heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike immunoglobulin IgG1 light chain variable region, partial [Homo sapiens]",2022-10-12
127,IGG1,IGG1,UUB73683,UUB73684,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgtslrlscaasgfsfshyvmywvrqapgkgldwvaiisfdgssqyyadsvkgrftisrdnskdtlylqmhslrpedtavyycaihggtyyydknilawgqgtlvtvss,airmtqspptlslspgeratlscrasqsvtnylvwyqqkpgqaprlliydtfnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpptfgqgtkvdik,"Chi,X. et al.; Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination; Signal Transduct Target Ther 7 (1), 139 (2022); 2022.",10.1038/s41392-022-00987-z,"anti-SARS-CoV-2 spike immunoglobulin IgG1 heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike immunoglobulin IgG1 light chain variable region, partial [Homo sapiens]",2022-10-12
128,IGG1,IGG1,UUB73681,UUB73682,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggalvqpggslrlscaasgftfanyamswvrqapgkglewvssmtgssidsyyadsvkgrftisrdnsrntlylqmnslraedtavyycakgellwfgdllhnwfdpwgrgtlvtvss,diqmtqspfslsvspgeratlscrasqsvstnlawyqqkpgqaprllihgastratglparfsgsgsgteftltisslqsedfavyfcqqydswpgtfgpgtkvdik,"Chi,X. et al.; Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination; Signal Transduct Target Ther 7 (1), 139 (2022); 2022.",10.1038/s41392-022-00987-z,"anti-SARS-CoV-2 spike immunoglobulin IgG1 heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike immunoglobulin IgG1 light chain variable region, partial [Homo sapiens]",2022-10-12
129,ZWD12,ZWD12,7WWL_J,7WWL_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggtlrlscvasgfsfsnywmswvrqapgkglewvanikqdgsethyvdsvkgrftisrdnaknslylqmnslraddtavyfcvkdrtdwelirgyfghwgqgtqitvss,divmtqtpsslslspgdratlscraseniinylawyqqrpgqsprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqriiwppytfgqgtkvdik,"Chi,X. et al.; Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination; Signal Transduct Target Ther 7 (1), 139 (2022); 2022.",10.1038/s41392-022-00987-z,"Chain J, heavy chain of ZWD12","Chain N, light chain of ZWD12",2022-10-12
132,ZWC6,ZWC6,7WWM_J,7WWM_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgtslrlscaasgfsfshyvmywvrqapgkgldwvaiisfdgssqyyadsvkgrftisrdnskdtlylqmhslrpedtavyycaihggtyyydknilawgqgtlvtvss,airmtqspptlslspgeratlscrasqsvtnylvwyqqkpgqaprlliydtfnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpptfgqgtkvdik,"Chi,X. et al.; Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination; Signal Transduct Target Ther 7 (1), 139 (2022); 2022.",10.1038/s41392-022-00987-z,"Chain J, heavy chain of ZWC6","Chain N, heavy chain of ZWC6",2022-10-12
135,DH1042,DH1042,7THE_B,7THE_C,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaylelsslrsedtavyycarymvtrdqyyydmdvwgqgttvtvs,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysppptfgqgtklei,"Gobeil,S.M. et al.; Structural diversity of the SARS-CoV-2 Omicron spike; Mol Cell 82 (11), 2050-2068 (2022); 2022.",10.1016/j.molcel.2022.03.028,"Chain B, DH1042 Fab Heavy Chain","Chain C, DH1042 Fab Light Chain",2022-10-12
136,DH898.1,DH898.1,7LUA_i,7LUA_j,unknown,Homo sapiens (human),qdlllqsgaevrepgasvtvscqasnytfpdyyihwvrlvpgqglewlgemkpkvgvtnvskkirdrlfmtadtstdtaymvlsaltpgdtaiyyctrlepdflsgwahwgkgvlvtvspastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrve,eivmtqtplslsvtpgepaslscrssasllhgngntylhwylrkagqspqllifggskrvpgisdrfigsgagtnftlkissveaddvgfyycaqgvafpwtfgqgtkveikravaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgvlktgnsqesvteqdskdntyslsstltlsntdyqshnvyacevthqglsspvtksfnrge,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.",NaN,"Chain i, DH898.1 heavy chain","Chain j, DH898.1 light chain",2022-10-12
138,DH851.3,DH851.3,7LU9_q,7LU9_r,unknown,Macaca mulatta (Rhesus monkey),qvtlmesgpalvkvtqtlavtctfsgfsirdsgkgvawirqppggalewltsiywddtkyhdtslkprltifrdtsqtqvililtnmapldtatyycgrinngggwkdhidfwgpgllvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgg,altqppsvsksleqsvtisctgtttgnsvswyqchsgtaprlliydvnkrpsgvsdrfsgskshntasltifglqaedeadyycgsygsggsllfgggtrltvlgqpxkasptvtlfppsseelqankatlvclisdfypgvvkvawkadgsavnagvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvapaec,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.",NaN,"Chain q, DH851.3 heavy chain","Chain r, DH851.3 light chain",2022-10-12
139,DH851.3,DH851.3,7LU9_p,7LU9_o,unknown,Macaca mulatta (Rhesus monkey),qvtlmesgpalvkvtqtlavtctfsgfsirdsgkgvawirqppggalewltsiywddtkyhdtslkprltifrdtsqtqvililtnmapldtatyycgrinngggwkdhidfwgpgllvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrve,altqppsvsksleqsvtisctgtttgnsvswyqchsgtaprlliydvnkrpsgvsdrfsgskshntasltifglqaedeadyycgsygsggsllfgggtrltvlgqpxkasptvtlfppsseelqankatlvclisdfypgvvkvawkadgsavnagvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvap,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.",NaN,"Chain p, DH851.3 heavy chain","Chain o, DH851.3 light chain",2022-10-12
146,DH717.1,DH717.1,6XRJ_H,6XRJ_L,unknown,Homo sapiens (human),qvqlqesgpglvkpsetlsltcavsgvsindgydwtwirqtpgkglewigyvfgrsgnfnlnpslrnrgiiskdtcknqfslnlnsataadtavyfcargmeglfaaynsldvwgrgllvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveikt,altqppsvsgspgqsviisctgtssdigqynsvswyqqhpdkapklviygvtsrpsgvsdrfsgskygdtasltisglqaedeadyycsshadenmalfgggtrltvlgqpkasptvtlfppsseelqankatlvclisdfypgvvkvawkadgsavnagvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvapa,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2020.",NaN,"Chain H, DH717.1 heavy chain Fab fragment","Chain L, DH717.1 light chain Fab fragment",2022-10-12
150,VACW-209,VACW-209,7WP2_H,7WP2_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssiamhwvrqapgkglewvavmsfdgsikyygdsvkgrftisrdnskstlylqmnslraedtavyycargvqgyydrsgyynldynygmdvwgqgttvtvss,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Ju,B. et al.; Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209; Cell Res. 32, 491 (2022); 2022.",NaN,"Chain H, VacW-209 heavy chain","Chain L, VacW-209 light chain",2022-10-12
154,CC12.1,CC12.1,8CWV_H,8CWV_L,unknown,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppkftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain H, CC12.1 Fab heavy chain","Chain L, CC12.1 Fab light chain",2022-10-12
155,ZCB11,ZCB11,7XH8_B,7XH8_C,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgpevkkpgtsvkvackasgftfitpvsmqwvrqargqrlewlgwivlasgntdyaqkfqervtiirdmststaymelsrlrtedtavyycaapscsrticsdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,eivltqspgtlslspgeratlscrasqsvsssylawfqqkpgqaprllifaassraigiparfsgsgsgtdftltisrlepedfavyycqqyssspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhou,B. et al.; A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge; Nat Commun 13 (1), 3589 (2022); 2022.",10.1038/s41467-022-31259-7,"Chain B, The heavy chain of ZCB11 antibody","Chain C, The light chain of ZCB11 antibody",2022-10-12
156,JMB2002,JMB2002,7XOD_R,7XOD_S,unknown,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaslasyssgwedvfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,diqmtqspsslsasvgdrvtitcrasqgisswlawyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Xu,Y. et al.; Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins; Cell Res 32 (7), 609-620 (2022); 2022.",10.1038/s41422-022-00672-4,"Chain R, Heavy chain of JMB2002 Fab","Chain S, Light chain of JMB2002 Fab",2022-10-12
159,76E1,76E1,7X9E_C,7X9E_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpggslrlsceasgfsfkdygmhwirqtpgkglewisrisgdtrgtsyvdsvkgrfivsrdnsrnslflqmnslrsedtalyycaalvivaagddfdlwgqgtvvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,qsaltqplsvsgspgqsvtisctgsssdigsynfvswyrqypgkapkvmiyevnkrpsgvpvrfsgsksgntasltvsglqhedeadyyccsyggrnnlifgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Sun,X. et al.; Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2; Nat Microbiol 7 (7), 1063-1074 (2022); 2022.",10.1038/s41564-022-01155-3,"Chain C, 76E1 Fab Heavy Chain","Chain D, 76E1 Fab Light Chain",2022-10-12
161,PVI.V6-14,PVI.V6-14,7RBV_H,7RBV_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarcrpeyyfgsgsyldfdywgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpltfgggtkveik,"Altomare,C.G. et al.; Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain; mBio 13 (3), e0358021 (2022); 2022.",10.1128/mbio.03580-21,"Chain H, PVI.V6-14 Fab heavy chain, variable region","Chain L, PVI.V6-14 Fab light chain, variable region",2022-10-12
164,M31A7,M31A7,7WUH_K,7WUH_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),mgwslillflvavatrvevqlqqsgpemvkpgasvkiscktsgytfteytiywvkqshgkslewlgginpnigdttynqkfkgkatltvdtssstaymelrsltsedsavyycarevynysfaywgqgtlvtvsaasttkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkaepksc,mrvpaqllgllllwlpgarcdivmsqspsslavsvgekvtmsckssqsllyssnqknylawyqqklgqtpklliywassresgvpdrftgsgsgtdftltissvraedlavyycqqyyrypltfgvgtklelkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Huang,H.Y. et al.; Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models; Sci Transl Med 14 (639), eabm0899 (2022); 2022.",10.1126/scitranslmed.abm0899,"Chain K, m31A7 Fab heavy chain","Chain L, m31A7 Fab light chain",2022-10-12
169,XG014,XG014,7V2A_I,7V2A_H,['COVID'],Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfsnywigwvrhmpgkglewmgiiypgdsdtryspsfqgqvtisvdtsistaylqwsslkasdtamyyctrhqygynygyfyyyidvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsvltqppsvsaapgqkvtiscsgsssnignnpvswyrqvpgtapklliydnnkrpsgipdrfsgsksgasatlgitglqtgdeadyycgtwhtslssgvfgggtkltvlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,Z. et al.; An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope; Protein Cell 13 (9), 655-675 (2022); 2021.",10.1007/s13238-021-00871-6,"Chain I, The heavy chain of XG014","Chain H, The light chain of XG014 Fab",2022-10-12
172,XG005,XG005,7V26_e,7V26_f,['COVID'],Homo sapiens (human),qvtlresgptlvkpkqtltltctfsgfslstpgggvgwirqppgkalewlaliywdddkryspslkssltitkdtsknqvvltmtnmdpvdtatyycarltaadtifdcwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspglsitisctatssdvgaynyvswyqqhpgqapklmiydvskrpsgvsnrfsgsksantasltisglqaedeadyycssytttsvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,Z. et al.; An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope; Protein Cell 13 (9), 655-675 (2022); 2021.",10.1007/s13238-021-00871-6,"Chain e, XG005 Heavy chain","Chain f, XG005 Light Chain",2022-10-12
175,OMI-6,OMI-6,7ZFA_H,7ZFA_L,unknown,Homo sapiens (human),evqllesgpglvkpsetlsltctvsggsisryswswirqpagrglewigrmyssggtnynpslesrvtmsldtskkqfslklssvtaadtavyycaaasidqvwgtyrdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,airmtqspsslaasvgdrvtiscragqsissflhwyqqkvgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfaayycqqsyenpltfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain H, Omi-6 heavy chain","Chain L, Omi-6 light chain",2022-10-12
177,COVOX-150,COVOX-150,7ZFA_Q,7ZFA_R,unknown,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiysggttyyadsvkgrftisrdssmntlylqmnslraedtavyycardlmvygidvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivmtqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqldsyppgytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain Q, COVOX-150 heavy chain","Chain R, COVOX-150 light chain",2022-10-12
183,OMI-18,OMI-18,7ZFB_J,7ZFB_K,unknown,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgitvssnymtwvrqapgkglewvsllyaggsafyadsvkgrftisrdnskntlyllmnslrvgdtavyycardlqvygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,syeltqppsvsvapgqtaritcggnndgaksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltitrieagdeadyycqvwdssrdhvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain J, Omi-18 heavy chain","Chain K, Omi-18 light chain",2022-10-12
184,OMI-31,OMI-31,7ZFB_C,7ZFB_D,unknown,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfssygiswvrqapglglewmggvipilsakhyaqrfqgrvtitadkstgtaymelsslrsedtavyycardilhhddlwgrfyydgmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvvtqppsasgtpgqrvtiscsgsssdigsntvnwyqqlpgtapklliytnnqrpsgvpdrfsgsksgtsaslaitglqsedeadyfcaawdeslngrvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain C, Omi-31 heavy chain","Chain D, Omi-31 light chain",2022-10-12
187,OMI-32,OMI-32,7ZFE_F,7ZFE_G,unknown,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavywydggnkfyadsvkgrftisrdnskntlylqmnslrvedtavyycardtappdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,airmtqspgtlslspgeratlscrasqsisssflawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtsprltfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain F, Omi-32 heavy chain","Chain G, Omi-32 light chain",2022-10-12
191,OMI-9,OMI-9,7ZF4_H,7ZF4_L,unknown,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfrtyavhwvrqapgkgpewvavisydgsnkyyadsvkgrftlsrdtskntlylqmnslraedtavyycasrgdtvttgdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,syeltqppsvsvspgqtaritcsgdalpkqytywyqqkpgqppvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqstdssatypgnvvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain H, Omi-9 heavy chain","Chain L, Omi-9 light chain",2022-10-12
192,OMI-3,OMI-3,7ZF3_A,7ZF3_B,unknown,Homo sapiens (human),evqlvesgggliqpggslrlscaaseiivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvvggtdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain A, Omi-3 heavy chain","Chain B, Omi-3 light chain",2022-10-12
193,EY6A,EY6A,7ZF3_H,7ZF3_L,unknown,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasaftfssydmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggklwvyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlaltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain H, EY6A heavy chain","Chain L, EY6A light chain",2022-10-12
194,OMI-12,OMI-12,7ZF5_G,7ZF5_I,unknown,Homo sapiens (human),evqlvesgpevkkpgtsvkvsckasgfsfsmsamqwvrrargqrlewigwivpgsgnanyaqkfqervtitrdestntgymelsslrsedtavyycaaphcnktncydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,airmtqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygastratgipdrfsgsgsgtdfiltinrlepedlavyycqqfgsspwtfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain G, Omi-12 heavy chain","Chain I, Omi-12 light chain",2022-10-12
196,BETA-54,BETA-54,7ZF5_B,7ZF5_C,unknown,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvfggsitssnhywvwirqppgkglewigsmyysgstaynpsltnrvtisvdtsknqfslklssvtaadtavyycarqigpkrpsqvadwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain B, Beta-54 heavy chain","Chain C, Beta-54 light chain",2022-10-12
204,OMI-25,OMI-25,7ZFD_A,7ZFD_B,unknown,Homo sapiens (human),qvqlvesggglvqpgrslrlscaasgftfddyamhwvrqvpgkglewvsgiswnsgsivyadfvkgrftiardnaknslflqmnslraedtalyycakstalrhqyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,aiqmtqspsslsasvgdrvtitcrtsqtissylnwyqqkpgkapklliydasslqsgvpsrfsgsgygtdftltisslqpedfatyfcqqsyntpyafgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain A, Omi-25 heavy chain","Chain B, Omi-25 light chain",2022-10-12
206,OMI-42,OMI-42,7ZFF_H,7ZFF_L,unknown,Homo sapiens (human),evqlletggglvqpgrslrlscaasgfpfddyaihwvrlapgkglewvssiswdsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakgafpgyssgwyygldvwgqgatvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvvtqppsasgslgqsvtisctgtssdvggynyvswyqqhpgkapklmifevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagnkgvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain H, Omi-42 Heavy chain","Chain L, Omi-42 light chain",2022-10-12
207,OMI-42,OMI-42,7ZR7_F,7ZR7_G,unknown,Homo sapiens (human),evqlletggglvqpgrslrlscaasgfpfddyaihwvrlapgkglewvssiswdsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakgafpgyssgwyygldvwgqgatvtvss,qsvvtqppsasgslgqsvtisctgtssdvggynyvswyqqhpgkapklmifevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagnkgvfgggtkltvl,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain F, Omi-42 heavy chain","Chain G, Omi-42 light chain",2022-10-12
210,OMI-38,OMI-38,7ZR8_H,7ZR8_L,unknown,Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggnfnmytiswvrqapgrglewmgrfipiankanyaqnfpgrvtitadkststvymelrsltsddtavyycarsgsydafdvwgqgtmvtvss,airmtqspstlsasvgdrvtitcrasqtinswlawyqqkpgkapklliydasnlesgvpsrfsgsgsgteftltisslqpddfatyycqqyesyspitfgqgtrleik,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain H, Omi-38 fab heavy chain","Chain L, Omi-38 Fab light chain",2022-10-12
211,OMI-2,OMI-2,7ZR9_F,7ZR9_G,unknown,Homo sapiens (human),evqlvesgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmggiipifrtphyaqkfqgrvtitadestgtaymelsslrsedtavyycaspscggdcpqylksskldwyfdlwgrgtlvtvss,viwmtqspgtlslspgeratlscrasqsvsstylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygsspltfgqgtrleik,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain F, Omi-2 Fab heavy chain","Chain G, Omi-2 Fab light chain",2022-10-12
217,A5-10,A5-10,7F3Q_C,7F3Q_B,['SARS-COV-2'],Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaivgsggstyyadsvkgrfiisrdnskntlylqmnslraedtavyycaksliyghydiltgayyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,aqmtqspssvsasvgdrvtipcrasqgignwlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfppfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtk,"Dou,Y. et al.; High throughput isolation of potent neutralizing antibodies from convalescent COVID-19 patients; Unpublished; 2022.",NaN,"Chain C, Heavy chain of A5-10 Fab","Chain B, Light chain of A5-10 Fab",2022-10-12
218,A34-2,A34-2,7F3Q_H,7F3Q_L,['SARS-COV-2'],Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfdesamhwvrqapgeglewvsgiswnsgriayadsvrgrftisrdnaknslylqmnslraedtalyfcalttsgwfsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvep,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvpviyydsdrpsgiperfsgsnsgntatltisrvevgdeadyycqvwdsssdravfgggttltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dou,Y. et al.; High throughput isolation of potent neutralizing antibodies from convalescent COVID-19 patients; Unpublished; 2022.",NaN,"Chain H, Heavy chain of A34-2 Fab","Chain L, Light chain of A34-2 Fab",2022-10-12
219,STS165,STS165,7XIC_K,7XIC_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcarvgycggdcyslslagfpdywgqgtlvtvsse,eivmtqspatlsvspgeratlscrasqsvsynlawyqqkpgqaprlliydastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppytfgqgtkleik,"Li,Y. et al.; Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants; iScience 25 (6), 104431 (2022); 2022.",10.1016/j.isci.2022.104431,"Chain K, heavy chain of STS165","Chain L, light chain of STS165",2022-10-12
222,C1717,C1717,7UAR_F,7UAR_G,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsggtfnsfainwvrqapgqgpewmgrvipvleianyaqkfqgrititadkststaymelssltsedtaiyycarhhiavaqpyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqhlpgtapkllmssddqrpsgvparfsgsksgtsaslaisglrsedeadyycaswddrlngvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpxqwkshrsyscqvthegstvektvaptecs,"Wang,Z. et al.; Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins; Immunity 55 (6), 998-1012 (2022); 2022.",10.1016/j.immuni.2022.04.003,"Chain F, C1717 Fab Heavy Chain","Chain G, C1717 Fab Light Chain",2022-10-12
225,C1520,C1520,7UAQ_H,7UAQ_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlacvasgftfsiyemnwvrqapgkglewvsyittsgharynadsvkgrftisrdnsknsfylqmnslraedtaiyycarpqyhyydtstyhsygfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qlvltqspsasaslgasvnltctlssghnsyaiawhqqqpekgprylmslnsdgshtkgdgipdrfsgsssgaerfltisslqsedeadyycqtwdtgirvfgggtrltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpxqwkshrsyscqvthegstvektvaptecs,"Wang,Z. et al.; Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins; Immunity 55 (6), 998-1012 (2022); 2022.",10.1016/j.immuni.2022.04.003,"Chain H, C1520 Fab Heavy Chain","Chain L, C1520 Fab Light Chain",2022-10-12
229,MW05,MW05,7DK0_A,7DK0_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgssnyaqkfqgrvtitadeststaymelsslrsedtavyycaesplgggsgysvswfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqysnwppwtfgqgtkveikrtvaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wang,S. et al.; Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcgammaRIIB and virus-antibody complex with bivalent interaction; Commun Biol 5 (1), 262 (2022); 2021.",10.1038/s42003-022-03207-0,"Chain A, MW05 heavy chain","Chain B, MW05 light chain",2022-10-12
230,MW01,MW01,7DJZ_A,7DJZ_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfssfsiswvrqapgqglewmgriipvlgianyaqevqgrvtitadkststaymelsslrsedtavyfcttdrfvepatgpffdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqysnwltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,S. et al.; Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcgammaRIIB and virus-antibody complex with bivalent interaction; Commun Biol 5 (1), 262 (2022); 2021.",10.1038/s42003-022-03207-0,"Chain A, MW01 heavy chain","Chain B, MW01 light chain",2022-10-12
231,P14-44,P14-44,7FCQ_H,7FCQ_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftsysmhwvrqapgqglewmgtikpsddstnyaqkfqgrvsmtrdtststvymelsslryedtavyycareargyydrsgyyhpgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,qsvltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiyevsdrpsgvssrfsgsksgntasltisglqaedeadyycfsyttsttwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zou,J. et al.; Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance; J Clin Invest 132 (4) (2022); 2022.",10.1172/JCI154987,"Chain H, P14-44 antibody Fab fragment heavy chain","Chain L, P14-44 antibody Fab fragment light chain",2022-10-12
232,P5-22,P5-22,7FCP_B,7FCP_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfrdydiiwirqapgkglewvsyisrsgstiyysdsvrgrftisrdnaknsvylqmnslraedtavyycardfgfegprmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdiknylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqfdnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zou,J. et al.; Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance; J Clin Invest 132 (4) (2022); 2022.",10.1172/JCI154987,"Chain B, P5-22 antibody Fab fragment heavy chain","Chain D, P5-22 antibody Fab fragment light chain",2022-10-12
234,A8-1,A8-1,7F7H_C,7F7H_D,['SARS-COV-2'],Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymtwvrqapgkglewvsviysggstfyaesvkgrftisrdnskntlylqmnslraedtavyycardlvvygmdvwgqgttvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,iqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnshplafgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Dou,Y. et al.; High throughput isolation of potent neutralizing antibodies from convalescent COVID-19 patients; Unpublished; 2022.",NaN,"Chain C, Heavy chain of A8-1 Fab","Chain D, Light chain of A8-1 Fab",2022-10-12
236,S2X303,S2X303,7SOE_H,7SOE_G,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltcklsgfsvntggvgvgwirqppgkalewlaliywnddklyspslksrltvtkdtsknqvvltmtnmdpvdtatyycahvlvwfgevlpdafdvwgqgtmvtvss,syeltqppsvsvspgqtasitcsgdklgetyaswyqqkpgqspilviyqdnkrpsgiperfsgsnsentatltisgtqtmdeadyycqawdktiagfgggtkltv,"McCallum,M. et al.; Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants; Science 374 (6575), 1621-1626 (2021); 2021.",10.1126/science.abl8506,"Chain H, S2X303 Fab heavy chain","Chain G, S2X303 Fab light chain",2022-10-12
239,510A5,510A5,7WS0_I,7WS0_H,['Spike protein'],Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsdsidyadsvkgrftisrdnaknslylqmnslraedtalyycakdrgyeiltpasfdywgqgtlvtvssas,diqmtqspsslsasvgdrvtitcrasqsissylnwfqhkpgkapklliygasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppytfgqgtkleik,"Guo,H. et al.; Structures of Omicron spike complexes and implications for neutralizing antibody development; Cell Rep 39 (5), 110770 (2022); 2022.",10.1016/j.celrep.2022.110770,"Chain I, 510A5 heavy chain","Chain H, 510A5 light chain",2022-10-12
246,510A5,510A5,7WS2_E,7WS2_D,['Spike protein'],Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsdsidyadsvkgrftisrdnaknslylqmnslraedtalyycakdrgyeiltpasfdywgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasqsissylnwfqhkpgkapklliygasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppytfgqgtkleik,"Guo,H. et al.; Structures of Omicron spike complexes and implications for neutralizing antibody development; Cell Rep 39 (5), 110770 (2022); 2022.",10.1016/j.celrep.2022.110770,"Chain E, 510A5 heavy chain","Chain D, 510A5 light chain",2022-10-12
257,J08,J08,7SBU_H,7SBU_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgriipildrvmyaqkfqgrvtitadkststaymelsslrsedtavyycarraidsdtyveqshfdywgqgtlvtvssastrgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqapslliydasnratgiparfsgsgsgtdftltisslepedfavyycqqpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Torres,J.L. et al.; Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody; Proc Natl Acad Sci U S A 119 (20), e2120976119 (2022); 2022.",10.1073/pnas.2120976119,"Chain H, J08 Fab heavy chain","Chain L, J08 Fab light chain",2022-10-12
258,J08,J08,7S6L_H,7S6L_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgriipildrvmyaqkfqgrvtitadkststaymelsslrsedtavyycarraidsdtyveqshfdywgqgtlvtvssas,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqapslliydasnratgiparfsgsgsgtdftltisslepedfavyycqqpltfgggtkveikrt,"Torres,J.L. et al.; Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody; Proc Natl Acad Sci U S A 119 (20), e2120976119 (2022); 2022.",10.1073/pnas.2120976119,"Chain H, J08 fragment antigen binding heavy chain variable domain","Chain L, J08 fragment antigen binding light chain variable domain",2022-10-12
262,J08,J08,7S6J_F,7S6J_G,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgriipildrvmyaqkfqgrvtitadkststaymelsslrsedtavyycarraidsdtyveqshfdywgqgtlvtvssas,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqapslliydasnratgiparfsgsgsgtdftltisslepedfavyycqqpltfgggtkveikrt,"Torres,J.L. et al.; Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody; Proc Natl Acad Sci U S A 119 (20), e2120976119 (2022); 2022.",10.1073/pnas.2120976119,"Chain F, J08 fragment antigen binding heavy chain variable domain","Chain G, J08 fragment antigen binding light chain variable domain",2022-10-12
265,UT28K,UT28K,7X7O_J,7X7O_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),mdwiwrilflvgaatgahsqmqlvqsgpevkkpgtsvkvsckasgftfsisavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrfedtavyycaapycggdcsdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksgssghhhhhhhhhh,metpaqllfllllwlpdttgeivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygnspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Ozawa,T. et al.; Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants; MAbs 14 (1), 2072455; 2022.",10.1080/19420862.2022.2072455,"Chain J, UT28K Fab, heavy chain","Chain L, UT28K Fab, light chain",2022-10-12
269,LP5,LP5,7MXP_H,7MXP_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmtslraedtavyycaradygdfffdywgqgtlvtvss,syeltqppsvsvspgqtaritcsgdalskhygywyqqkpgqapvlvifkdserpsgiperfsgsssgttitltvsgvqaedeadyycqsadssatywvfgggtkltv,"Reddem,E.R. et al.; Cryo-EM structure of NTD-directed neutralizing antibody LP5 Fab in complex with SARS-CoV-2 S2P spike; Unpublished; 2022.",NaN,"Chain H, LP5 Fab Heavy Chain","Chain L, LP5 Fab Light Chain",2022-10-12
272,GW01,GW01,7EPX_I,7EPX_M,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpggslrlscaasgfrfddhamhwvrqapgkglewvsvisgdggstyyadsvkgrfsisrddsknslylqmnslrtedtalyycakdrsygppdvfnyeygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslnwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wang,Y. et al.; Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses; Cell Discov 8 (1), 36 (2022); 2022.",10.1038/s41421-022-00401-6,"Chain I, heavy chain of GW01","Chain M, light chain of GW01",2022-10-12
274,THSC20.HVTR04,THSC20.HVTR04,7Z0Y_H,7Z0Y_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),xvqlvesgggvvqpgrslrlscaasgftfsnyaihwvrqapgkglewvavvsydgsnkyyaesvkgrftisrdnskntlslqmislrpedtavyycasvadtamvpewyfdlwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscglevlfq,xsvltqprsvsgspgqsvtisctgtssdvgaynyvswyqqhpgkapklmiydvsarpsgvpdrfsgsksgntasltisglqaedeadyyccsyagswvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Hingankar,N. et al.; A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant; Biorxiv (2021); 2022.",NaN,"Chain H, THSC20.HVTR04 Fab heavy chain","Chain L, THSC20.HVTR04 Fab light chain",2022-10-12
275,THSC20.HVTR26,THSC20.HVTR26,7Z0X_H,7Z0X_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsaiysgdstyyadsvkgrftisrhnpkntlylqmnslraedtavyycarlvgaltnivvsgdggafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscglevlfq,syeltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedevdyyccsyagsstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Hingankar,N. et al.; A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant; Biorxiv (2021); 2022.",NaN,"Chain H, THSC20.HVTR26 Fab heavy chain","Chain L, THSC20.HVTR26 Fab light chain",2022-10-12
276,XGV289,XGV289,7WEF_C,7WEF_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgaslkvscrasgytftshfihwvrqapgqglewmgiinpsggasyaqnfrdrvtmttdpststvymelgslrsedtavyycaraegsswlgwfdpwgqgtlvtvss,svltqppsasgtpgqrvtipcsgsssnignnyvywyqqlpgtapkllvygnnqrpsgvpdrfsvsksgtsaslaisglrsedeadyycaawddglsgsgwvfgggtkltvl,"Wang,K. et al.; Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants; Nature 603 (7903), 919-925 (2022); 2022.",10.1038/s41586-022-04466-x,"Chain C, The heavy chain of Fab XGv289","Chain L, The light chain of Fab XGv289",2022-10-12
277,XGV265,XGV265,7WEE_H,7WEE_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltcnfsgfslntygvgvgwirqppgkalewlaliywdgderygpffknkvtiakdtsknqvvltmtnmdpvdtatyycarhliptifdywgqgtlvtvss,saltqpasvsgspgqsitisctgtssdvggsnyvswyqhhpdrapklliyevtnrpsgvsnrfsgsksantasltisglqaedeadyycssytttsthilfgggtkltv,"Wang,K. et al.; Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants; Nature 603 (7903), 919-925 (2022); 2022.",10.1038/s41586-022-04466-x,"Chain H, The heavy chain of Fab XGv265","Chain L, The light chain of Fab XGv265",2022-10-12
278,XGV347,XGV347,7WEC_I,7WEC_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftdvsslqwvrqargqrlewigwtvvgtgntnyaprfqervtittdkststaymelsslrsedtavyycaapfcsetscsdgfdlwgqgtkvtvs,eivltqspgtlslspgdratlscrasqsvrisylawyqqkpgqaprllisgsssratgipdrfsasgsgtdftltisrlepedfavyycqqyanspwtfgqgtkvev,"Wang,K. et al.; Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants; Nature 603 (7903), 919-925 (2022); 2022.",10.1038/s41586-022-04466-x,"Chain I, The heavy chain of Fab XGv347","Chain L, The light chain of Fab XGv347",2022-10-12
288,XGV282,XGV282,7WLC_H,7WLC_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vqlvqsgaevkkpgssvkvsckasgdtfssytfswvrqapgqglewmgrsipivgkaiyaqefqgrvtisadrstttvymelsslrsddtavyycardqsgfdffyydhwgqgtlvav,qsvltqppsasgtpgqrvtiscsgsgsnigsntinwyqqlpgtapkvliyrnnerpsgvpdrfsgsksgtsasltisglqsedeayyhcaawddslngpvfgggtkltvlg,"Wang,K. et al.; Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants; Nature 603 (7903), 919-925 (2022); 2022.",10.1038/s41586-022-04466-x,"Chain H, Heavy chain of XGv282","Chain L, Light chain of XGv282",2022-10-12
290,ADI-55688,ADI-55688,7U2E_H,7U2E_L,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qpvltqppsvsgapgqritisctgsssnigagydvhwyqqlpgtapklliygsssrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yuan,M. et al.; A broad and potent neutralization epitope in SARS-related coronaviruses; bioRxiv (2022); 2022.",10.1101/2022.03.13.484037,"Chain H, ADI-55688 heavy chain","Chain L, ADI-55688 light chain",2022-10-12
291,ADG20,ADG20,7U2D_H,7U2D_L,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgystyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qpvltqppsvsgapgqritisctgsssnigagydvhwyqqlpgtapklliygsssrnsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlytfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yuan,M. et al.; A broad and potent neutralization epitope in SARS-related coronaviruses; bioRxiv (2022); 2022.",10.1101/2022.03.13.484037,"Chain H, ADG20 heavy chain","Chain L, ADG20 light chain",2022-10-12
292,AB17,AB17,7TE1_H,7TE1_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlqqsgpelvkpgasvkisckasgysftdyymnwvkqspekslewigeinpntggttynqkfkakatltvdkssstaymqlksltsedsavyycaryygnlyamdywgqgtsvtvssgaakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdc,dilmtqspssmsvslgdtvsitchasqgissnigwlqqkpgksfkgliyhgtnledgvpsrfsgsgsgadysltisslesedfadyycvqyvqfpytlgggtkleikradgaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Hauser,B.M. et al.; Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting; Cell Rep 38 (12), 110561 (2022); 2022.",10.1016/j.celrep.2022.110561,"Chain H, Ab17 heavy chain","Chain L, Ab17 light chain",2022-10-12
294,S304,S304,7TN0_M,7TN0_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science 375 (6583), 864-868 (2022); 2022.",10.1126/science.abn8652,"Chain M, S304 Fab heavy chain","Chain N, S304 Fab light chain",2022-10-12
296,S309,S309,7TN0_C,7TN0_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science 375 (6583), 864-868 (2022); 2022.",10.1126/science.abn8652,"Chain C, S309 heavy chain","Chain D, S309 light chain",2022-10-12
298,S309,S309,7TM0_N,7TM0_O,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,ivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkve,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science 375 (6583), 864-868 (2022); 2022.",10.1126/science.abn8652,"Chain N, S309 Fab Heavy Chain","Chain O, S309 Fab light chain",2022-10-12
301,S2L20,S2L20,7TM0_I,7TM0_H,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfnsygmhwvrqapgkglewvafirydggnkyyadsvkgrftisrdnskntlylqmkslraedtavyycanlkdsrysgsyydywgqgtlvtvss,viwmtqspsslsasvgdrvtitcqasqdirfylnwyqqkpgkapkllisdasnmetgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpftfgpgtkvdfk,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science 375 (6583), 864-868 (2022); 2022.",10.1126/science.abn8652,"Chain I, S2L20 Fab heavy chain","Chain H, S2L20 Fab light chain",2022-10-12
304,S309,S309,7TLY_A,7TLY_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvs,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science 375 (6583), 864-868 (2022); 2022.",10.1126/science.abn8652,"Chain A, S309 Fab heavy chain","Chain B, S309 Fab light chain",2022-10-12
306,CC40.8,CC40.8,7SJS_H,7SJS_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyvmtwarqapgkglewvsaisgtgytyyadsvkgrftvsrdnskntlflqmsslraedtavyycaitmapvvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,syeltqppsvsvspgqtaritcsgdalpkryaywyqqksgqapilviyedkkrpsgiperlsgsksgtvatltisgaqvedeadyycystdssgnhavfgggtqltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshksyscqvthegstvektvaptecs,"Zhou,P. et al.; A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection; Sci Transl Med 14 (637), eabi9215 (2022); 2022.",10.1126/scitranslmed.abi9215,"Chain H, CC40.8 Fab heavy chain","Chain L, CC40.8 Fab light chain",2022-10-12
307,N-612-004,N-612-004,7S0E_H,7S0E_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyymhwvrqapgkglewvsaisgsggytyyadsvkgrftisrdnskntlylqmnslraedtavyycardrdhaydwgfdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqwadwpltfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.",10.1101/2021.09.14.460356,"Chain H, N-612-004 Fab heavy chain","Chain L, N-612-004 Light Chain",2022-10-12
308,N-612-056,N-612-056,7S0B_C,7S0B_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvslisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlwgsgffafdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqdagtpltfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.",10.1101/2021.09.14.460356,"Chain C, N-612-056 Fab Heavy Chain","Chain D, N-612-056 Light Chain",2022-10-12
310,N-612-014,N-612-014,7S0D_O,7S0D_P,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamtwvrqapgkglewvsyisgsgggtyyadsvkgrftisrdnskntlylqmnslraedtavyycardrwasgwlafdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqayaypltfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.",10.1101/2021.09.14.460356,"Chain O, N-612-014 Fab Heavy Chain","Chain P, N-612-014 Light Chain",2022-10-12
313,N-612-017,N-612-017,7S0C_M,7S0C_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaiwgsgsntyyadsvkgrftisrdnskntlylqmnslraedtavyycargrdlaaftktafdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqhdalpwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.",10.1101/2021.09.14.460356,"Chain M, N-612-017 Fab Heavy Chain","Chain N, N-612-017 Light Chain",2022-10-12
315,WRAIR-2173,WRAIR-2173,7N4J_H,7N4J_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsgdsisssdyswgwirqppgkglewigtiyyikntyynpslrsrvtlsvdtsknlfslklssvtaadtavyycarerppfdvvvvpaarpynwfdpwglgtlvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvlmqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaddeadyycqsydsslsgskvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.",10.1038/s41590-021-01068-z,"Chain H, WRAIR-2173 antibody Fab heavy chain","Chain L, WRAIR-2173 antibody Fab light chain",2022-10-12
316,WRAIR-2151,WRAIR-2151,7N4M_H,7N4M_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgprlvkpsetlsltctvsggsisgsnyfwgwirqppgkglewigtiyyggstyynpslksrvtisvdtsenqfslklssvtaadtavyycanlawlrgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsvsltisglktedeadyycqsydssnwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.",10.1038/s41590-021-01068-z,"Chain H, WRAIR-2151 antibody Fab heavy chain","Chain L, WRAIR-2151 antibody Fab light chain",2022-10-12
317,WRAIR-2125,WRAIR-2125,7N4L_H,7N4L_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlslqmnslrpedtavyycakdspyyydssgyypgyfqdwgqgslvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasigdrvtitcrasqtisdylnwyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.",10.1038/s41590-021-01068-z,"Chain H, WRAIR-2125 antibody Fab heavy chain","Chain L, WRAIR-2125 antibody Fab light chain",2022-10-12
318,WRAIR-2057,WRAIR-2057,7N4I_H,7N4I_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfisywiawvrqmpgkglewmgiiypgdsdttyspsfqgqvtisadksistaylqwsslkasdtaiyycarllyysdsspldswgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqshstprtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.",10.1038/s41590-021-01068-z,"Chain H, WRAIR-2057 Antibody Fab Heavy Chain","Chain L, WRAIR-2057 Antibody Fab Light Chain",2022-10-12
319,T6,T6,7FJS_C,7FJS_A,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlqqpgtelvnpgaslkmscktsgyrftsyiihwvkqtpgqglewigaifpenddtsysqkfkgkatlttdtssstaymqlssltsedsavyycardgenvldywgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrve,rtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecqivltqspsslavsvgekvtlsckssqsllysnnqknylawyqqksgrspklllhwtstresgvpdrftgsgsgtdftltissvkaedlavyycqqyytypwtfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liang,Q. et al.; RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants; iScience 25 (4), 104043 (2022); 2022.",10.1016/j.isci.2022.104043,"Chain C, T6 heavy chain","Chain A, T6 light chain",2022-10-12
321,T6,T6,7FJN_I,7FJN_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlqqpgtelvnpgaslkmscktsgyrftsyiihwvkqtpgqglewigaifpenddtsysqkfkgkatlttdtssstaymqlssltsedsavyycardgenvldywgqgtsvtvss,qivltqspsslavsvgekvtlsckssqsllysnnqknylawyqqksgrspklllhwtstresgvpdrftgsgsgtdftltissvkaedlavyycqqyytypwtfgggtkleik,"Liang,Q. et al.; RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants; iScience 25 (4), 104043 (2022); 2022.",10.1016/j.isci.2022.104043,"Chain I, T6 heavy chain","Chain L, T6 light chain",2022-10-12
323,T6,T6,7FJO_J,7FJO_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlqqpgtelvnpgaslkmscktsgyrftsyiihwvkqtpgqglewigaifpenddtsysqkfkgkatlttdtssstaymqlssltsedsavyycardgenvldywgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrve,qivltqspsslavsvgekvtlsckssqsllysnnqknylawyqqksgrspklllhwtstresgvpdrftgsgsgtdftltissvkaedlavyycqqyytypwtfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liang,Q. et al.; RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants; iScience 25 (4), 104043 (2022); 2022.",10.1016/j.isci.2022.104043,"Chain J, T6 heavy chain","Chain L, T6 light chain",2022-10-12
326,NCOV617,NCOV617,7E3O_H,7E3O_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgsnkyadsvkgrftisrdnskntlylqmnslraedtavyycarglglrflewpissywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapkllifsnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslkgvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yang,M. et al.; Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain; Microbiol Spectr 9 (2), e0135221 (2021); 2021.",10.1128/Spectrum.01352-21,"Chain H, nCoV617 Heigh Chain","Chain L, nCoV617 Light Chain",2022-10-12
327,AZD8895,AZD8895,7L7E_T,7L7E_U,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvssastkgpsvfplapssxxxsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dong,J. et al.; Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail; Nat Microbiol 6 (10), 1233-1244 (2021); 2021.",10.1038/s41564-021-00972-2,"Chain T, heavy chain of human monoclonal antibody AZD8895","Chain U, light chain of human monoclonal antibody Fab AZD8895",2022-10-12
328,AZD1061,AZD1061,7L7E_O,7L7E_P,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfrdvwmswvrqapgkglewvgrikskidggttdyaapvkgrftisrddskntlylqmnslktedtavyycttagsyyydtvgpglpegkfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppkllmywastresgvpdrfsgsgsgaeftltisslqaedvaiyycqqyystltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglrspvtksfnrgec,"Dong,J. et al.; Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail; Nat Microbiol 6 (10), 1233-1244 (2021); 2021.",10.1038/s41564-021-00972-2,"Chain O, heavy chain of human monoclonal antibody Fab AZD1061","Chain P, light chain of human monoclonal antibody Fab AZD1061",2022-10-12
335,AZD8895,AZD8895,7L7D_H,7L7D_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvssastkgpsvfplapsxxxxxxgtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglrspvtksfnrgec,"Dong,J. et al.; Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail; Nat Microbiol 6 (10), 1233-1244 (2021); 2021.",10.1038/s41564-021-00972-2,"Chain H, heavy chain of human monoclonal antibody Fab AZD8895","Chain L, light chain of human monoclonal antibody Fab AZD8895",2022-10-12
336,NaN,NaN,7O7F_H,7O7F_F,unknown,Mus musculus (house mouse),dvqlvesggglvqpggsrklscsasgfafssfgmhwvrqapekglewvayissgsgtiyyadtvkgrftisrddpkntlflqmtslrsedtamyycvrsiyyygsspfdfwgqgttltvssakttppsvyplapgcgdttgssvtlgclvkgyfpesvtvtwnsgslsssvhtfpallqsglytmsssvtvpsstwpsqtvtcsvahpassttvdkkleps,divmtqatssvpvtpgesvsiscrssksllhsngntylywflqrpgqspqlliyrmsnlasgvpdrfsgsgsgtaftltisrleaedvgvyycmqhleypltfgagtklelkradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrn,"Isaikina,P. et al.; Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist; Sci Adv 7 (25) (2021); 2021.",10.1126/sciadv.abg8685,"Chain H, Fab antibody fragment heavy chain","Chain F, Fab antibody fragment light chain",2022-10-12
337,PG16,PG16,6PWU_H,6PWU_L,unknown,Homo sapiens (human),mefglswvflvallrgvqcqeqlvesgggvvqpggslrlsclasgftfhkygmhwvrqapgkglewvalisddgmrkyhsdsmwgrvtisrdnskntlylqfsslkvedtamffcareaggpiwhddvkyydfndgyynyhymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkasgggsawshpqfekgggsgggsggssawshpqfek,mawalllltlltqgtgswaqsaltqpasvsgspgqtitiscngtssdvggfdsvswyqqspgkapkvmvfdvshrpsgisnrfsgsksgntasltisglhiedegdyfcssltdrshrifgggtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshksyscqvthegstvektvaptecsggsgghhhhhhhhhh,"Pan,J. et al.; Cryo-EM Structure of Full-length HIV-1 Env Bound With the Fab of Antibody PG16; J Mol Biol 432 (4), 1158-1168 (2020); 2020.",10.1016/j.jmb.2019.11.028,"Chain H, Antibody PG16 Fab heavy chain","Chain L, Antibody PG16 Fab light chain",2022-10-12
339,CV30,CV30,6XE1_H,6XE1_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),xvqlvesgggliqpggslrlscaasgvivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardldvsggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,xivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Hurlburt,N.K. et al.; Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation; Nat Commun 11 (1), 5413 (2020); 2020.",10.1038/s41467-020-19231-9,"Chain H, CV30 Fab Heavy chain","Chain L, CV30 Fab Kappa chain",2022-10-12
340,CV3-13,CV3-13,7RQ6_J,7RQ6_K,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsqtlsltctvaggsissgtyywswirqpagkglewigriytsgsanynpslksrvtisvdtsknqfslrlssvtaedtavyycareysssyyyfyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliyvasnletgvpsrfsgsgfgtdftftisslqpediatyycqqfdnlpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrg,"Beaudoin-Bussieres,G. et al.; A SARS-CoV-2 non-neutralizing antibody with enhanced Fc-effector function defines a novel NTD epitope and delays neuroinvasion and death in mice; Cell Rep (2022); 2022.",NaN,"Chain J, CV3-13 Fab heavy chain","Chain K, CV3-13 Fab light chain",2022-10-12
343,47C9,47C9,7PO5_H,7PO5_L,"['COVID', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywnwirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargnyygsgsyvdygmdvwgqgttvtvss,eivmtqspatlsvspgeratlscrasqsissnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqsnnwpltfgggtkveik,"Wang,C. et al.; Neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,"Chain H, 47C9 antibody heavy chain","Chain L, 47C9 antibody light chain",2022-10-12
346,43E6,43E6,7PNQ_D,7PNQ_F,"['COVID', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywnwirqspgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargnyygsgsyvdygmdvwgqgttvtvss,eivmtqspatlsvspgeratlscrasqsissnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqsnswpltfgggtkveik,"Wang,C. et al.; Neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,"Chain D, 43E6 antibody heavy chain","Chain F, 43E6 antibody light chain",2022-10-12
349,46C12,46C12,7PNM_I,7PNM_E,"['COVID', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyvmhwvrqapgkglewvaviwfdgdnkyyadsvkarftisrdnskntlylqmnslraedtavyycardpqwldyhdldvwgqgttvtvss,divmtqsplslsvtpgepasiscrssqsllhsngykyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgsdftlkisrveaedvgvyycmqalqtpltfgggtkveik,"Wang,C. et al.; Neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,"Chain I, 46C12 antibody heavy chain","Chain E, 46C12 antibody light chain",2022-10-12
352,54042-4,54042-4,7T01_H,7T01_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstigvgvswirqppgkaldwlaliywdddkryspslksrltvtmdtsknqvvltltnmdpvdtatyfcahglfsssdwggldvwgqgttvt,dmqmtqspsslsasvgdrvtitcrasqsvftylnwyqqkpgkapklliyaasrlqsgvpsrfrgsgsgtdftltisslqpedfatyycqqshstpfifgpgtkvdik,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Cell Rep 37 (1), 109784 (2021); 2022.",10.1016/j.celrep.2021.109784,"Chain H, 54042-4 Fab - Heavy Chain","Chain L, 54042-4 Fab - Light Chain",2022-10-12
353,CV3-25,CV3-25,7RAQ_H,7RAQ_L,['Spike protein'],Homo sapiens (human),xvqlvesgaevkkpgeslkisckgsgytftrywigwvrqmpgkglewmgiiypgdsdtryspsfqghvtisadksistaylqwnslkasdtamyycarlpqycsngvcqrwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,eivltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpytfgqgtnleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Hurlburt,N.K. et al.; Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit; Commun Biol 5 (1), 342 (2022); 2022.",10.1038/s42003-022-03262-7,"Chain H, CV3-25 Fab Heavy Chain","Chain L, CV3-25 Fab Light Chain",2022-10-12
354,JMB2002,JMB2002,7WRV_U,7WRV_V,['Spike protein'],Mus musculus (house mouse),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaslasyssgwedvfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkththhhhhh,gdiqmtqspsslsasvgdrvtitcrasqgisswlawyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yin,W. et al.; Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody; Science 375 (6584), 1048-1053 (2022); 2022.",10.1126/science.abn8863,"Chain U, JMB2002 Fab heavy chain","Chain V, JMB2002 Fab light chain",2022-10-12
357,JMB2002,JMB2002,7WPF_X,7WPF_Y,['Spike protein'],Mus musculus (house mouse),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaslasyssgwedvfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkththhhhhh,diqmtqspsslsasvgdrvtitcrasqgisswlawyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yin,W. et al.; Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody; Science 375 (6584), 1048-1053 (2022); 2022.",10.1126/science.abn8863,"Chain X, JMB2002 Fab heavy chain","Chain Y, JMB2002 Fab light chain",2022-10-12
361,CV07-287,CV07-287,7S5R_B,7S5R_C,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsstncydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Reincke,S.M. et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science 375 (6582), 782-787 (2022); 2022.",10.1126/science.abm5835,"Chain B, CV07-287 Heavy chain","Chain C, CV07-287 Light chain",2022-10-12
362,COVA1-16,COVA1-16,7S5R_H,7S5R_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Reincke,S.M. et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science 375 (6582), 782-787 (2022); 2022.",10.1126/science.abm5835,"Chain H, COVA1-16 Heavy chain","Chain L, COVA1-16 Light chain",2022-10-12
364,CS44,CS44,7S5Q_B,7S5Q_C,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgitftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggtchdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Reincke,S.M. et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science 375 (6582), 782-787 (2022); 2022.",10.1126/science.abm5835,"Chain B, CS44 Heavy chain","Chain C, CS44 Light chain",2022-10-12
365,CS23,CS23,7S5P_H,7S5P_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargtamaygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,yeltqppsvsvapgqtaritcggnniggqsvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Reincke,S.M. et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science 375 (6582), 782-787 (2022); 2022.",10.1126/science.abm5835,"Chain H, CS23 Heavy chain","Chain L, CS23 Light chain",2022-10-12
366,8D3,8D3,7W9F_A,7W9F_B,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgkslewigginpnigdtsynqnfkgkatltvdrssstaymelrsltsedsavyycardgypyyyaldhwgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgckpcictvpevssvfifppkpkdvltitltpkvtcvvvdiskddpevqfswfvddvevhtaqtqpreeqfnstfrsvselpimhqdwlngkefkcrvnsaafpapiektisktkgrpkapqvytipppkeqmakdkvsltcmitdffpeditvewqwngqpaenykntqpimdtdgsyfvysklnvqksnweagntftcsvlheglhnhhtekslshspgk,divmtqsqkfmstsvgdrvsvtckasqnvgtnvawyqqkpgqspkaliystsyrysgvpdrftgsgsgtdftltisnvqsedlaeyfcqqynsypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Wang,Y. et al.; Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies; Nat Commun 13 (1), 871 (2022); 2022.",10.1038/s41467-022-28528-w,"Chain A, The heavy chain of 8D3","Chain B, The light chain of 8D3",2022-10-12
367,58G6,58G6,7E3L_D,7E3L_E,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqhlewigwivvgsgntnyaqkfqervtltrdmstrtaymelsslrsedtavyycaapncnsttchdgfdiwgqgtvvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,eivltqspgtlslspgeratlscrasqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlesedfavyycqqydnspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,T. et al.; Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants; Nat Commun 12 (1), 6304 (2021); 2021.",10.1038/s41467-021-26539-7,"Chain D, 58G6 heavy chain","Chain E, 58G6 light chain",2022-10-12
370,13G9,13G9,7E3K_H,7E3K_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfsgsavqwvrqargqrlewigwivvgsgntnyaqrfqervtitrdmststaymelsslrsedtavyycaapycsstscrdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,eivltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,T. et al.; Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants; Nat Commun 12 (1), 6304 (2021); 2021.",10.1038/s41467-021-26539-7,"Chain H, 13G9 heavy chain","Chain L, 13G9 light chain",2022-10-12
373,D27,D27,7VYR_A,7VYR_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),mewswvflfflsvttgvlsqvqlqqsgaevkkpgssvkvsckasggtfgnwsiswvrqapgqglewmggidpsrgeatyaqkfqgrvtittdeststaymelsslrsedtavyycareteqggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthhhhhhhhh,mgikmethsqvfvymllwlsgvegsyeltqppsvsvapgktaritcggnnigrksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvydlfsdyvfgtgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Jeong,B.S. et al.; Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants; MAbs 14 (1), 2021601 (2022); 2022.",10.1080/19420862.2021.2021601,"Chain A, D27 heavy chain","Chain B, D27 light chain",2022-10-12
378,DH1058,DH1058,7TOW_A,7TOW_B,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgfnfgdfgmhwvrqapgkglewvavisyegrnknhadsvrgrftisrdnsrnmlylqmnslrrgdtavyycakenrdrnydswsasysdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspsflsasvgdrvtitcrasqgidrylawyqqkpgsapklliyaastlqsgvpsrfsgsgsetdftltisslqpddfatyycqqlstyptitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Gobeil,S.M. et al.; Structural diversity of the SARS-CoV-2 Omicron spike; bioRxiv (2022); 2022.",10.1101/2022.01.25.477784,"Chain A, DH1058 Fab heavy chain","Chain B, DH1058 Fab Light chain",2022-10-12
380,A5-10,A5-10,7F7E_C,7F7E_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaivgsggstyyadsvkgrfiisrdnskntlylqmnslraedtavyycaksliyghydiltgayyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,aqmtqspssvsasvgdrvtipcrasqgignwlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfppfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtk,"Wang,F. et al.; Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants; Emerg Microbes Infect 11 (1), 548-551 (2022); 2022.",10.1080/22221751.2022.2032374,"Chain C, Heavy chain of A5-10 Fab","Chain L, Light chain of A5-10 Fab",2022-10-12
381,P36-5D2,P36-5D2,7FAF_g,7FAF_f,"['COVID', 'SARS-COV-2']",Homo sapiens (human),mgwsciilflvatatgvhsqvqlvqsgaevkkpgasvkvsckasgytfttyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyycaggggrrlqfdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,mgwsciilflvatatgvhsdiqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyngypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Shan,S. et al.; A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants; Front Immunol 12, 766821 (2021); 2021.",10.3389/fimmu.2021.766821,"Chain g, P36-5D2 heavy chain","Chain f, P36-5D2 light chain",2022-10-12
387,CV503,CV503,7LQ7_H,7LQ7_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfgiswvrqapgqglewmgriipilgtanhaqkfqgrvtitadkstgtvymelsslrsedtavyycardgdsgsyyetlgfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevnkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"Chain H, CV503 heavy chain","Chain L, CV503 light chain",2022-10-12
388,COVA1-16,COVA1-16,7LQ7_y,7LQ7_z,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"Chain y, COVA1-16 heavy chain","Chain z, COVA1-16 light chain",2022-10-12
393,836H,836L,7EZV_M,7EZV_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),mgwslillflvavatrvlsqvqlvqsgpevkkpgtsvrvsckasgftfstsavqwvrqargqrlewigwiavgsgktdylqkfqervtmtrdestntaymqlsslrsedtavyycaaphcsggtcydgfdiwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,mgwsciilflvatatgvhseivltqspgtlslspgeratlscrasqsvrsgyfawyqqrpgraprlliygassrataipdrfsgsgsgtdftltinrlepedfavyycqqygtspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain M, 836H","Chain N, 836L",2022-10-12
394,BD-804H,BD-804L,7EYA_H,7EYA_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vqlvesggglvkpggslrlscaasgftfsnydmnwvrqapgkglewvssisssstythyadsvkgrftisrdnaknslylqmnslraedtavyycardrayrlgelsslwgddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,vwmtqspsllsastgdrvtvscrmsqdissylawyqqkpgkapelliyaaftlqsgvpsrfsgsgsgteftltisslqsedfatyycqqyysfphtfgqgtklerrrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain H, BD-804H","Chain L, BD-804L",2022-10-12
395,BD-771H,BD-771L,7EY5_H,7EY5_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggfvkpggslrlscaasgfkfsdawmnwvrqapgkglewvgrikskadgqttdyaapvkgrfsisrddskntlflqihnlesddtavyycttgalvesryfdwftgyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,diqmtqspsslsasvgdrvtitcrtsqgiynylawyqqkpgkvpklliygastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkyksapltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain H, BD-771H","Chain L, BD-771L",2022-10-12
396,BD-821H,BD-821L,7EY5_B,7EY5_C,"['COVID', 'SARS-COV-2']",Homo sapiens (human),elqlvqsgaevkkpgeslkisckysgnispnfwigwvrqmagkglewmgiiypddsdsryspsfqgqviisadksittallhwsslkvsdtakyycvygsgspsnwfhpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,evvmtqspatlsvspgeratlscrasqsvrynlawyqqkpgqaprlliydastratgipgrfsgsgsgteftltisslqsedfavyycqqydnwppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain B, BD-821H","Chain C, BD-821L",2022-10-12
397,BD-667,BD-667,7EY4_H,7EY4_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgfrfsdyymnwirqapgkglewisyigsggfatyygdsvkgrftvsrddaenslylqmnslraedtavyycargvtsysdnsgnyrtddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,eivmtqspatlsvspgeratlscrasqsvsrnlawyqqrpgqaprlliygastratgvaarftgsgfgteftltisglqsedfavyycqeynnwppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain H, BD-667 H","Chain L, BD-667 L",2022-10-12
398,BD-813H,BD-813L,7EY0_H,7EY0_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasefivsanymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrvedtavyfcarflptydyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcrtsqsistylhwyqqkpgkapklliyaasslhsgvpsrfsgsgsgthfvltinglqpedfatyycqhtdttpltffgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain H, BD-813H","Chain L, BD-813L",2022-10-12
399,BD-744H,BD-744L,7EY0_A,7EY0_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgaswnsgtigyadsvkgrfiiirdnaknslylqmnslrsedtasyycakdfsrdgdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,yvlpqppsvsvapgktaritcggnniehksvhwyqqkprqapvvvmyydsdrpsgiperfsgsnsgntatliisrveagdeaeyycqvwdrssdqpvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain A, BD-744H","Chain B, BD-744L",2022-10-12
400,NT-193,NT-193,7E5O_H,7E5O_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargwdldyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkgsslevlfqgplghhhhhh,airmtqspsamsasvgdrvtvtcrasqgignylawfqlkpgkvpkrliyaasslqsgvparfsgggsgteftltisslqpedfatyyclqhgflpwtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Onodera,T. et al.; A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site; Immunity 54 (10), 2385-2398 (2021); 2021.",10.1016/j.immuni.2021.08.025,"Chain H, NT-193 Heavy chain","Chain L, NT-193 Light chain",2022-10-12
401,RBD-CHAB45,RBD-CHAB45,7F63_H,7F63_L,"['SARS-COV-2', 'RBD']",Homo sapiens (human),evqlqqsgpelvkpgasvkiscktsgytfteytiywvkqslgkslewiggnnpnnddttykqffkgkatltvdkssstaymelrsltsedsavyycardgypyyyaldfwgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,divmtqsqkfmstsvgdrvsvtckssqnvgtnvawyqqkpgqspkaliysasyrysgvpdhftgsgsgtdftltisnvqsadlaeyfcqqynnypwtfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Su,S.C. et al.; Structure-guided antibody cocktail for prevention and treatment of COVID-19; PLoS Pathog 17 (10), e1009704 (2021); 2021.",10.1371/journal.ppat.1009704,"Chain H, RBD-chAb45, Heavy chain","Chain L, RBD-chAb45, Light chain",2022-10-12
402,RBD-CHAB-25,RBD-CHAB-25,7F62_H,7F62_L,"['SARS-COV-2', 'RBD']",Homo sapiens (human),evqleesggglvkpggslklscaasgftfssytmswvrqspekrlewvaeissggtytnypdtatgrftisrdnakntlylemsslrsedtamyycanfgnyeeiaywgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,qivltqspaimsvslgervtmtctasssvsssylhwyqqkpgsspklwiystsnlasgvparfsgsgsgtsysltissmeaedaatyychqyhrspytfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Su,S.C. et al.; Structure-guided antibody cocktail for prevention and treatment of COVID-19; PLoS Pathog 17 (10), e1009704 (2021); 2021.",10.1371/journal.ppat.1009704,"Chain H, RBD-chAb-25, Heavy chain","Chain L, RBD-chAb-25, Light chain",2022-10-12
403,HB27,HB27,7CYP_I,7CYP_H,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vklvesggglvkpggslrlscaasgftftnygmswvrqapgkrlewvaeissggsytyypdtvtgrftisrdnakntlylqmnslraedtavyycarfryggggtvdywgqgtlvtvss,ivltqsptlslspgeratlscrasesvdnygisfmnwfqqkpgqaprlliyaasnqgsgipsrfsgsgsgtdfsltisslepedfavyfcqqskevprifgqgtkveilk,"Zhu,L. et al.; Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2; Natl Sci Rev 8 (3), nwaa297 (2020); 2021.",10.1093/nsr/nwaa297,"Chain I, Heavy chain of HB27","Chain H, Light chain of HB27",2022-10-12
406,FC08,FC08,7DX4_H,7DX4_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qllqqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipiigianyaqkfqgrvtitadkststaymelsslrsedtavyycarergysgygaayyfdywgqgtlvtvssa,svltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvlgq,"Zhang,L. et al.; A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2; Natl Sci Rev 8 (8), nwab053 (2021); 2021.",10.1093/nsr/nwab053,"Chain H, Heavy chain of FC08 Fab","Chain L, Light chain of FC08 Fab",2022-10-12
407,FC05,FC05,7D4G_N,7D4G_G,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlleqsgaevkkpgasvrvsckvsgytlpevamhwvrqapgkglewmggfdpedgetmyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatttpfsssywfdpwgqgtlvtvss,qsvltqapsvsgapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsavvfgggtkltvl,"Zhang,L. et al.; A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2; Natl Sci Rev 8 (8), nwab053 (2021); 2021.",10.1093/nsr/nwab053,"Chain N, Heavy chain of FC05 Fab","Chain G, Light chain of FC05 Fab",2022-10-12
408,COVA2-39,COVA2-39,7JMP_H,7JMP_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviytggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarahvdtamvesgafdiwgqgtrvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkschhhhhh,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevtkrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wu,N.C. et al.; An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain; Cell Rep 33 (3), 108274 (2020); 2020.",10.1016/j.celrep.2020.108274,"Chain H, COVA2-39 heavy chain","Chain L, COVA2-39 light chain",2022-10-12
409,COVA2-04,COVA2-04,7JMO_H,7JMO_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardleraggmdvwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkschhhhhh,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygslytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wu,N.C. et al.; An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain; Cell Rep 33 (3), 108274 (2020); 2020.",10.1016/j.celrep.2020.108274,"Chain H, COVA2-04 heavy chain","Chain L, COVA2-04 light chain",2022-10-12
410,FI3A,FI3A,7Q0A_Y,7Q0A_Z,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvs,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdik,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.",10.7150/thno.65563,"Chain Y, FI3A fab heavy chain","Chain Z, FI3A fab Light chain",2022-10-12
411,FD-5D,FD-5D,7PR0_G,7PR0_F,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycaspggitaagtsvlfgyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpitwtfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.",10.7150/thno.65563,"Chain G, FD-5D Fab heavy chain","Chain F, FD-5D Fab light chain",2022-10-12
414,FD-11A,FD-11A,7PQZ_A,7PQZ_B,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgpdiltgyynyyyygmdvwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgfyvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.",10.7150/thno.65563,"Chain A, FD-11A Fab heavy chain","Chain B, FD-11A Fab light chain",2022-10-12
415,FI-3A,FI-3A,7PQZ_H,7PQZ_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.",10.7150/thno.65563,"Chain H, FI-3A Fab heavy chain","Chain L, FI-3A Fab light chain",2022-10-12
418,S2K146,S2K146,7TAT_F,7TAT_G,unknown,Homo sapiens (human),qvqlvesggvvvqpggslrlscaasgftfhdhtmhwvrqapgkglewvslitwnggtihysdsvkgrftisrdnsknslylqmnslrtedtalyycakdlgrggwylpsdawgqgtlvtvss,qsvltqppsasgtpgqrvtiscsgssanigsntvnwyqhlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslkgvfgggtkltvl,"Park,Y.J. et al.; Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry; Science 375 (6579), 449-454 (2022); 2022.",10.1126/science.abm8143,"Chain F, S2K146 Fab heavy chain","Chain G, S2K146 Fab light chain",2022-10-12
422,CV38-142,CV38-142,7LM9_H,7LM9_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkiscqgsgysftsywigwvrqmpgkglewmgiiypgesdtrysssfqghvtisadksistaylqwsslkasdtamyycarirgvyssgwiggdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprqwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Liu,H. et al.; A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection; bioRxiv (2021); 2021.",10.1101/2021.02.11.430866,"Chain H, CV38-142 Fab heavy chain","Chain L, CV38-142 Fab light chain",2022-10-12
424,COVA1-16,COVA1-16,7LM8_H,7LM8_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Liu,H. et al.; A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection; bioRxiv (2021); 2021.",10.1101/2021.02.11.430866,"Chain H, COVA1-16 Fab heavy chain","Chain L, COVA1-16 Fab light chain",2022-10-12
425,COVA1-16,COVA1-16,7JMX_H,7JMX_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkschhhhhh,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,H. et al.; Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity; bioRxiv (2020); 2020.",10.1101/2020.08.02.233536,"Chain H, COVA1-16 heavy chain","Chain L, COVA1-16 light chain",2022-10-12
427,AB-3467,AB-3467,7MSQ_H,7MSQ_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyhwnwirqppgkglewigyiyysgntnynpslksrvsistdtsknqfslklssvtaadtavyycvremrrgysgydywdlyafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgshhhhhh,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyphtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Burnett,D.L. et al.; Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability; Immunity 54 (12), 2908-2921 (2021); 2022.",10.1016/j.immuni.2021.10.019,"Chain H, AB-3467 Fab Heavy Chain","Chain L, AB-3467 Fab Light Chain",2022-10-12
429,BETA-43,BETA-43,7Q0I_A,7Q0I_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnnfyadsvkgrftisrdnfkntlylqmnslraedtavyycarsycsggfcfgyyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvapgktatitcggnnigtksvhwyqqkpgqapvlviyynsdrpsgiperfsgsnsgntvtltisrveagdeadyycqvwdsgsdhyvfgtgtkvtvvgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain A, Beta-43 heavy chain","Chain B, Beta-43 Fab light chain",2022-10-12
431,BETA-50,BETA-50,7Q0H_A,7Q0H_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasrgtfntyvftwvrqapgqglewmggiipffgtadyaqkfqgrvtitaddststaymelsslrsedtavyycsrlsqwdllpmwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspgtlslspgeratlscrasqsftssylawyqqkpgqaprlliygassratgipdrfsgtgsgtdftltisrlepedfavyycqqygtsprmytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain A, Beta-50 Fab heavy chain","Chain B, Beta-50 Fab light chain",2022-10-12
432,BETA-54,BETA-54,7Q0H_H,7Q0H_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvfggsitssnhywvwirqppgkglewigsmyysgstaynpsltnrvtisvdtsknqfslklssvtaadtavyycarqigpkrpsqvadwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain H, Beta-54 Fab heavy chain","Chain L, Beta-54 Fab light chain",2022-10-12
433,BETA-49,BETA-49,7Q0G_A,7Q0G_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfsssviswvrqapgqglewmggiiplfgsanyaqkfqgrvtitadeststaymemtslrsedtavyycakvsqwalilfwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspswtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain A, Beta-49 Fab heavy chain","Chain B, Beta-49 Fab light chain",2022-10-12
434,FI-3A,FI-3A,7Q0G_H,7Q0G_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain H, FI-3A Fab heavy chain","Chain L, FI-3A Fab light chain",2022-10-12
435,BETA-06,BETA-06,7Q9P_J,7Q9P_K,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisssshywgwirqppgkglewigsiyysesayynpslksrvtmsidtsknqfslklnsvtaadtavyycarvteprwtscyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivmtqspatlslspgeratlscrtsqsvtsylawyqqrpgqaprlliydasdratgiparfsgsgsgtdftltisnlepedfavyycqlrsnwppitfgqgtrletkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain J, Beta-06 heavy chain","Chain K, Beta-06 light chain",2022-10-12
438,BETA-53,BETA-53,7Q9M_E,7Q9M_F,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslrisckgsghnspsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslqasdtaiyycarhvvalthlypdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspatlsvspgeratlscrasqsvsstlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwstwtfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain E, Beta-53 fab heavy chain","Chain F, Beta-53 fab light chain",2022-10-12
441,BETA-32,BETA-32,7Q9K_D,7Q9K_E,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittgymelsslrsddtalyycarvgahdyydssdnwfdpwgqgtlvtvfsastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspssvsasvgdrltitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain D, Beta-32 heavy chain","Chain E, Beta-32 light chain",2022-10-12
443,BETA-26,BETA-26,7Q9J_J,7Q9J_K,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsetlsltctvsgasisnyywswirqppgkglewvgyiyytgstnhnpslksrvtisldtsknqfslrlssvtaadtavyycaraycsggscfdtfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvapgqtaritcggnnigsksvhwfqqkpgqapvlvvyddsdrpsgiperfsgsnsgntasltisrveagdeadyycqvwdsasdsgvfgtgtkltvpgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain J, Beta-26 heavy chain","Chain K, Beta-26 light chain",2022-10-12
449,COVOX-222,COVOX-222,7Q9G_E,7Q9G_F,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslgaedtavyycargegspgnwfdpwgqgtlvtvss,dvvmtqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqhydtsprfgggtkvdik,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain E, COVOX-222 heavy chain","Chain F, COVOX-222 light chain",2022-10-12
454,BETA-40,BETA-40,7PS7_H,7PS7_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgpgqvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgsayynpslksrvtisvdtsknqfslklnsvtaadtavfycarhaapspgdnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qsvltqppsvsvspgqtaritcsgdalstqngnwyqqkpgqapvmvickdserpsgiperfsgsrsgttvtltisgvqaedeadyhcqsadnrahvvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain H, Beta-40 heavy chain","Chain B, Beta-40 Fab light chain",2022-10-12
456,BETA-44,BETA-44,7PS6_C,7PS6_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwispyngnthyaqklqgrvtmttdtststaymelrslrsddtavyycardgellgwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvvtqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyagskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecsec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain C, Beta-44 Fab heavy chain","Chain D, Beta-44 Fab light chain",2022-10-12
458,BETA-47,BETA-47,7PS5_H,7PS5_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgpemkkpgtsvkvsckasgftfitsavqwvrqargqrlewmgwiavgsgntnyaqkfqdrvtinrdmststaymelsslrsedtavyycaaphcnrtschdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqsvsrnylawyqqkpgqvprlliygassratgipdrfrgsgsgtdftltinrlesedfavyycqqygsslftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain H, Beta-47 Fab heavy chain","Chain L, Beta-47 Fab light chain",2022-10-12
459,BETA-38,BETA-38,7PS4_B,7PS4_C,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftnywigwvrqmpgkglewmgiiypgdsgtryspsfqgqvtisadksirtaylqwsslkasdsamyycarsrvgatggyydyymdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qsvltqppsasgtpgqrvtiscsgsssnlggntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain B, Beta-38 Fab heavy chain","Chain C, Beta-38 Fab light chain",2022-10-12
462,BETA-29,BETA-29,7PS2_A,7PS2_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygmhrvrqapgkglewvalisyeesnryygdsvrgrftisrdnskntlylqmnslrpedtavyycakdqgpatvmvtairgamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyfgspsitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain A, Beta-29 Fab heavy chain","Chain B, Beta-29 Fab light chain",2022-10-12
463,BETA-27,BETA-27,7PS1_A,7PS1_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgltvrsnymnwvrqapgkglewvsliysggstfyadsvkgrftisrhdskntlylqmnslraedtavyycardlvvygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgeratlscrasqsvsssslawyqqkhgqaprlliygtssratgipdrfsgsgsgtdftltisglepedfavyycqqygssplfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain A, Beta-27 Fab heavy chain","Chain B, Beta-27 Fab light chain",2022-10-12
464,BETA-24,BETA-24,7PS0_B,7PS0_C,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpglvkpsqtlsltcsvsdgsisssdyywswirqppgkglewigyiyytgstyynpslksrvsisvdrsknqfslklssvtaadtavyycarlvvpspkgswfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqpasvsgspgqsitisctgtsidvgnynlaswyqqhpgkapkliiyegsrrpsgvsnrfsgaksgntasltisglqaedeadyyccsyvgsstyvfgsgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain B, Beta-24 heavy chain","Chain C, Beta-24 light chain",2022-10-12
466,BETA-22,BETA-22,7PRZ_H,7PRZ_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygihwvrqapgkglewvavisydgshkyyadsvkgrftisrdnskntlylqmnslktedtavyycakdssaaipyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,aiqmtqspdslavslgeratinckssqsilynsnnktylawyqqkpgqppkllifwastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiplifgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain H, Beta-22 Fab heavy chain","Chain L, Beta-22 Fab light chain",2022-10-12
467,BETA-6,BETA-6,7PRY_C,7PRY_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisssshywgwirqppgkglewigsiyysesayynpslksrvtmsidtsknqfslklnsvtaadtavyycarvteprwtscyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivmtqspatlslspgeratlscrtsqsvtsylawyqqrpgqaprlliydasdratgiparfsgsgsgtdftltisnlepedfavyycqlrsnwppitfgqgtrletkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain C, Beta-6 Fab heavy chain","Chain D, Beta-6 Fab light chain",2022-10-12
468,COVOX-45,COVOX-45,7PRY_F,7PRY_G,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavlsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggsyayyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftitslqpediatyycqqydnlpltfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain F, COVOX-45 Fab heavy chain","Chain G, COVOX-45 Fab light chain",2022-10-12
472,BETA-49,BETA-49,7Q6E_J,7Q6E_K,unknown,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfsssviswvrqapgqglewmggiiplfgsanyaqkfqgrvtitadeststaymemtslrsedtavyycakvsqwalilfwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspswtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Afonine,P.V. et al.; Real-space refinement in PHENIX for cryo-EM and crystallography; Acta Crystallogr., Sect. D: Biol. Crystallogr. 74, 531 (2018); 2021.",NaN,"Chain J, Beta-49 heavy chain","Chain K, Beta-49 light chain",2022-10-12
475,CV3-25,CV3-25,7NAB_A,7NAB_B,"['COVID', 'Spike protein']",Homo sapiens (human),evqlvesgaevkkpgeslkisckgsgytftrywigwvrqmpgkglewmgiiypgdsdtryspsfqghvtisadksistaylqwnslkasdtamyycarlpqycsngvcqrwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,eivltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpytfgqgtnleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Zhou,P. et al.; A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes; bioRxiv (2021); 2021.",10.1101/2021.03.30.437769,"Chain A, CV3-25 Fab Heavy Chain","Chain B, CV3-25 Fab Light Chain",2022-10-12
477,LY-COV1404,LY-COV1404,7MMO_D,7MMO_E,"['COVID', 'SARS-COV-2']",Homo sapiens (human),xitlkesgptlvkptqtltltctfsgfslsisgvgvgwlrqppgkalewlaliywdddkryspslksrltiskdtsknqvvlkmtnidpvdtatyycahhsistifdhwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,qsaltqpasvsgspgqsitisctatssdvgdynyvswyqqhpgkapklmifevsdrpsgisnrfsgsksgntasltisglqaedeadyycssyttssavfgggtkltvlgrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Westendorf,K. et al.; LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants; bioRxiv (2022); 2021.",10.1101/2021.04.30.442182,"Chain D, LY-CoV1404 Fab heavy chain","Chain E, LY-CoV1404 Fab light chain",2022-10-12
479,P22A-1D1,P22A-1D1,7CHS_H,7CHS_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrdyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyyclhlnsyrtfglgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.",10.1038/s41467-021-24514-w,"Chain H, antibody P22A-1D1 heavy chain","Chain L, antibody P22A-1D1 light chain",2022-10-12
480,P5A-3C8,P5A-3C8,7CHP_H,7CHP_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsfiysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlqehgmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkke,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqhlnsyppgytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.",10.1038/s41467-021-24514-w,"Chain H, antibody P5A-3C8 heavy chain","Chain L, antibody P5A-3C8 light chain",2022-10-12
481,P5A-1D2,P5A-1D2,7CHO_B,7CHO_C,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsiiysggstyyadsvkgrftisrdnsnntlylqmnslraedtavyycaralqvgatsdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedetdyycqscdsslsvvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.",10.1038/s41467-021-24514-w,"Chain B, antibody P5A-1D2 heavy chain","Chain C, antibody P5A-1D2 light chain",2022-10-12
483,SARS2-38,SARS2-38,7MKL_H,7MKL_L,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),qvqlkesgpglvapsqslsitctvsgfsltrygvhwvrqppgkglewlgviwadgstyynsalmsrlsiskdnsksqvflnmnslqtddtakyycardgrgyddywgqgttlt,qivltqspaimsaspgekvtmtcsasstvsfiywyqqkpgssprlliydtsnpasgvpvrfsgsgcgtsyyltisrmeaedaatyycqqwntypltfgagtklel,"VanBlargan,L. et al.; A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope; bioRxiv (2021); 2021.",10.1101/2021.04.26.441501,"Chain H, SARS2-38 Fv heavy chain","Chain L, SARS2-38 Fv light chain",2022-10-12
485,P2C-1A3,P2C-1A3,7CDJ_H,7CDJ_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardfshqqlvpswgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Ge,J. et al.; Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry; Nat Commun 12 (1), 250 (2021); 2020.",10.1038/s41467-020-20501-9,"Chain H, antibody P2C-1A3 heavy chain","Chain L, antibody P2C-1A3 light chain",2022-10-12
486,P2C-1F11,P2C-1F11,7CDI_H,7CDI_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyhcardlvvygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Ge,J. et al.; Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry; Nat Commun 12 (1), 250 (2021); 2020.",10.1038/s41467-020-20501-9,"Chain H, antibody P2C-1F11 heavy chain","Chain L, antibody P2C-1F11 light chain",2022-10-12
487,EY6A,EY6A,6ZDG_F,6ZDG_G,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasaftfssydmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggklwvyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlaltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhou,D. et al.; Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient; Nat Struct Mol Biol 27 (10), 950-958 (2020); 2020.",10.1038/s41594-020-0480-y,"Chain F, EY6A heavy chain","Chain G, EY6A light chain",2022-10-12
499,2-36,2-36,7N5H_J,7N5H_K,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvsssnyywswirqppgkglewigymyysgstkynpslksrvtisvdtsknqfslklssvtaadtavyycarevyyydrsgyyasdgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkveik,"Wang,P. et al.; A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses; bioRxiv (2021); 2021.",10.1101/2021.10.13.464307,"Chain J, 2-36 Fab heavy chain","Chain K, 2-36 Fab light chain",2022-10-12
502,7D6,7D6,7EAM_C,7EAM_D,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),evqlqqsgaelvrpgasvklsctasgfnikdtyihwvkqrpeqglewigridpgdgdteydpsfqgkatitadtssntaylelssltsedtavyyctrfydyvdygmdywgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkiepr,diqmtqspaslsasvgetvtitcrasgnihnylawyqqkqgkspqllvynaktladgvpsrfsgsgsgtqyslkinslqpedfgsyycqhfwstppwtfgggtklevkradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnn,"Li,T. et al.; Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants; Nat Commun 12 (1), 5652 (2021); 2021.",10.1038/s41467-021-25997-3,"Chain C, the heavy chain of Fab fragment of antibody 7D6","Chain D, the light chain of Fab fragment of antibody 7D6",2022-10-12
504,6D6,6D6,7EAN_H,7EAN_L,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),evqlqqsgaelvkpgasvklscttsgfniidtymhwvkqrpeeglewiggidpvngnseydpkfqdkatitadtssntaylhlsrltsedtavyycasahyygssssfpywgqgtdlvtvsakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsspwpsetvtcnvahpasstkvdkkivprg,divmtqsqkfmstsvgdrvsvtckasqnvgthvawyqqkpgqspkaliysasyrysgvpdrftgsgvgtdftltitnvqsedlaeyfcqqynsyftfgsgtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnr,"Li,T. et al.; Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants; Nat Commun 12 (1), 5652 (2021); 2021.",10.1038/s41467-021-25997-3,"Chain H, Heavy chain of SARS-CoV-2 cross-neutralizing mAb 6D6","Chain L, Light chain of SARS-CoV-2 cross-neutralizing mAb 6D6",2022-10-12
508,GH12-FAB,GH12-FAB,7D6I_B,7D6I_C,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyyctragwvrgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkththhhhhhhh,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnlwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Shi,R. et al.; A neutralizing MAb targeting receptor-binding-domain of SARS-CoV-2; Unpublished; 2021.",NaN,"Chain B, Heavy chain of GH12-Fab","Chain C, Light chain of GH12-Fab",2022-10-12
509,2H04,2H04,7K9K_H,7K9K_L,"['COVID', 'SARS-COV-2', 'RBD']",Mus musculus (house mouse),evqlqqsgaelvkpgasvkmsckasgytftsywitwvkqrpgqglewigdiypgsgstkynekfrseatltvdtssttaymqlssltsedsavyycarwdfygsrtfdywgqgttltvssa,divltqspailsvspgervsfscrasqnigtiihwyqqrtngsprllikyasesvsgipsrfsgsgsgtdftlsinsvesediadyycqqssswpltfgagtklel,"Errico,J.M. et al.; Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD; Cell Rep 37 (4), 109881 (2021); 2021.",10.1016/j.celrep.2021.109881,"Chain H, 2H04 heavy chain","Chain L, 2H04 light chain",2022-10-12
513,2B04,2B04,7K9I_H,7K9I_L,"['COVID', 'SARS-COV-2', 'RBD']",Mus musculus (house mouse),qvqlkqsgpglvapsqslsitctvsgfslinyaiswvrqppgkglewlgviwtgggtnynsalksrlsiskdnsksqvflkmnslqtddtaryycarkdyygryygmdywgqgtsvtvs,qavvtqesalttspgetvtltcrsstgavttsnyanwvqekpdhlftgliggtnnrapgvparfsgsligdkaaltitgaqtedeaiyfcalwynnhwvfgggtkltvl,"Errico,J.M. et al.; Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD; Cell Rep 37 (4), 109881 (2021); 2021.",10.1016/j.celrep.2021.109881,"Chain H, 2B04 heavy chain","Chain L, 2B04 light chain",2022-10-12
516,C118,C118,7RKV_G,7RKV_L,['SARS-COV-2'],Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycasgytgydyfvrgdyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qpvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmklntdgshskgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgilvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.",10.1016/j.celrep.2021.109760,"Chain G, C118 Fab Heavy Chain","Chain L, C118 Fab Light Chain",2022-10-12
519,C022,C022,7RKU_J,7RKU_L,['SARS-COV-2'],Homo sapiens (human),qvqlqesgpglvkpsetlsvtctvsggsisssryywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhaaayydrsgyyfieyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,diqmtqspstlsasvgdsvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynnyrytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.",10.1016/j.celrep.2021.109760,"Chain J, C022 Antibody Fab Heavy Chain","Chain L, C022 Antibody Fab Light Chain",2022-10-12
523,C118,C118,7RKS_I,7RKS_M,['SARS-COV-2'],Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycasgytgydyfvrgdyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,qpvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmklntdgshskgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgilvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvapt,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.",10.1016/j.celrep.2021.109760,"Chain I, C118 Antibody Fab Heavy Chain","Chain M, C118 Antibody Fab Light Chain",2022-10-12
525,5-7,5-7,7RW2_I,7RW2_K,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgvinpsggstsyaekfrgrvtmtrdtststvymelsslrsedtavyycardrephsdssgywdslkyyyyyaldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthhhhhhhh,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapelliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlntypftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain; bioRxiv (2021); 2021.",10.1101/2021.06.29.450397,"Chain I, 5-7 heavy chain","Chain K, 5-7 light chain",2022-10-12
528,AB1,AB1,7E3C_B,7E3C_C,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evllvesggglvqpggslrlscaasgltvssnymtwvrqapgkglewvsviysggstfyadsvkgrctisrhnskntlylqmnslraedtavyycardldyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqtgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppltfgggsrveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.",10.1038/s41421-021-00292-z,"Chain B, Heavy chain of Ab1","Chain C, Light chain of Ab1",2022-10-12
529,AB5,AB5,7E3B_B,7E3B_C,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycardrgyssgwtdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnipftfglgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.",10.1038/s41421-021-00292-z,"Chain B, Heavy Chain of Ab5","Chain C, Light Chain of Ab5",2022-10-12
530,AB4,AB4,7E39_C,7E39_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifssygmhwvrqapgkglewvaviwfdgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaretvsygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,niqmtqspsamsasvgdrvtitcrarqgisnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgseteftltisslqpedfatyyclqhnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.",10.1038/s41421-021-00292-z,"Chain C, Heavy Chain of Ab4","Chain B, Light Chain of Ab4",2022-10-12
531,S2X259,S2X259,7RAL_H,7RAL_L,unknown,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggifntytiswvrqapgqglewmgriilmsgmanyaqkiqgrvtitadkststaymeltslrsddtavyycargfngnyygwgdddafdiwgqgtlvtvys,qtvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapkllicgnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgpnwvfgggtkltvl,"Tortorici,M.A. et al.; Broad sarbecovirus neutralization by a human monoclonal antibody; Nature 597 (7874), 103-108 (2021); 2021.",10.1038/s41586-021-03817-4,"Chain H, S2X259 Fab heavy chain","Chain L, S2X259 Fab light chain",2022-10-12
535,C548,C548,7R8O_O,7R8O_P,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarreaygprdyyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsaltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadqgsgsnfvgvfgggtkltvgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain O, C548 Fab Heavy Chain","Chain P, C548 Fab Light Chain",2022-10-12
538,C051,C051,7R8N_O,7R8N_P,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqaggslrlscaasgfgvrnnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntvflqmnslraedtavyycaregdvegfsdlwsgysrdryyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqpasvsgspgqsitfsctgtssdvggynyvswyqqypgkapklliydvtnrpsgvsdrfsgsksgntasltisglqaedeadyycssftssntrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain O, C051 Fab Heavy Chain","Chain P, C051 Fab Light Chain",2022-10-12
541,C032,C032,7R8M_H,7R8M_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargvavdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain H, C032 Fab Heavy Chain","Chain L, C032 Fab Light Chain",2022-10-12
543,CR3022,CR3022,7R8L_C,7R8L_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain C, CR3022 Fab heavy chain","Chain D, CR3022 Fab light chain",2022-10-12
544,C099,C099,7R8L_H,7R8L_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsvmyaggstfyadsvkgrftisrddskntlflqmnslraedtaiyycardlyssggtdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,eivltqspgtlslspgeratlscrasqsigssylawyqqkpglaprlliygasrratgipdkfsgsgsgadftltisrlepedfavyycqqygsspgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrg,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain H, C099 Fab Heavy Chain","Chain L, C099 Fab Light Chain",2022-10-12
545,C098,C098,7N3I_H,7N3I_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlyssggtdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain H, C098 Fab heavy chain","Chain L, C098 Fab light chain",2022-10-12
546,C032,C032,7N3E_H,7N3E_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargvavdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain H, C032 Fab Heavy Chain","Chain L, C032 Fab Light Chain",2022-10-12
547,C099,C099,7N3H_H,7N3H_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsvmyaggstfyadsvkgrftisrddskntlflqmnslraedtaiyycardlyssggtdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtlslspgeratlscrasqsigssylawyqqkpglaprlliygasrratgipdkfsgsgsgadftltisrlepedfavyycqqygsspgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain H, C099 Fab Heavy Chain","Chain L, C099 Fab Light Chain",2022-10-12
549,C080,C080,7N3F_H,7N3F_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslnisckasgysftiywiawvrqlpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwrslkasdsavyycargvavdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsvltqppsvsgapgqrvtiscagsssnigagfdvywyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqssgsvlsdlyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain H, C080 Fab Heavy Chain","Chain L, C080 Fab Light Chain",2022-10-12
550,B1-182.1,B1-182.1,7MM0_H,7MM0_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggscfdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgfpdrfsgsgsgtdftltisrlepedfavyycqqygnspwtfgqgtkveirrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants; Science 373 (6556) (2021); 2021.",10.1126/science.abh1766,"Chain H, B1-182.1 Fab heavy chain","Chain L, B1-182.1 Fab light chain",2022-10-12
552,A23-58.1,A23-58.1,7LRT_D,7LRT_E,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsnvvcydgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygtspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants; Science 373 (6556) (2021); 2021.",10.1126/science.abh1766,"Chain D, antibody A23-58.1 heavy chain","Chain E, antibody A23-58.1 light chain",2022-10-12
556,REGN10985,REGN10985,7M42_D,7M42_C,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Copin,R. et al.; The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies; Cell 184 (15), 3949-3961 (2021); 2021.",10.1016/j.cell.2021.06.002,"Chain D, REGN10985 antibody Fab fragment heavy chain","Chain C, REGN10985 antibody Fab fragment light chain",2022-10-12
557,REGN10989,REGN10989,7M42_B,7M42_A,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Copin,R. et al.; The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies; Cell 184 (15), 3949-3961 (2021); 2021.",10.1016/j.cell.2021.06.002,"Chain B, REGN10989 antibody Fab fragment heavy chain","Chain A, REGN10989 antibody Fab fragment light chain",2022-10-12
558,S2D106,S2D106,7R7N_H,7R7N_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggpfsssaiswvrqapgqglewmggiipmvgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardsrycsggscysvwfdpwgqgtlvtvss,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkvliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvemk,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,"Chain H, S2D106 FAB heavy chain","Chain L, S2D106 FAB light chain",2022-10-12
559,S2E12,S2E12,7R6X_C,7R6X_D,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,"Chain C, Monoclonal antibody S2E12 Fab heavy chain","Chain D, Monoclonal antibody S2E12 Fab light chain",2022-10-12
560,S309,S309,7R6X_A,7R6X_B,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,"Chain A, Monoclonal antibody S309 Fab heavy chain","Chain B, Monoclonal antibody S309 Fab light chain",2022-10-12
561,S304,S304,7R6X_H,7R6X_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,"Chain H, Monoclonal antibody S304 Fab heavy chain","Chain L, Monoclonal antibody S304 Fab light chain",2022-10-12
562,S2X35,S2X35,7R6W_H,7R6W_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnygiswvrqapgqglewmgwisaykgntnyaqklqgrvtmttdtststaymelrslrsddtavyycarpdyqvlgydfwigyygmdvwgqgttvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsevvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,"Chain H, Heavy Chain of Fab domain of monoclonal antibody S2X35","Chain L, Light Chain of Fab domain of monoclonal antibody S2X35",2022-10-12
564,S2L20,S2L20,7N8I_H,7N8I_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfnsygmhwvrqapgkglewvafirydggnkyyadsvkgrftisrdnskntlylqmkslraedtavyycanlkdsrysgsyydywgqgtlvtvs,viwmtqspsslsasvgdrvtitcqasqdirfylnwyqqkpgkapkllisdasnmetgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpftfgpgtkvdf,"McCallum,M. et al.; SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern; Science 373 (6555), 648-654 (2021); 2021.",10.1126/science.abi7994,"Chain H, S2L20 Fab Heavy Chain Variable Region","Chain L, S2L20 Fab Light Chain Variable Region",2022-10-12
566,S2M11,S2M11,7N8H_M,7N8H_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpissgtsyaqtfqgrvtmtsdtsittaymelsrlrsddtavyycaraapfydfwsgysyfdywgqgtlvtv,ivmmqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssawtfgqgtkv,"McCallum,M. et al.; SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern; Science 373 (6555), 648-654 (2021); 2021.",10.1126/science.abi7994,"Chain M, S2M11 Fab Heavy Chain variable region","Chain L, S2M11 Fab Light Chain variable region",2022-10-12
571,COVOX-75,COVOX-75,7ORB_E,7ORB_F,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.",10.1016/j.cell.2021.06.020,"Chain E, COVOX-75 Fab heavy chain","Chain F, COVOX-75 Fab light chain",2022-10-12
572,COVOX-253,COVOX-253,7ORB_C,7ORB_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgegatlscrasqsvsssylawyqqkpgqaprlliygassgatgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.",10.1016/j.cell.2021.06.020,"Chain C, COVOX-253 Fab heavy chain","Chain D, COVOX-253 Fab light chain",2022-10-12
579,COVOX-278,COVOX-278,7OR9_H,7OR9_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifirygiswvrqapgqglewmgwisanngytnyaqklqgrvtmttdtststaymelrslrsddtavyycardggiltgyldyfdhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrltitcrasqsiasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyhcqqsystlgitfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.",10.1016/j.cell.2021.06.020,"Chain H, COVOX-278 Fab heavy chain","Chain L, COVOX-278 Fab light chain",2022-10-12
580,COVOX-222,COVOX-222,7OR9_A,7OR9_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslgaedtavyycargegspgnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,dvvmtqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqhydtsprfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.",10.1016/j.cell.2021.06.020,"Chain A, COVOX-222 Fab heavy chain","Chain B, COVOX-222 Fab light chain",2022-10-12
581,RBD-CHAB45,RBD-CHAB45,7EJ5_J,7EJ5_N,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Homo sapiens (human),evqlqqsgpelvkpgasvkiscktsgytfteytiywvkqslgkslewiggnnpnnddttykqffkgkatltvdkssstaymelrsltsedsavyycardgypyyyaldfwgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,divmtqsqkfmstsvgdrvsvtckssqnvgtnvawyqqkpgqspkaliysasyrysgvpdhftgsgsgtdftltisnvqsadlaeyfcqqynnypwtfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yang,T.J. et al.; Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-45; Unpublished; 2021.",NaN,"Chain J, RBD-chAb45, Heavy chain","Chain N, RBD-chAb45, Light chain",2022-10-12
584,RBD-CHAB-25,RBD-CHAB-25,7EJ4_J,7EJ4_N,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Homo sapiens (human),evqleesggglvkpggslklscaasgftfssytmswvrqspekrlewvaeissggtytnypdtatgrftisrdnakntlylemsslrsedtamyycanfgnyeeiaywgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,qivltqspaimsvslgervtmtctasssvsssylhwyqqkpgsspklwiystsnlasgvparfsgsgsgtsysltissmeaedaatyychqyhrspytfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yang,T.J. et al.; Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-25; Unpublished; 2021.",NaN,"Chain J, RBD-chAb-25, Heavy chain","Chain N, RBD-chAb-25, Light chain",2022-10-12
587,368-2,368-2,7E8F_C,7E8F_B,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqllesgggvvqpggslrlscaasgfafttyamnwvrqapgrglewvsaisdgggsayyadsvkgrftisrdnskntlylqmnslraedtavyycaktrgrglydyvwgskdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqsplslpvtpgepasiscrssqsllhsngylyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain C, 368-2 H","Chain B, 368-2 L",2022-10-12
588,N9,N9,7E8F_H,7E8F_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvkpggslrlscaaseftfssysmnwvrqapgkglewvssisssgsqiyyadsvkgrftisrdnakkslylqmnslrvedtavyycatnggahsstwsfygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvspgqtatitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltiggtqamdeaayfcqawdsntgvfgggtkltvlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain H, N9 H","Chain L, N9 L",2022-10-12
595,BD-515,BD-515,7E88_J,7E88_K,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtgvyycardrglvsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapkllifdashletgvpsrfsasgsgtdftftisslqpediatyychqydnlprtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain J, BD-515 Fab Heavy Chain","Chain K, BD-515 Fab Light Chain",2022-10-12
599,BD-508,BD-508,7E86_A,7E86_B,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlflqmnslraedtavyycardaqnygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkllifaasslqtgapsrfsgsgsgtdftltisslqpedfatyycqqsystppytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain A, BD-508 Fab Heavy Chain","Chain B, BD-508 Fab Light Chain",2022-10-12
600,BD-623,BD-623,7E7Y_C,7E7Y_D,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsavysggstyyadsvkgrftisrhnskntlylqmkslrpedtaiyycarlinhyydssgdggafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,ltqpasvsgspgqsitisctgtssdvgsynlvswyqqrpgkapklilyevtkrpsgvsnrfsgsksgntaslaisglqaedeadyyccsyagsstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvap,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain C, BD-623 Fab H","Chain D, BD-623 Fab L",2022-10-12
602,N11,N11,7E7X_M,7E7X_N,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqvvqsgaevkkpgasvkvsckvsgytlieisihwvrqapgkglewmggfdpeagetiyaqkfqgrvtmtedtstdtaymevsslrsedtavyycatgpaiaaaetnwfdlwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,qsaltqpasvsgspgqsitisctgtssdvgsynyvswyqqhpgkapklmiydvtkrpsgvpdrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshksyscqvthegstvektvaptecs,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain M, N11 Fab heavy chain","Chain N, N11 Fab Light chain",2022-10-12
604,HB27,HB27,7CYH_E,7CYH_D,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),vklvesggglvkpggslrlscaasgftftnygmswvrqapgkrlewvaeissggsytyypdtvtgrftisrdnakntlylqmnslraedtavyycarfryggggtvdywgqgtlvtvss,ivltqsptlslspgeratlscrasesvdnygisfmnwfqqkpgqaprlliyaasnqgsgipsrfsgsgsgtdfsltisslepedfavyfcqqskevprifgqgtkveilk,"Wang,X. et al.; Binding interface of SARS-CoV-2 RBD and its neutralizing antibody HB27; Unpublished; 2021.",NaN,"Chain E, Heavy chain of HB27","Chain D, Light chain of HB27",2022-10-12
605,B6,B6,7M55_H,7M55_L,['COVID'],Mus musculus (house mouse),evqlqqsgpvlvkpgasvrmsckasgytitdyylnwvkqshgkslewlgvlnpysggslysqtfkgkatltvdrssstaylelnsltsedsavyycarqlgrgngldywgqgtsvtvssvstkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,nimmtqspsslavsagekvtmsckssqsvlhssdqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvqaedlavyfchqylssytfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Sauer,M.M. et al.; Structural basis for broad coronavirus neutralization; Nat Struct Mol Biol 28 (6), 478-486 (2021); 2021.",10.1038/s41594-021-00596-4,"Chain H, B6 antigen binding fragment (Fab) heavy chain","Chain L, B6 antigen binding fragment (Fab) light chain",2022-10-12
609,3D11,3D11,7M7B_H,7M7B_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarrwwlrgafdiwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfllyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,nfmltqphsvsaspgktvtipctgssgniasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydnniqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Asarnow,D. et al.; Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia; Cell 184 (12), 3192-3204 (2021); 2021.",10.1016/j.cell.2021.04.033,"Chain H, Antibody Fab 3D11 heavy chain","Chain L, Antibody Fab 3D11 light chain",2022-10-12
610,5A6,5A6,7M71_H,7M71_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnaknslylqmnslraedtavyycarlitmvrgedywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsslsasvghrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsynlprtfgggtklevlgtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Asarnow,D. et al.; Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia; Cell 184 (12), 3192-3204 (2021); 2021.",10.1016/j.cell.2021.04.033,"Chain H, Antibody 5A6 Fab heavy chain","Chain L, Antibody 5A6 Fab light chain",2022-10-12
613,3D11,3D11,7KQE_I,7KQE_N,unknown,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarrwwlrgafdiwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfllyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,nfmltqphsvsaspgktvtipctgssgniasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydnniqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Goddard,T.D. et al.; UCSF ChimeraX: Meeting modern challenges in visualization and analysis; Protein Sci 27 (1), 14-25 (2018); 2021.",10.1002/pro.3235,"Chain I, Fab 3D11 heavy chain","Chain N, Fab 3D11 light chain",2022-10-12
616,47D11,47D11,7AKD_H,7AKD_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsggsisshywswirqppgkglewigyiyysgstnhnpslksrvtisvdtsknqfslklssvtaadtavyycargvllwfgepifeiwgqgtmvtvss,eivmtqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliygastrapgiparfsgsgsgteftltisslqsedfavyycqqynnwpltfgggtkvei,"Fedry,J. et al.; Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11; Sci Adv 7 (23) (2021); 2021.",10.1126/sciadv.abf5632,"Chain H, 47D11 neutralizing antibody heavy chain","Chain L, 47D11 neutralizing antibody light chain",2022-10-12
621,CV2-75,CV2-75,7M3I_H,7M3I_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),xvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgstnynpslksrvtisvdtsknefslklssvtaadtavyycassqrpdgnlyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,syvltqppsvsvapgqtaritcggnnigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Jennewein,M.F. et al.; Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects; Cell Rep 36 (2), 109353 (2021); 2021.",10.1016/j.celrep.2021.109353,"Chain H, CV2-75 Fab Heavy chain","Chain L, CV2-75 Fab Light chain",2022-10-12
623,47D1,47D1,7MF1_H,7MF1_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvrvsckasggtfstypiswvrqapgqglewmggiipifgtaksaqkfqgrvtitadeftstaymemsslrsedtamyycaregrrygsgwyistgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qlvltqpasvsgspgqsiivsctgtssdvggykfvswyqqhpgkaprvmiydvsnrpsgvsnrfsgsksgntasltisglqaddeadyycssytnsstvvfgggtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhou,X. et al.; Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2; Cell Rep 35 (6), 109109 (2021); 2021.",10.1016/j.celrep.2021.109109,"Chain H, 47D1 Fab heavy chain","Chain L, 47D1 Fab light chain",2022-10-12
624,S2H97,S2H97,7M7W_E,7M7W_F,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvrlvqsgaevkksgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistvylqwsslkasdtamyycarqwshytydyyywgqgtlvtissastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsvltqpasvsgspgqsitisctgissdvggynsvswyqqhpgkapklmiydvtnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstppyvfgtgtkvsvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Starr,T.N. et al.; Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape; bioRxiv (2021); 2021.",10.1101/2021.04.06.438709,"Chain E, Monoclonal antibody S2H97 Fab heavy chain","Chain F, Monoclonal antibody S2H97 Fab light chain",2022-10-12
625,S2X259,S2X259,7M7W_H,7M7W_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggifntytiswvrqapgqglewmgriilmsgmanyaqkiqgrvtitadkststaymeltslrsddtavyycargfngnyygwgdddafdiwgqgtlvtvysastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qtvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapkllicgnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgpnwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Starr,T.N. et al.; Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape; bioRxiv (2021); 2021.",10.1101/2021.04.06.438709,"Chain H, Monoclonal antibody S2X259 Fab heavy chain","Chain L, Monoclonal antibody S2X259 Fab light chain",2022-10-12
628,BG1-24,BG1-24,7M6I_M,7M6I_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriismfgiannaqkfqgrltitadtststaymelsslrsedtavyycargpyyydsggyyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,eivltqspgtlslspgeratlscrasqsvgsgylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyagsprtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,"Chain M, BG1-24 Fab Heavy Chain","Chain N, BG1-24 Fab Light Chain",2022-10-12
630,BG7-20,BG7-20,7M6H_E,7M6H_G,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkagasvkvsckasgytftsydinwvrqasgqglewmgwmnpisgntgyaqkfqgrvtmtrntsittaymelsslrsedtavyfcarggrycssttcysgvgmdvwgqgttvtvpsastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyhqlpgtapkfliygnsnrpsgvpdrfsgsksgtsaslaitrlqaedeadyycqsydsslsgwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,"Chain E, BG7-20 Fab Heavy Chain","Chain G, BG7-20 Fab Light Chain",2022-10-12
632,BG7-15,BG7-15,7M6G_R,7M6G_S,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyaiswvrqapgqglewmgwvsayngntnyaqklqgrvtmttdtstntaymelrslrsddtaiyycaipyssvtfdcwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,eivltqspgtlslspgeratlscrasqsvsgtflawyqqkpgqaprllisgassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,"Chain R, BG7-15 Fab Heavy Chain","Chain S, BG7-15 Fab Light Chain",2022-10-12
634,BG1-22,BG1-22,7M6F_H,7M6F_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscsvsgftvssnymnwvrqapgkglewvsviypggstfypdsvkgrftisrddskntlylqmnslrpedtaayycassrppigqlvpgldldwfdpwgqgtlvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagyyvhwyqqhpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,"Chain H, BG1-22 Fab Heavy Chain","Chain L, BG1-22 Fab Light Chain",2022-10-12
636,BG10-19,BG10-19,7M6E_H,7M6E_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgviypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycartqwgynygshffymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsasgtpgqrvtiscsgsssnigsdhvywyqqlpgtapklfiyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawdaslsgyvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,"Chain H, BG10-19 Fab Heavy Chain","Chain L, BG10-19 Fab Light Chain",2022-10-12
639,BG4-25,BG4-25,7M6D_H,7M6D_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvvrnymtwvrqapgkglewvsviysggttyyadsvkgrftisrdnskntmylqmnslraedtaiyycardlevvgamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,eivltqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygspmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,"Chain H, BG4-25 Fab Heavy Chain","Chain L, BG4-25 Fab Light Chain",2022-10-12
640,CR3022,CR3022,7M6D_A,7M6D_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,"Chain A, CR3022 Fab Heavy Chain","Chain B, CR3022 Fab Light Chain",2022-10-12
641,2-15,2-15,7L57_H,7L57_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vqlvqsgaevkkpgasvrvsckasgytftgyymhwvrqapgqglewmgwinpisdgtnyaqkfqgwvtmtrdtsistvymelsrlrsddtavyycarggsrcsggncygwaydafdiwgqgtmitv,saltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadcycssytssstfvfgtgtkvtvlg,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.",10.1016/j.celrep.2021.108950,"Chain H, Fab 2-15 variable domain heavy chain","Chain L, Fab 2-15 variable domain light chain",2022-10-12
642,H4,H4,7L58_H,7L58_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarvpycsstschrdwyfdlwgrgtlvt,diqmtqsplslpvtpgepasiscrssqslldsddgntyldwylqkpgqspqlliytlsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqriefpltfgggtkvei,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.",10.1016/j.celrep.2021.108950,"Chain H, Fab H4 variable domain heavy chain","Chain L, Fab H4 variable domain light chain",2022-10-12
643,2-43,2-43,7L56_J,7L56_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittaymelrrlrsddtavyycarglgvgcsggncyldyyymdvwgkgttvtvss,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedegdyycssytssstwvfgggtkltvl,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.",10.1016/j.celrep.2021.108950,"Chain J, Fab 2-43 variable domain heavy chain","Chain L, Fab 2-43 variable domain light chain",2022-10-12
646,2-17,2-17,7LQW_H,7LQW_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggnipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycargvgyrgviplnwfdpwgqgtvvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,eivmtqspatlsvspgeratlscrasqsvssdlawyqhkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppftfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,"Chain H, 2-17 Heavy Chain","Chain L, 2-17 Light Chain",2022-10-12
647,5-24,5-24,7L2F_I,7L2F_K,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgltfssyvmhwvrqapgkgldwvgviwydgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycardprdyydfwsgydyyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,eivltqspgilslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssgaltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,"Chain I, 5-24 heavy chain","Chain K, 5-24 light chain",2022-10-12
650,4-18,4-18,7L2E_I,7L2E_K,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkhyadsvkgrftisrdnskntlylqmnslraedtavyycakdsgynygyswfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,syeltqppsvsvspgqtaritcsadalakqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqstdnsgtypnwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,"Chain I, 4-18 heavy chain","Chain K, 4-18 light chain",2022-10-12
653,1-87,1-87,7L2D_H,7L2D_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgiavigpppstyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,"Chain H, 1-87 heavy chain","Chain L, 1-87 light chain",2022-10-12
654,2-51,2-51,7L2C_C,7L2C_D,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedvetiyaqqfqgrvtmtedtstdtaymelsslrsedtavyycatgwaykstwyfgywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsrmgfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,"Chain C, 2-51 heavy chain","Chain D, 2-51 light chain",2022-10-12
656,4-8,4-8,7LQV_Y,7LQV_Z,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkagssvkvsckasggtfsshtitwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaslqtvdtaiekyygmdvwgqgttvtvss,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Cerutti,G. et al.; Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite; Cell Host Microbe (2021); 2021.",NaN,"Chain Y, 4-8 Heavy Chain","Chain Z, 4-8 Light chain",2022-10-12
659,2-7,2-7,7LSS_H,7LSS_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahhkierifdywgqgtlvtvss,salaqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssyttsstvfgggtkltvl,"Cerutti,G. et al.; Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies; bioRxiv (2021); 2021.",10.1101/2021.02.21.432168,"Chain H, Fab 2-7 variable heavy chain","Chain L, Fab 2-7 variable light chain",2022-10-12
660,1-57,1-57,7LS9_E,7LS9_G,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evhlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddaknslylqmnslktedtavyycarvhrwaycingvcfgaysdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthhhhhhhh,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspstfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies; bioRxiv (2021); 2021.",10.1101/2021.02.21.432168,"Chain E, 1-57 Fab heavy chain","Chain G, 1-57 Fab light chain",2022-10-12
663,DH1041,DH1041,7LAA_H,7LAA_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtfssywmswvrqapgkglewvanirqdgsekysvdsvkgrftisrdnaknslylqmnslraedtavyycararradnsgyygfhfdcwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsdsksgtsaslaitrlqaedeadyycqsydsslsgwvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,"Chain H, DH1041 heavy chain","Chain L, DH1041 light chain",2022-10-12
664,DH1052,DH1052,7LAB_H,7LAB_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgatvkisckvsgytftdyymhwvqqapgkglewmglvdpedgetiyaekfqgrvtitadtstdtaymelsslrsedtavyycatssgpsrlcgggscyhsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve,ltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqg,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,"Chain H, DH1052 heavy chain","Chain L, DH1052 light chain",2022-10-12
667,DH1047,DH1047,7LD1_H,7LD1_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvqvscqasantftnhyihwvrqapgqglewmgiiyptggntiyaqgfqgrvtmtrdtslntiylelsslrsedtavyycardvrvddswsgydllsggtyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,divmtqspdslavslgeratincrssqsvlyssnnenylawyqqkpgqppklliywastresgipdrfsgsgsgtdftltisrlqaedvavyycqqyyslprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,"Chain H, DH1047 heavy chain","Chain L, DH1047 light chain",2022-10-12
670,DH1050.1,DH1050.1,7LCN_M,7LCN_S,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlpelsmhwvrqapgkglewmggfhpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgspfgvvtdwfdpwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnpyvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,"Chain M, DH1050.1 heavy chain","Chain S, DH1050.1 light chain",2022-10-12
673,CV05-163,CV05-163,7LOP_H,7LOP_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarevmvrgalppygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants; Science 373 (6556), 818-823 (2021); 2021.",10.1126/science.abh1139,"Chain H, CV05-163 Fab heavy chain","Chain L, CV05-163 Fab light chain",2022-10-12
677,MW06,MW06,7DPM_J,7DPM_K,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvsvisgsggstyyadsvrgrftisrdnskntlylqmnslraedtavyccakgyyydssgyyfredafdiwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsamsasvgdrvtitcrasqgisnylawfqqkpgkvpkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Jiang,W. et al.; Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV; MAbs 13 (1), 1953683 (2021); 2021.",10.1080/19420862.2021.1953683,"Chain J, heavy chain of MW06","Chain K, light chain of MW06",2022-10-12
681,15033-7,15033-7,7KML_J,7KML_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfdlggysmhwvrqapgkglewvagiyasggatayadsvkgrftisadtskntaylqmnslraedtavyycarsyyyggfgmdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcrasqsvssavawyqqkpgkapklliysasdlysgvpsrfsgsrsgtdftltisslqpedfatyycqqshtypitfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Miersch,S. et al.; Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations; bioRxiv (2020); 2021.",10.1101/2020.10.31.362848,"Chain J, Fab 15033-7 heavy chain","Chain N, Fab 15033-7 light chain",2022-10-12
688,CR3022-B6,CR3022-B6,7KZB_A,7KZB_B,"['COVID', 'SARS-COV-2', 'SARS-COV-1']",Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgshhhhhh,diqmtqspsslsasvgdrvtitcrasqsiysalnwyqqkpgkapklliyaasalqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtdihpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Rouet,R. et al.; Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies; MAbs 13 (1), 1922134 (2021); 2021.",10.1080/19420862.2021.1922134,"Chain A, Fab heavy chain of CR3022-B6 antibody","Chain B, Fab light chain of CR3022-B6 antibody",2022-10-12
689,CR3014-C8,CR3014-C8,7KZB_H,7KZB_L,"['COVID', 'SARS-COV-2', 'SARS-COV-1']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycargispfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgshhhhhh,diqmtqspsslsasvgdrvtitcrasqyiydslnwyqqkpgkapklliydssylqsgvpsrfsgsgsgtdftltisslqpedfatyycqqswdtpvtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Rouet,R. et al.; Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies; MAbs 13 (1), 1922134 (2021); 2021.",10.1080/19420862.2021.1922134,"Chain H, Fab heavy chain of CR3014-C8 antibody","Chain L, Fab light chain of CR3014-C8 antibody",2022-10-12
696,LY-COV481,LY-COV481,7KMI_A,7KMI_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycarevagtydywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpggtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.",10.1126/scitranslmed.abf1906,"Chain A, LY-CoV481 Fab heavy chain","Chain B, LY-CoV481 Fab light chain",2022-10-12
697,LY-COV488,LY-COV488,7KMH_A,7KMH_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarspyggnswgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.",10.1126/scitranslmed.abf1906,"Chain A, LY-CoV488 Fab heavy chain","Chain B, LY-CoV488 Fab light chain",2022-10-12
698,LY-COV555,LY-COV555,7KMG_D,7KMG_E,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycargyyearhyyyyyamdvwgqgtavtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,diqmtqspsslsasvgdrvtitcrasqsissylswyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltitslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.",10.1126/scitranslmed.abf1906,"Chain D, LY-CoV555 Fab heavy chain","Chain E, LY-CoV555 Fab light chain",2022-10-12
700,2G12,2G12,7L09_M,7L09_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkaggslilscgvsnfrisahtmnwvrrvpggglewvasistsstyrdyadavkgrftvsrddledfvylqmhkmrvedtaiyycarkgsdrlsdndpfdawgpgtvvtvspastkgpsvfplapsxxxxxxxxgtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,dvvmtqspstlsasvgdtititcrasqsietwlawyqqkpgkapklliykastlktgvpsrfsgsgsgteftltisglqfddfatyhcqhyagysatfgqgtrveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Acharya,P. et al.; A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies; bioRxiv (2020); 2020.",10.1101/2020.06.30.178897,"Chain M, 2G12 heavy chain","Chain L, 2G12 light chain",2022-10-12
708,NaN,NaN,7B3O_H,7B3O_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrddskntlylqmnslraedtavyycardvadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscaaahhhhhh,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglrspvtksfnrgec,"Bertoglio,F. et al.; A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations; Biorxiv (2020); 2020.",NaN,"Chain H, Heavy Chain of Fab Fragment","Chain L, Light Chain of Fab Fragment",2022-10-12
709,C1A-C2,C1A-C2,7KFX_H,7KFX_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscavsgftvsnnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsafvgdrvtitcrasegissylawyqqkpgnapklliyaastlesgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,"Chain H, heavy chain of human antibody C1A-C2 Fab","Chain L, light chain of human antibody C1A-C2 Fab",2022-10-12
710,C1A-B3,C1A-B3,7KFW_H,7KFW_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntvflqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,"Chain H, heavy chain of antibody C1A-B3 Fab","Chain L, light chain of antibody C1A-B3 Fab",2022-10-12
713,C1A-F10,C1A-F10,7KFY_H,7KFY_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlengvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,"Chain H, heavy chain of human antibody C1A-F10 Fab","Chain L, light chain of human antibody C1A-F10 Fab",2022-10-12
714,NaN,NaN,7CJF_A,7CJF_B,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsiiysggstfyadsvkgrftisrdnskntlylqmnslrvedtavyycardlqelgsldywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcp,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqeansfpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Guo,Y. et al.; A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes; Nat Commun 12 (1), 2623 (2021); 2020.",10.1038/s41467-021-22926-2,"Chain A, antibody heavy chain","Chain B, antibody light chain",2022-10-12
715,S2A4,S2A4,7JVC_F,7JVC_G,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslflqmnslraedtavyycarvwwlrgsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtc,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,"Chain F, S2A4 Fab heavy chain","Chain G, S2A4 Fab light chain",2022-10-12
718,S2H13,S2H13,7JV6_F,7JV6_G,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggdsvqpggslrlscaaagftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycalssgysgyagnywgqgtlvtvss,qavvtqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkhswtparfsgsllggkaaltlsgarpedeaeyycllsysgargvfgggtkltvl,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,"Chain F, S2H13 Fab heavy chain","Chain G, S2H13 Fab light chain",2022-10-12
721,S304,S304,7JX3_H,7JX3_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diemtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,"Chain H, Heavy chain of Fab domain of monoclonal antibody S304","Chain L, Light chain of Fab domain of monoclonal antibody S304",2022-10-12
722,S2H14,S2H14,7JX3_C,7JX3_D,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttgsetyyydssgpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,"Chain C, Heavy chain of Fab domain of monoclonal antibody S2H14","Chain D, Light chain of Fab domain of monoclonal antibody S2H14",2022-10-12
723,S309,S309,7JX3_A,7JX3_B,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,"Chain A, Heavy chain of Fab domain of monoclonal antibody S309","Chain B, Light chain of Fab domain of monoclonal antibody S309",2022-10-12
724,S304,S304,7JW0_G,7JW0_F,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),vqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diemtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,"Chain G, S304 Fab heavy chain","Chain F, S304 Fab light chain",2022-10-12
727,S2A4,S2A4,7JVA_H,7JVA_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslflqmnslraedtavyycarvwwlrgsfdywgqgtlvtvss,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhvvfgggtkltvl,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,"Chain H, S2A4 Fab heavy chain","Chain L, S2A4 Fab light chain",2022-10-12
732,S2X35,S2X35,7JXE_H,7JXE_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnygiswvrqapgqglewmgwisaykgntnyaqklqgrvtmttdtststaymelrslrsddtavyycarpdyqvlgydfwigyygmdvwgqgttvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsevvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.037,"Chain H, S2X35 antigen-binding (Fab) fragment","Chain L, S2X35 antigen-binding (Fab) fragment",2022-10-12
735,S2H14,S2H14,7JXC_H,7JXC_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttgsetyyydssgpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtc,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.037,"Chain H, S2H14 antigen-binding (Fab) fragment","Chain L, S2H14 antigen-binding (Fab) fragment",2022-10-12
736,C121,C121,7K8X_E,7K8X_G,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwispvsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaraplfptgvlagdyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstlvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.",10.1038/s41586-020-2852-1,"Chain E, C121 Fab Heavy chain","Chain G, C121 Fab Light chain",2022-10-12
738,C144,C144,7K90_O,7K90_P,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvsnnymswvrqapgkglewvsviysggstyyadsvkgrftisrdkskntlylqmnrlraedtavyycaregevegyndfwsgysrdryyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain O, C144 Fab Heavy Chain","Chain P, C144 Fab Light Chain",2022-10-12
741,C135,C135,7K8Z_M,7K8Z_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavipfdgrnkyyadsvtgrftisrdnskntlylqmnslraedtavyycasssgylfhsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsasvgdrvtitcrasqsisnwlawfqqkpgkapklliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain M, C135 Fab Heavy Chain","Chain N, C135 Fab Light Chain",2022-10-12
744,C119,C119,7K8W_N,7K8W_S,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqklqgrvtmtrdtststvymelsslrsedtavyycaranhettmdtyyyyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspgqsitisctgtssdvggykyvswyqrhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstsvvfgggtqltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain N, C119 Fab Heavy Chain","Chain S, C119 Fab Light Chain",2022-10-12
746,C110,C110,7K8V_M,7K8V_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaymqwsslkasdtamyycarsfrddpriavagpadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsasvgdrvtitcrasqsisywlawyqqkpgkapklliyqasslesgvpsrfsgsesgteftltisslqpddfatyycqqynsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain M, C110 Fab Heavy Chain","Chain N, C110 Fab Light Chain",2022-10-12
748,C104,C104,7K8U_H,7K8U_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlslscavyggslsgyywswirqppgkglewigeinhfgstgynpslksrvtisvdtsksqfsvklssvtaadtavyycarkpllysnlspgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtvslspgeratlscwasqsvsasylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygttprtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain H, C104 Fab Heavy Chain","Chain L, C104 Fab Light Chain",2022-10-12
749,C002,C002,7K8T_O,7K8T_P,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsiygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakegrpsdivvvvafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain O, C002 Fab Heavy Chain","Chain P, C002 Fab Light Chain",2022-10-12
755,C102,C102,7K8M_A,7K8M_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.",10.1038/s41586-020-2852-1,"Chain A, C102 Fab Heavy Chain","Chain B, C102 Fab Light Chain",2022-10-12
756,C135,C135,7K8R_H,7K8R_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavipfdgrnkyyadsvtgrftisrdnskntlylqmnslraedtavyycasssgylfhsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqmtqspstlsasvgdrvtitcrasqsisnwlawfqqkpgkapklliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.",10.1038/s41586-020-2852-1,"Chain H, C135 Fab Heavy Chain","Chain L, C135 Fab Light Chain",2022-10-12
758,C110,C110,7K8P_H,7K8P_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaymqwsslkasdtamyycarsfrddpriavagpadafdiwgqgtmvtvssastkgpsvfplapsskstsgptaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsasvgdrvtitcrasqsisywlawyqqkpgkapklliyqasslesgvpsrfsgsesgteftltisslqpddfatyycqqynsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain H, C110 Fab Heavy Chain","Chain L, C110 Fab Light Chain",2022-10-12
760,C102,C102,7K8N_A,7K8N_B,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapssksxxxxtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain A, C102 Fab Heavy Chain","Chain B, C102 Fab Light Chain",2022-10-12
761,S2E12,S2E12,7K4N_F,7K4N_G,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvss,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveik,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science 370 (6519), 950-957 (2020); 2020.",10.1126/science.abe3354,"Chain F, S2E12 neutralizing antibody Fab fragment (heavy chain)","Chain G, S2E12 neutralizing antibody Fab fragment (light chain)",2022-10-12
765,S2M11,S2M11,7K43_F,7K43_G,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpissgtsyaqtfqgrvtmtsdtsittaymelsrlrsddtavyycaraapfydfwsgysyfdywgqgtlvtvss,eivmmqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssawtfgqgtkveik,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science 370 (6519), 950-957 (2020); 2020.",10.1126/science.abe3354,"Chain F, S2M11 Fab fragment (heavy chain)","Chain G, S2M11 Fab fragment (light chain)",2022-10-12
768,S2E12,S2E12,7K3Q_H,7K3Q_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science (2020) In press; 2020.",10.1126/science.abe3354,"Chain H, Fab fragment of S2E12 monoclonal antibody, heavy chain","Chain L, Fab fragment of S2E12 monoclonal antibody, light chain",2022-10-12
769,CC12.3,CC12.3,6XC7_C,6XC7_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskstlylqmnslrvedtavyycardfgdfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; Structural basis of a public antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.06.08.141267,"Chain C, CC12.3 heavy chain","Chain D, CC12.3 light chain",2022-10-12
773,CC12.1,CC12.1,6XC2_X,6XC2_Y,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppkftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; Structural basis of a public antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.06.08.141267,"Chain X, CC12.1 heavy chain","Chain Y, CC12.1 light chain",2022-10-12
777,ITS90.03,ITS90.03,6TYB_H,6TYB_L,unknown,Macaca mulatta (Rhesus monkey),evqlvqsgtevkrpgesltiscktsgysfsgtwiswvrqmpgkglewmgsiypgdsdtryhpsfqghvtisadrsvsttylqwsslkasdtatyycarsyednygyydlffffdywgqgalvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkglevlfq,diqmtqspsslsasvgdrvtitcrasqgistylawyqqkpgkapklliykayllqngvpsrfsgggsgtdftltisslqpedfatyycqqhnnnpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Gorman,J. et al.; Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields; Immunity 51 (4), 724-734 (2019); 2019.",10.1016/j.immuni.2019.09.007,"Chain H, NEUTRALIZING ANTIBODY ITS90.03 FAB HEAVY CHAIN","Chain L, NEUTRALIZING ANTIBODY ITS90.03 FAB LIGHT CHAIN",2022-10-12
778,G2,G2,6PXH_H,6PXH_L,['MERS'],Mus musculus (house mouse),qvqlqqsggelvkpgasvklscktsgftfsssyiswlkqkpgqslewiawiyagtggteynqkftgkaqvtvdtssstaymqfsslttedsaiyycarggssfamdywgqgtsvtvssasttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgkglevlfq,qlvltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllihtasnqgsgvparfsgsgsgtdfslnihpvedddtamyfcqqseevpltfgagtkleikrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Wang,N. et al.; Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD; Cell Rep 28 (13), 3395-3405 (2019); 2019.",10.1016/j.celrep.2019.08.052,"Chain H, G2 heavy chain","Chain L, G2 light chain",2022-10-12
787,G4,G4,5W9O_H,5W9O_I,"['MERS', 'Spike protein']",Mus musculus (house mouse),qvqlqqsgpelvrpgvsvkisckgsgytftdyaihwvkqshakslewigvfstyygntnynqkfkgratmtvdkssstaymelarltsedsaiyycarksyyvdyvdamdywgqgtsvtvssasttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgkglevlfq,divltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllisatsnqgsgvparfigsgsgtdfslnihpveeddtamyfcqqskevprtfgggtkleikrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Pallesen,J. et al.; Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen; Proc Natl Acad Sci U S A 114 (35), E7348-E7357 (2017); 2017.",10.1073/pnas.1707304114,"Chain H, G4 VH","Chain I, G4 VL",2022-10-12
811,G4,G4,5VZR_A,5VZR_B,"['MERS', 'Spike protein']",Mus musculus (house mouse),xvqlqqsgpelvrpgvsvkisckgsgytftdyaihwvkqshakslewigvfstyygntnynqkfkgratmtvdkssstaymelarltsedsaiyycarksyyvdyvdamdywgqgtsvtvssasttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgkglevlfq,divltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllisatsnqgsgvparfigsgsgtdfslnihpveeddtamyfcqqskevprtfgggtkleikrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Pallesen,J. et al.; Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen; Proc Natl Acad Sci U S A 114 (35), E7348-E7357 (2017); 2017.",10.1073/pnas.1707304114,"Chain A, G4 antibody heavy chain","Chain B, G4 antibody light chain",2022-10-12
813,S3H3,S3H3,7WDF_F,7WDF_G,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),qvqlqqpgaelvrpgasvklsckasgysftrfwmnwvkqrpgqglewigmihpsdsetrlnqkfkdkatltvdkssttaymqlssptsedsavyycarkdydydawfaywgqgtlvtvsaakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkki,divltqspaslavslgqratiscrasksvsasvysymhwyqqkpgqppklliylasslesgvparfsgsgsgtdftlnihpveeedaatyychhsrelppafgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnr,"Xu,S. et al.; Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein; Emerg Microbes Infect 11 (1), 351-367 (2022); 2022.",10.1080/22221751.2021.2024455,"Chain F, Heavy chain of S3H3 Fab","Chain G, Light chain of S3H3 Fab",2022-10-12
819,S5D2,S5D2,7WD7_e,7WD7_f,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgqslewigginpniddttynqnfkdkatltvdkssstaymefrsltfddsavyycarddkasfafwgqgtlvtvsaakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkki,divmsqspsslavsdgervtltckssqsllystnqknylawyqqkpgqspklliywassresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypltfgagtklelradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrn,"Xu,S. et al.; Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein; Emerg Microbes Infect 11 (1), 351-367 (2022); 2022.",10.1080/22221751.2021.2024455,"Chain e, Heavy chain of S5D2 Fab","Chain f, Light chain of S5D2 Fab",2022-10-12
826,R40-1G8,R40-1G8,7SC1_P,7SC1_Q,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymrwvrqapgkglewvsliyaggstfyadsvkgrfiisrhnsknilylqmnslraedtavyfcardlyvfgmdvwgqgtavtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkth,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgrapklliyaastlqsgvpsrfsgsgsgtvftltisslqpedfatyycqqlnsdsstfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe 30 (1), 69-82 (2022); 2022.",10.1016/j.chom.2021.12.010,"Chain P, R40-1G8 Fab heavy chain","Chain Q, R40-1G8 Fab light chain",2022-10-12
829,COVOX-158,COVOX-158,7QNY_H,7QNY_L,unknown,Homo sapiens (human),evqllesggdliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiypggstfyadsvkgrftisrdnskntlylqmhslraedtavyycardlgsgdmdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliqaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyrytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.",10.1101/2021.12.03.471045,"Chain H, COVOX-158 heavy chain","Chain L, COVOX-158 light chain",2022-10-12
830,COVOX-58,COVOX-58,7QNY_A,7QNY_B,unknown,Homo sapiens (human),qvqlvesggglvqpgrslrlscaasgftfddyamhwvrqppgkglewvsgvswnsgtigyadsvkgrfiisrdnaknslylqmnslkaedtalyycarevggtfgvlisreggldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvapgqtaritcggntigsksvhwyqqrpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdrvvfgggtkltvlgqpkaaptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.",10.1101/2021.12.03.471045,"Chain A, COVOX-58 heavy chain","Chain B, COVOX-58 light chain",2022-10-12
831,BETA-55,BETA-55,7QNX_A,7QNX_B,unknown,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsisssryywgwirqppgkglewigtfyysgityynpslksrvtifvdtsknqfslklssvtaadtavyycarprppdyydnsgallfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspstlsasvgdrvtiacrasqsisawlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltinslqpddfatyycqqyissspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.",10.1101/2021.12.03.471045,"Chain A, Beta-55 heavy chain","Chain B, Beta-55 light chain",2022-10-12
832,EY6A,EY6A,7QNX_H,7QNX_L,unknown,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasaftfssydmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggklwvyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlaltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.",10.1101/2021.12.03.471045,"Chain H, EY6A heavy chain","Chain L, EY6A light chain",2022-10-12
835,C1C-A3,C1C-A3,7SN3_H,7SN3_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),mkrglccvlllcgavfvspsasqvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgtntyyadsvkgrftisrdnskntlylqmnslraedtavyycardlayrdyvwryfdlwgrgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,mkrglccvlllcgavfvspsaseivltqspatlslspgeratlscrasqsvstylawyqqkfgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqcrsnwppgitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nabel,K.G. et al.; Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain; Science 375 (6578), eabl6251 (2022); 2021.",10.1126/science.abl6251,"Chain H, neutralizing antibody C1C-A3 heavy chain variable region","Chain L, neutralizing antibody C1C-A3 light chain variable region",2022-10-12
840,AB1,AB1,7MJK_H,7MJK_I,"['COVID', 'SARS-COV-2', 'Spike protein']",synthetic construct,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsgqaghhhhhhgdykddddkg,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,"Chain H, Fab ab1 Heavy Chain","Chain I, Fab ab1 Light Chain",2022-10-12
846,CA521,CA521,7E23_B,7E23_C,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigevnhsgstnynpslksrvtisvdtsknqlslklnsvtaadtavyycargntmvrgviipfeywdkgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslg,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Song,D. et al.; Structure and function analysis of a potent human neutralizing antibody CA521(FALA) against SARS-CoV-2; Commun Biol 4 (1), 500 (2021); 2021.",10.1038/s42003-021-02029-w,"Chain B, CA521 Heavy Chain","Chain C, CA521 Light Chain",2022-10-12
847,P008_056,P008_056,7NTC_H,7NTC_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),mgwsciilflvatatgvhsevqlvesggglvkpggslrlscaasgfsfssysmnwvrqapgkglewvssissnsnyiyyadsmkgrftisrdnaknslylqmnslraedtavyycasnrspydssnyyfdywgqgtrvtissastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksgtkhhhhhh,mgwsciilflvatatgvhcairmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqhhdslpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Rosa,A. et al.; SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity; Sci Adv (2021) In press; 2021.",10.1126/sciadv.abg7607,"Chain H, P008_056 Fab Heavy chain","Chain L, P008_056 Fab Light chain",2022-10-12
848,S2M28,S2M28,7LY3_F,7LY3_E,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvtviwydgsnryyadsvkgrftisrdnskntlylqmdslraedtavyycaravagewyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,syeltqppsvsvspgqtaritcsgdalakhyaywyrqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsigsswvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvapte,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.",10.1016/j.cell.2021.03.028,"Chain F, S2M28 Fab Heavy Chain","Chain E, S2M28 Fab Light Chain",2022-10-12
850,S2M28,S2M28,7LY2_N,7LY2_O,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvtviwydgsnryyadsvkgrftisrdnskntlylqmdslraedtavyycaravagewyfdywgqgtlvtvs,yeltqppsvsvspgqtaritcsgdalakhyaywyrqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsigsswvfgggtkltv,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.",10.1016/j.cell.2021.03.028,"Chain N, S2M28 Fab Heavy Chain variable region","Chain O, S2M28 Fab Light Chain variable region",2022-10-12
857,S2L28,S2L28,7LXZ_N,7LXZ_O,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvnpggslrlscaasgftfsdytihwvrqapgkglewvssissssnyiyyadsvkgrftisrdnaknslslqmnslraedtavyycardgnaykwllaenvrfdywgqgtlvtvss,vtqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsdrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpnwvfgggtklt,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.",10.1016/j.cell.2021.03.028,"Chain N, S2L28 Fab Heavy Chain variable region","Chain O, S2L28 Fab Light Chain variable region",2022-10-12
863,S2X333,S2X333,7LXY_N,7LXY_O,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnsknslylqmnslraedtavyfcarafpdssswsgftidywgqgtlvtv,yeltqppsvstaritcggnnierksvhwcqqkpgqapalvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsgsdqvifgggtklt,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.",10.1016/j.cell.2021.03.028,"Chain N, S2X333 Fab Heavy Chain variable region","Chain O, S2X333 Fab Light Chain variable region",2022-10-12
883,DH1043,DH1043,7LJR_S,7LJR_T,"['COVID', 'SARS-COV-2']",Homo sapiens (human),mgwsciilflvatatgvhsqvqlvqsgaevkkpgssvkvsckasggtfsryainwvrqapgqglewmgriipifgianyaqkfqgkvtitadkststaymelsslrsedtavyycaradyyydssgyffdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvlhealhshytqkslslspgk,mgwsciilflvatatgvhseivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqtprlliygassratgiparfsgsgsgtnftltisrlepedfavyycqqysssrtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,"Chain S, Fab DH1043 heavy chain","Chain T, Fab DH1043 light chain",2022-10-12
884,CR3022,CR3022,6ZH9_HHH,6ZH9_LLL,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Homo sapiens (human),tqmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvastkgpsvfplapssggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Huo,J. et al.; Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2; Nat Struct Mol Biol 27 (9), 846-854 (2020); 2021.",10.1038/s41594-020-0469-6,"Chain HHH, CR3022 heavy","Chain LLL, CR3022 Light chain",2022-10-12
885,P5A-3C12,P5A-3C12,7D0D_G,7D0D_F,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahslfltvgyssswspfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystphtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain G, Heavy chain of P5A-3C12","Chain F, Light chain of P5A-3C12",2022-10-12
887,P5A-3A1,P5A-3A1,7D0C_G,7D0C_F,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardygdfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain G, Heavy chain of P5A-3A1","Chain F, Light chain of P5A-3A1",2022-10-12
890,COVOX-269,COVOX-269,7NEH_H,7NEH_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgltvnrnymswirqapgkglewvsviysggstfyadsvkgrftisrdnskntlslqmnslraedtaiyycardfyegsfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,aiqltqspsflsasigdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfasyycqqlnsypapvfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Supasa,P. et al.; Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera; Cell 184 (8), 2201-2211 (2021); 2021.",10.1016/j.cell.2021.02.033,"Chain H, COVOX-269 Fab heavy chain","Chain L, COVOX-269 fab light chain",2022-10-12
892,COVOX-159,COVOX-159,7NDD_H,7NDD_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),ilflvatatgvhsevqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvalisydggnryyadsvkgrftisrdnskntlylqmnrlraedtamyycakdrddgwdwyyfmdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspgtlslspgeratlscrasqsisgnylawyqhkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-159 Fab heavy chain","Chain L, COVOX-159 Fab light chain",2022-10-12
898,COVOX-253H165L,COVOX-253H165L,7NDB_H,7NDB_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),ilflvatatgvhsqvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygasrrgtgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-253H165L Fab heavy chain","Chain L, COVOX-253H165L Fab light chain",2022-10-12
899,COVOX-253H55L,COVOX-253H55L,7NDA_H,7NDA_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),ilflvatatgvhsqvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfgvyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-253H55L Fab heavy chain","Chain L, COVOX-253H55L Fab light chain",2022-10-12
901,COVOX-384,COVOX-384,7ND8_H,7ND8_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),ilflvatatgvhsevqlvesggglvkpgeslrlscaasgftfsdyymtwirqapgkglewvsyirssghtiyyadsvkgrftisrdnaknslylqmnslrvedtavyycarggvlrflewplnafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynnalgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-384 Fab heavy chain","Chain L, COVOX-384 Fab light chain",2022-10-12
902,COVOX-316,COVOX-316,7ND7_J,7ND7_K,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqkfqgrvtmtrdtsistaymelsrlrsddtavyscardmafsmvrgsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qavltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnhwvfgggtkltvlgqpkaaptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain J, COVOX-316 Fab heavy chain","Chain K, COVOX-316 Fab light chain",2022-10-12
905,COVOX-158,COVOX-158,7ND6_H,7ND6_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqllesggdliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiypggstfyadsvkgrftisrdnskntlylqmhslraedtavyycardlgsgdmdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliqaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyrytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-158 Fab heavy chain","Chain L, COVOX-158 Fab light chain",2022-10-12
906,COVOX-150,COVOX-150,7ND5_H,7ND5_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),ilflvatatgvhsqvqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiysggttyyadsvkgrftisrdssmntlylqmnslraedtavyycardlmvygidvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhseivmtqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqldsyppgytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-150 Fab heavy chain","Chain L, COVOX-150 Fab light chain",2022-10-12
907,COVOX-88,COVOX-88,7ND4_F,7ND4_G,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),ilflvatatgvhsqlqlqesgpglvkpsqtlsltctvsggsissgsynwtwirqpagkglewigriynsgstnynpslksrvtisvdtsknqlslkvrsvtaadtavyycarhcsggtcypkyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgswaqsaltqppsvseaprqrvtiscsgsssnignnavnwyqqfpgkapklliyyddllpsgvsdrfsgsksgtsaslaisgvqsedeadyycaawddslnvvvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain F, COVOX-88 Fab heavy chain","Chain G, COVOX-88 Fab light chain",2022-10-12
910,COVOX-40,COVOX-40,7ND3_H,7ND3_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),ilflvatatgvhsqvqlvesggglvqpggslrlscavsgftvsrnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlfhrsgyhdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsviwmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapkllifdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpafgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-40 heavy chain","Chain L, COVOX-40 light chain",2022-10-12
911,S309,S309,7BEP_G,7BEP_I,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain G, S309 heavy chain","Chain I, S309 light chain",2022-10-12
915,COVOX-75,COVOX-75,7BEO_E,7BEO_F,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),ilflvatatgvhsqvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain E, COVOX-75 heavy chain","Chain F, COVOX-75 light chain",2022-10-12
916,COVOX-253H55L,COVOX-253H55L,7BEO_C,7BEO_D,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfgvyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain C, COVOX-253H55L heavy chain","Chain D, COVOX-253H55L light chain",2022-10-12
919,COVOX-75,COVOX-75,7BEN_G,7BEN_I,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain G, COVOX-75 heavy chain","Chain I, COVOX-75 light chain",2022-10-12
920,COVOX-253,COVOX-253,7BEN_D,7BEN_F,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgegatlscrasqsvsssylawyqqkpgqaprlliygassgatgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain D, COVOX-253 heavy chain","Chain F, COVOX-253 light chain",2022-10-12
923,COVOX-269,COVOX-269,7BEM_H,7BEM_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgltvnrnymswirqapgkglewvsviysggstfyadsvkgrftisrdnskntlslqmnslraedtaiyycardfyegsfdiwgqgtmvtvssastggsggggsggggsgg,gasaiqltqspsflsasigdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfasyycqqlnsypapvfgpgtkvdikaaalvprgssawshpqfekggsgggsggsawshpqfek,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-269 Vh domain","Chain L, COVOX-269 Vl domain",2022-10-12
925,COVOX-45,COVOX-45,7BEL_C,7BEL_D,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavlsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggsyayyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftitslqpediatyycqqydnlpltfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain C, COVOX-45 heavy chain","Chain D, COVOX-45 light chain",2022-10-12
931,COVOX-316,COVOX-316,7BEH_H,7BEH_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),ilflvatatgvhsqvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqkfqgrvtmtrdtsistaymelsrlrsddtavyscardmafsmvrgsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsqavltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnhwvfgggtkltvlgqpkaaptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-316 heavy chain","Chain L, COVOX-316 light chain",2022-10-12
932,H014,H014,7CAC_E,7CAC_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleilkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsesvteqdskdstyslsstltlskadyekhkvyacevthqglsstksfnrgec,"Lv,Z. et al.; Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody; Science 369 (6510), 1505-1509 (2020); 2021.",10.1126/science.abc5881,"Chain E, Heavy chain of H014 Fab","Chain D, Light chain of H014 Fab",2022-10-12
938,H014,H014,7CAH_E,7CAH_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleil,"Lv,Z. et al.; Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody; Science 369 (6510), 1505-1509 (2020); 2020.",10.1126/science.abc5881,"Chain E, Heavy chain of H014 Fab","Chain D, Light chain of H014 Fab",2022-10-12
939,S304,S304,7L0N_M,7L0N_N,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Thomson,E.C. et al.; Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity; Cell 184 (5), 1171-1187 (2021); 2021.",10.1016/j.cell.2021.01.037,"Chain M, Monoclonal antibody S304 Fab heavy chain","Chain N, Monoclonal antibody S304 Fab light chain",2022-10-12
943,2-15,2-15,7L5B_H,7L5B_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgytftgyymhwvrqapgqglewmgwinpisdgtnyaqkfqgwvtmtrdtsistvymelsrlrsddtavyycarggsrcsggncygwaydafdiwgqgtmitvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadcycssytssstfvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Biorxiv (2021); 2021.",NaN,"Chain H, 2-15 Heavy chain","Chain L, 2-15 Light Chain",2022-10-12
944,910-30,910-30,7KS9_H,7KS9_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycariygdyawgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsrsgtdftftisslqpediatyychqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Banach,B.B. et al.; Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses; bioRxiv (2021); 2021.",10.1101/2020.12.31.424987,"Chain H, 910-30 Fab heavy chain","Chain L, 910-30 Fab light chain",2022-10-12
945,LY-COV555,LY-COV555,7L3N_D,7L3N_E,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycargyyearhyyyyyamdvwgqgtavtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhh,diqmtqspsslsasvgdrvtitcrasqsissylswyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltitslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection; bioRxiv (2020); 2021.",10.1101/2020.09.30.318972,"Chain D, LY-CoV555 Fab heavy chain","Chain E, LY-CoV555 Fab light chain",2022-10-12
946,P17,P17,7CWL_I,7CWL_K,['COVID'],Homo sapiens (human),qqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarhatlmnnkdiwgqgtlvtvssas,gdiqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res 31 (1), 25-36 (2021); 2021.",10.1038/s41422-020-00444-y,"Chain I, Fab P17 heavy chain","Chain K, Fab P17 light chain",2022-10-12
950,H014,H014,7CWN_O,7CWN_M,['COVID'],Homo sapiens (human),vqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvssastkgpsvfplapsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleilkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsesvteqdskdstyslsstltlskadyekhkvyacevthqglsstksfnr,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res (2020) In press; 2020.",10.1038/s41422-020-00444-y,"Chain O, heavy chain of H014 Fab","Chain M, light chain of H014 Fab",2022-10-12
951,P17,P17,7CWN_G,7CWN_F,['COVID'],Homo sapiens (human),qqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarhatlmnnkdiwgqgtlvtvssastkgpsvfplapsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,gdiqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsesvteqdskdstyslsstltlskadyekhkvyacevthqglsstksfnr,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res (2020) In press; 2020.",10.1038/s41422-020-00444-y,"Chain G, heavy chain of P17 Fab","Chain F, light chain of P17 Fab",2022-10-12
959,CC12.3,CC12.3,7KN7_H,7KN7_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskstlylqmnslrvedtavyycardfgdfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain H, CC12.3 Fab heavy chain","Chain L, CC12.3 Fab light chain",2022-10-12
961,NaN,NaN,7CM4_H,7CM4_L,unknown,Homo sapiens (human),qitlkesgptlvkptqtltltcsfsgfslstsgvgvgwirqppgkalewlalidwddnkyhttslktrltiskdtsknqvvltmtnmdpvdtatyycaripgflryrnryyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,elvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggteltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Kim,Y.G. et al.; to be publish; Unpublished; 2021.",NaN,"Chain H, IgG heavy chain","Chain L, IgG light chain",2022-10-12
962,2H2,2H2,7DK7_c,7DK7_d,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),qvqlkqsgpslvqpsqslsitctvsgfsltsygvhwvrqspgkglewlgvmwrggntdynaafmsrlsitkdnsksqvffkmnslqtddtaiyycaknggahamdfwgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkki,nivltqspaslavslgqratiscrasesvdsygnsflhwyqqkpgqppklliylasnlesgvparfsgsgsrtdftltidpveaddaatyycqqnnedpftfgsgtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.",10.1038/s41467-020-20465-w,"Chain c, The heavy chain fragment of 2H2 Fab","Chain d, The light chain fragment of 2H2 Fab",2022-10-12
971,3C1,3C1,7DD8_A,7DD8_B,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),evqlqesgpslvkpsqtlsltcsvtgdsitngywnwirkfpgnkleymgyisysgstyyspslksrisitrdtsknqhylqlnsvtsedtatyycasdyhgskyyfdywgqgttltvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcg,divmtqshkfmstsvghrvsitckasqdvgndvawyqqkpgqspklliywastrhtgvpdrftgsgsgtdftltisnvqsedladyfcqqynrypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.",10.1038/s41467-020-20465-w,"Chain A, The heavy chain of 3C1 fab","Chain B, The light chain of 3C1 chain",2022-10-12
974,3C1,3C1,7DCX_E,7DCX_H,"['COVID', 'SARS-COV-2', 'RBD']",Mus musculus (house mouse),evqlqesgpslvkpsqtlsltcsvtgdsitngywnwirkfpgnkleymgyisysgstyyspslksrisitrdtsknqhylqlnsvtsedtatyycasdyhgskyyfdywgqgttltvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcg,divmtqshkfmstsvghrvsitckasqdvgndvawyqqkpgqspklliywastrhtgvpdrftgsgsgtdftltisnvqsedladyfcqqynrypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.",10.1038/s41467-020-20465-w,"Chain E, The heavy chain of 3C1 fab that binds with the up RBD","Chain H, The light chain of 3C1 fab",2022-10-12
980,CV07-250,CV07-250,6XKQ_H,6XKQ_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqseaevkepgasvevsckasgynftnfaiswvrqapgqglewmgwisgyngdtnsaqkflgrvtmttdtstttaymelrslrsddtavyycagsdnygfpyngmdvwgqgttvtvfnqikppsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsaltqppsasgspgqsvtisctgtssdlgayhfvtwyqhypgkapkvmiygvrkrpsgvpdrfsgsksgntasltvsglqdedeadyycssyagnndfvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell(Cambridge,Mass.) (2020); 2020.",NaN,"Chain H, CV07-250 Heavy Chain","Chain L, CV07-250 Light Chain",2022-10-12
981,CV07-270,CV07-270,6XKP_M,6XKP_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymtwirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarargssgwyrigtrwgnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssnvvfgggtmltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell(Cambridge,Mass.) (2020); 2020.",NaN,"Chain M, CV07-270 Heavy Chain","Chain N, CV07-270 Light Chain",2022-10-12
983,BD-368-2,BD-368-2,7CHH_J,7CHH_K,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpggslrlscaasgfafttyamnwvrqapgrglewvsaisdgggsayyadsvkgrftisrdnskntlylqmnslraedtavyycaktrgrglydyvwgskdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.035,"Chain J, BD-368-2 Fab heavy chain","Chain K, BD-368-2 Fab light chain",2022-10-12
987,BD-604,BD-604,7CHF_H,7CHF_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdlytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.",10.1016/j.cell.2020.09.035,"Chain H, BD-604 Fab heavy chain","Chain L, BD-604 Fab light chain",2022-10-12
989,BD-236,BD-236,7CHE_H,7CHE_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstdyadsvkgrftisrdkskntlylqmnslraedtavyycardlgeaggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.",10.1016/j.cell.2020.09.035,"Chain H, BD-236 Fab heavy chain","Chain L, BD-236 Fab light chain",2022-10-12
991,BD-629,BD-629,7CHC_H,7CH5_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlnlqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqgvssflawyqqkpgqaprllihgassratgipdrfsgsgsgtdftltitrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.",10.1016/j.cell.2020.09.035,"Chain H, BD-629 Fab H","Chain L, BD-629 Fab L",2022-10-12
994,2-4,2-4,6XEY_J,6XEY_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqmfqgrvtmtrdtsistaymevsrlrsddtavyycardrswavvyyymdvwgkgttvtvss,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,"Liu,L. et al.; Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike; bioRxiv (2020); 2020.",10.1101/2020.06.17.153486,"Chain J, 2-4 Heavy Chain","Chain L, 2-4 Light Chain",2022-10-12
997,4A8,4A8,7C2L_J,7C2L_N,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetmyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatstavagtpdlfdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,eivmtqsplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfpytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Chi,X. et al.; A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2; Science 369 (6504), 650-655 (2020); 2020.",10.1126/science.abc6952,"Chain J, heavy chain of 4A8","Chain N, light chain of 4A8",2022-10-12
1000,C105,C105,6XCN_H,6XCN_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargegwelpydywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssxlyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqppsasgspgqsvtisctgtssdvggykyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyegsnnfvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies; Cell 182 (4), 828-842 (2020); 2020.",10.1016/j.cell.2020.06.025,"Chain H, C105 Fab Heavy Chain","Chain L, C105 Fab Light Chain",2022-10-12
1005,C105,C105,6XCA_H,6XCA_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargegwelpydywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqppsgsgspgqsvtisctgtssdvggykyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyegsnnfvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies; Cell 182 (4), 828-842 (2020); 2020.",10.1016/j.cell.2020.06.025,"Chain H, C105 Heavy Chain","Chain L, C105 Light Chain",2022-10-12
1006,REGN10987,REGN10987,6XDG_C,6XDG_A,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Hansen,J. et al.; Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail; Science 369 (6506), 1010-1014 (2020); 2020.",10.1126/science.abd0827,"Chain C, REGN10987 antibody Fab fragment heavy chain","Chain A, REGN10987 antibody Fab fragment light chain",2022-10-12
1007,REGN10933,REGN10933,6XDG_B,6XDG_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Hansen,J. et al.; Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail; Science 369 (6506), 1010-1014 (2020); 2020.",10.1126/science.abd0827,"Chain B, REGN10933 antibody Fab fragment heavy chain","Chain D, REGN10933 antibody Fab fragment light chain",2022-10-12
1008,AB23-FAB-HEAVY,AB23-FAB-LIGHT,7BYR_H,7BYR_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarpqggsswyrdyyygmdvwgqgttvtvss,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypytfgqgtkleik,"Cao,Y. et al.; Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells; Cell 182 (1), 73-84 (2020); 2020.",10.1016/j.cell.2020.05.025,"Chain H, Ab23-Fab-Heavy Chain","Chain L, Ab23-Fab-Light Chain",2022-10-12
1009,NaN,NaN,7BWJ_H,7BWJ_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslktrvtisvdtsknqfslklssvtaadtavyycaravvgivvvpaagrrafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Ju,B. et al.; Human neutralizing antibodies elicited by SARS-CoV-2 infection; Nature 584 (7819), 115-119 (2020); 2020.",10.1038/s41586-020-2380-z,"Chain H, antibody heavy chain","Chain L, antibody light chain",2022-10-12
1010,CB6,CB6,7C01_C,7C01_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsmntlflqmnslraedtavyycarvlpmygdyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkththhhhhh,divmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Shi,R. et al.; A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2; Nature 584 (7819), 120-124 (2020); 2020.",10.1038/s41586-020-2381-y,"Chain C, CB6 heavy chain","Chain D, CB6 light chain",2022-10-12
1012,S309,S309,6WPT_D,6WPT_E,unknown,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveik,"Pinto,D. et al.; Structural and functional analysis of a potent sarbecovirus neutralizing antibody; bioRxiv (2020); 2020.",10.1101/2020.04.07.023903,"Chain D, S309 neutralizing antibody heavy chain","Chain E, S309 neutralizing antibody light chain",2022-10-12
1017,S309,S309,6WS6_E,6WS6_F,unknown,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Pinto,D. et al.; Structural and functional analysis of a potent sarbecovirus neutralizing antibody; bioRxiv (2020); 2020.",10.1101/2020.04.07.023903,"Chain E, S309 antigen-binding (Fab) fragment, heavy chain","Chain F, S309 antigen-binding (Fab) fragment, light chain",2022-10-12
1020,B38,B38,7BZ5_H,7BZ5_L,['SARS-COV-2'],Homo sapiens (human),gdevqlvesggglvqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycareaygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,gddivmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Wu,Y. et al.; A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2; Science 368 (6496), 1274-1278 (2020); 2020.",10.1126/science.abc2241,"Chain H, Heavy chain of B38","Chain L, Light chain of B38",2022-10-12
1021,CR3022,CR3022,6W41_H,6W41_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV; Science 368 (6491), 630-633 (2020); 2020.",10.1126/science.abb7269,"Chain H, CR3022 Fab heavy chain","Chain L, CR3022 Fab light chain",2022-10-12
1022,7D10,7D10,6J11_F,6J11_G,"['MERS', 'Spike protein']",Mus musculus (house mouse),gggsgggsgggsevqlvesgaevvkpgasvkmsckasgypftsynihwikqtpgqglewigaiypgngdtsytqkfkvkatltsdkssstaymqlssltsedsavyfcarygnypsyamdywgqgtsvtvss,divmtqspasltvslgqratiscrasksvsasgynylhwyqqrpgqppklliylafnlesgvparfngsgsgtdftlnihpveeedaatyycqhsrdlpftfgsgtkleik,"Zhou,H. et al.; Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein; Nat Commun 10 (1), 3068 (2019); 2019.",10.1038/s41467-019-10897-4,"Chain F, VH of 7D10","Chain G, VL of 7D10",2022-10-12
1025,LCA60,LCA60,6NB4_H,6NB4_L,['COVID'],Homo sapiens (human),evqllesggglvkpggslrlsceasgltfsnvwmswvrqapgkglewvgrikrksegattdygapvkgrftlsrddskntvylqmnslkiddtavyycstltrggdvwsssyyfdywgqgalvtvss,qsaltqpasvsgspgqsitisctgtssdvgtydlvswyqqhpgkspklmiyadikrpsgvshrfsgsksgntasltisglqsadeadyycclyagsstsvifgggtkvt,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.",10.1016/j.cell.2018.12.028,"Chain H, LCA60 heavy chain","Chain L, LCA60 light chain",2022-10-12
1028,S230,S230,6NB7_H,6NB7_L,['COVID'],Homo sapiens (human),qaqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgttvavss,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveik,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.",10.1016/j.cell.2018.12.028,"Chain H, S230 heavy chain","Chain L, S230 light chain",2022-10-12
1033,S230,S230,6NB8_H,6NB8_L,['COVID'],Homo sapiens (human),qaqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgttvavssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.",10.1016/j.cell.2018.12.028,"Chain H, S230 antigen-binding (Fab) fragment, heavy chain","Chain L, S230 antigen-binding (Fab) fragment, light chain",2022-10-12
1034,LCA60,LCA60,6NB5_I,6NB5_M,['COVID'],Homo sapiens (human),evqllesggglvkpggslrlsceasgltfsnvwmswvrqapgkglewvgrikrksegattdygapvkgrftlsrddskntvylqmnslkiddtavyycstltrggdvwsssyyfdywgqgalvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qsaltqpasvsgspgqsitisctgtssdvgtydlvswyqqhpgkspklmiyadikrpsgvshrfsgsksgntasltisglqsadeadyycclyagsstsvifgggtkvtgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.",10.1016/j.cell.2018.12.028,"Chain I, LCA60 antigen-binding (Fab) fragment, heavy chain","Chain M, LCA60 antigen-binding (Fab) fragment, light chain",2022-10-12
1036,CDC2-C2,CDC2-C2,6C6Z_H,6C6Z_L,"['COVID', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsiyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycaregghqgycsggscydfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkglevlfq,dvvmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpafgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J. Virol. 92 (10), e02002-17 (2018); 2018.",10.1128/JVI.02002-17,"Chain H, Antibody CDC2-C2 heavy chain","Chain L, Antibody CDC2-C2 light chain",2022-10-12
1038,JC57-14,JC57-14,6C6Y_H,6C6Y_L,"['COVID', 'Spike protein']",Macaca mulatta (Rhesus monkey),qvqlqesgpglvkpsetlsltcavsgdsissnywswirqppgkglewigrfsgsggstdfnpslksrvtistdtsknqfslnlrsvtaadtavyycaktysgtfdywgqgvlvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveia,diqmtqspsslsasvgdrvtitcrasqdinnylswyqqkpgkapkpliyyassletgvpsrfsgsrsgtdytltisslqledfatyycqqynnspysfgqgtkveikrtvaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlssteyqshkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J Virol 92 (10), e02002-17 (2018); 2018.",10.1128/JVI.02002-17,"Chain H, JC57-14 Heavy chain","Chain L, JC57-14 Light chain",2022-10-12
1040,JC57-14,JC57-14,6C6X_H,6C6X_L,"['COVID', 'Spike protein']",Macaca mulatta (Rhesus monkey),qvqlqesgpglvkpsetlsltcavsgdsissnywswirqppgkglewigrfsgsggstdfnpslksrvtistdtsknqfslnlrsvtaadtavyycaktysgtfdywgqgvlvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgggsk,diqmtqspsslsasvgdrvtitcrasqdinnylswyqqkpgkapkpliyyassletgvpsrfsgsrsgtdytltisslqledfatyycqqynnspysfgqgtkveikrtvaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlssteyqshkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J Virol 92 (10), e02002-17 (2018); 2018.",10.1128/JVI.02002-17,"Chain H, JC57-14 Heavy chain","Chain L, JC57-14 Light chain",2022-10-12
1044,MCA1,MCA1,5GMQ_B,5GMQ_C,['COVID'],Homo sapiens (human),atrleesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaskqgdyydrtsyafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkts,dveltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Chen,Z. et al.; Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset; J. Infect. Dis. 215 (12), 1807-1815 (2017); 2017.",10.1093/infdis/jix209,"Chain B, MCA1 heavy chain","Chain C, MCA1 light chain",2022-10-12
1045,36D5,36D5,3JCB_C,3JCB_B,['Spike protein'],Homo sapiens (human),qvhlqesgpglvkpsetlsltcnvsgtlvrdnywswirqplgkqpewigyvhdsgdtnynpslksrvhlsldksknlvslrltgvtaadsaiyycattkhgrriygvvafkewftyfymdvwgkgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvep,tfvsvapgqtaritcgeeslgsrsviwyqqrpgqapsliiynnndrpsgipdrfsgspgstfgttatltitsveagdeadyychiwdsrrptnwvfgegttlivlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshksyscqvthegstvektvap,"Hu,G. et al.; Structure of Simian Immunodeficiency Virus Envelope Spikes Bound with CD4 and Monoclonal Antibody 36D5; J. Virol. 91 (16), e00134-17 (2017); 2017.",10.1128/JVI.00134-17,"Chain C, Antibody 36D5 heavy chain","Chain B, Antibody 36D5 light chain",2022-10-12
1046,4C2,4C2,5DO2_C,5DO2_D,"['MERS', 'Spike protein']",Mus musculus (house mouse),dvklvesggglvkpggslklscaasgftfssytmswvrqtpekrlewvatissggsytyypdsvkgrftisrdnakntlylqmsslksedtamyyctrdgndydywgqgttltvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcg,diqmtqttsslsaslgdrvtiscrasqdisnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgtdysltisnleqediatyfcqqgntlprtfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Li,Y. et al.; A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein; Cell Res. 25 (11), 1237-1249 (2015); 2015.",10.1038/cr.2015.113,"Chain C, 4C2 heavy chain","Chain D, 4C2 light chain",2022-10-12
1048,E16,E16,1ZTX_H,1ZTX_L,unknown,Mus musculus (house mouse),qvqlqqsgselmkpgasvqisckatgytfsdywiewvkqrpghglewigdilcgtgrtryneklkamatftadtssntafmqlssltsedsavyycarsasygdyadywghgttltvssakttppsvyplapgcgdttgssvtlgclvkgyfpesvtvtwnsgslsssvhtfpallqsglytmsssvtvpsstwpsqtvtcsvahpassttvdkkleps,divmtqshkfmstsvgdrvsitckasqdvstavawyqqkpgqspklliswastrhtgvpdrftgsgsgtdytltissvqaedlalyycqqhyttpltfgagtklelkradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrn,"Nybakken,G.E. et al.; Structural basis of West Nile virus neutralization by a therapeutic antibody; Nature 437 (7059), 764-769 (2005); 2005.",10.1038/nature03956,"Chain H, Heavy Chain of E16 Antibody","Chain L, Light Chain of E16 Antibody",2022-10-12
1049,H11B11-FAB,H11B11-FAB,7E7E_C,7E7E_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfidyymnwvrqapgkglewvgfirnkandytteystsvkgrftisrdnskntlylqmnslraedtavyycarhmyddgfdfwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveshhhhhhhh,diqmtqspsslsasvgdrvtitcrasssvrymhwyqqkpgkapklliydtsklasgvpsrfsgsgsgtdytltisslqpedfatyycqqwsynpltfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Du,Y. et al.; A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants; Nat Commun 12 (1), 5000 (2021); 2021.",10.1038/s41467-021-25331-x,"Chain C, h11B11-Fab","Chain D, h11B11-Fab",2022-10-12
1051,S-E6,S-E6,7KN4_M,7KN4_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlresgpglvkpsetlsltcavsggslssvnyywswirqhpgkglewigyiyysgstnynpslksrvtmsldtsknqfslklssvtaadtavyycatpgaimgalhiwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qavltqpssasstpgqrviiscsgsssnigsntvswyqqvpgaapklliyfdyrrpsgvpdrfsgtrsgtsaslgisglqsedeadyycaawddslsawvfgrgtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Qiang,M. et al.; Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago; Adv Sci (Weinh) 9 (1), e2102181 (2022); 2021.",10.1002/advs.202102181,"Chain M, S-E6 Fab heavy chain","Chain N, S-E6 Fab light chain",2022-10-12
1053,S-B8,S-B8,7KN3_M,7KN3_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggliqpggslrlscaasgftvslshmnwvrqapgkglewvsitygdgnsdyadsvkgrftisrdnskntlylqmnslraedtavyycareyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyslpltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Qiang,M. et al.; Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago; Adv Sci (Weinh) 9 (1), e2102181 (2022); 2021.",10.1002/advs.202102181,"Chain M, S-B8 Fab heavy chain","Chain N, S-B8 Fab light chain",2022-10-12
1055,RBD-CHAB15,RBD-CHAB15,7EH5_E,7EH5_Q,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Homo sapiens (human),evqleesgpglvqpsqslsitctvsdfslttygvhwvrqspgkglewlgviwsggstdynaafisrlsiskdnsksqvffkmnslqtndtaiyycarmgdgyyvgamdywgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,diqltqspailsvspgervsfscrasqsigtsihwyqqrtngsprhlikyasesisgipsrfsgsgsgtdftltingvesediadyycqqghnwpltfgagtklelkratvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yang,T.J. et al.; Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function; Nat Struct Mol Biol 28 (9), 731-739 (2021); 2021.",10.1038/s41594-021-00652-z,"Chain E, RBD-chAb15, heavy chain","Chain Q, RBD-chAb15, light chain",2022-10-12
1061,F26G19,F26G19,3BGF_B,3BGF_C,"['COVID', 'RBD']",Mus musculus (house mouse),evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiep,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrn,"Pak,J.E. et al.; Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain; J. Mol. Biol. 388 (4), 815-823 (2009); 2008.",10.1016/j.jmb.2009.03.042,"Chain B, F26G19 Fab","Chain C, F26G19 Fab",2022-10-12
1063,TN1,TN1,1V7N_K,1V7N_O,unknown,Mus musculus (house mouse),evkleesggglvqpggsmklscaasgftfsdawmdwvrqspekglewvaeirskvnnhaihyaesvkgrftvsrddskssvylqmnslraedtgiyycsgwsflywgqgtlvtvsaakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprd,qvvltqspgimsaspgekvtitcsasssvsymywfqqkpgtspklwiystsnlasgvparfrgsgsgtsysltisrmeaedaatyycqqrsgyprtfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Kuroki,R. et al.; Crystallization of the functional domain of human thrombopoietin using an antigen-binding fragment derived from neutralizing monoclonal antibody; Acta Crystallogr D Biol Crystallogr 58 (Pt 5), 856-858 (2002); 2004.",10.1107/s0907444902004791,"Chain K, Monoclonal TN1 Fab Heavy Chain","Chain O, Monoclonal TN1 Fab Light Chain",2022-10-12
1069,S8V2-18,S8V2-18,6XQ0_E,6XQ0_F,unknown,Homo sapiens (human),evqlvesggglvrpggsltltcagsgfmfrsydmhwvrqaagkglewvagmgkggetfyagsvkgrftisrenarnslylqmhslragdtavyycaraltewlfqrgtrnhyyygmdvwgqgttitvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,eivltqspgtlslspgeratlscrasqiidnkylawyqqkpgqaprlliygasnratgipdrfsgsgsgteftliisrlepedlavyycqqfgssvytfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCarthy,K.R. et al.; A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface; mBio 12 (3), e0114421 (2021); 2021.",10.1128/mBio.01144-21,"Chain E, antibody S8V2-18 heavy chain","Chain F, antibody S8V2-18 light chain",2022-10-12
1071,S1V2-83,S1V2-83,6XPZ_E,6XPZ_F,unknown,Homo sapiens (human),qvqlvesgggvvqpgrsvrltcagsgfsfsnfgmnwvrqapgkglewlaiisydgskkwyadsvkgrftisrddakntlflqmnsltaedtavyycskdrgdvwsgyyrggdyhyyfgmdvwgqgttvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,diqmtqspsslstsvgdrvtitcqasqdisnflnwyqqkpgkapelliydasylqggvpsrfsgsgsgtdfsftisslqpediatyycqqynslpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCarthy,K.R. et al.; A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface; mBio 12 (3), e0114421 (2021); 2021.",10.1128/mBio.01144-21,"Chain E, antibody S1V2-83 heavy chain","Chain F, antibody S1V2-83 light chain",2022-10-12
1073,S8V2-47,S8V2-47,6XQ4_E,6XQ4_F,unknown,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvsrnymswvrqapgkglewvsiiysgddtyyadsvkgrftisrdnskntlylemnslraedtavyycargemgdgyywapfdywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,divmtqspdslavslgeratinckssqsllyssrnknylawyqqkpgqppklliywastresgvpdrlsgsgsgtdftltisslqaedvavyycqqyysipltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCarthy,K.R. et al.; A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface; mBio 12 (3), e0114421 (2021); 2021.",10.1128/mBio.01144-21,"Chain E, antibody S8V2-47 heavy chain","Chain F, antibody S8V2-47 light chain",2022-10-12
1075,S8V2-37,S8V2-37,6XQ2_F,6XQ2_E,unknown,Homo sapiens (human),evqlvesggglvqpggslrlsceasgftfsnyemnwvrqapgkglewlsyirssgtvtsyadsvkgrftisrdnaknslylqmnslraedtavyycardlvytgsyygmdvwgqgtrvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,aiqltqspsslsasvgdrvtitcrtsqgistplawyqhkpgkspkllihdafslesgvpsrfsgsgsgtdfsltissvqpedfatyycqqfydypitfgqgtrleirrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCarthy,K.R. et al.; A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface; mBio 12 (3), e0114421 (2021); 2021.",10.1128/mBio.01144-21,"Chain F, antibody S8V2-37 heavy chain","Chain E, antibody S8V2-37 light chain",2022-10-12
1077,S1V2-51,S1V2-51,6XPX_B,6XPX_C,unknown,Homo sapiens (human),qvqlvesgggvvqpgrslrlscvasgftfrdsvmhwvrqapgkglewvavtsfdggesysadsvkgrftisrdnskstlslqmnilrpedtgvyycardrggldvwgqgttvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,divmtqspeslavslgeratinckssqsvsfgssdknylgwyqqkpgqppkllinwastresgvsdrfrgtgsgtdftltisslqaedaavyychqyytppysfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCarthy,K.R. et al.; A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface; mBio 12 (3), e0114421 (2021); 2021.",10.1128/mBio.01144-21,"Chain B, S1V2-51 Fab heavy chain","Chain C, S1V2-51 Fab light chain",2022-10-12
1078,D2,D2,6XPR_E,6XPR_F,unknown,Homo sapiens (human),qvqlvqsggglvrpggslrlscaasgftfssawmtwvrqapgkglewvanikedgsekyyvdsvkgrfsisrdnaknslylqisslraedtavyycarrfverlwgqskpydavdiwgqgtmvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyvasnlqsgvpsrfsgsgsgtdfaltisslqpedfasyycqqsyspvttfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCarthy,K.R. et al.; A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface; mBio 12 (3), e0114421 (2021); 2021.",10.1128/mBio.01144-21,"Chain E, antibody D2 H1-1/H3-1 H3 heavy chain","Chain F, antibody D2 H1-1/H3-1 H3 light chain",2022-10-12
1080,D1,D1,6XPQ_B,6XPQ_C,unknown,Homo sapiens (human),qvqlqesgpglvkpseslsltcsvsggsvssnlhywswirqlpgkglewigyisytgstkynpslngrvtlsidasknqfslelssvtaadtavyycardffekliaddlnafdiwgqgtmvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkgsslevlfqgplghhhhhh,dirvtqspsslsasvgdrvtitcrasqsisrslnwyqqrpgkapkfliyaasnlqsgvpsrfsgggsgtdftltisslqpedfatyycqetysrtfgqgtkadikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCarthy,K.R. et al.; A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface; mBio 12 (3), e0114421 (2021); 2021.",10.1128/mBio.01144-21,"Chain B, antibody D1 H1-17/H3-14 heavy chain","Chain C, antibody D1 H1-17/H3-14 light chain",2022-10-12
1081,CR3022,CR3022,7JN5_H,7JN5_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvvsrrlppsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Wu,N.C. et al.; A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody; PLoS Pathog 16 (12), e1009089 (2020); 2020.",10.1371/journal.ppat.1009089,"Chain H, CR3022 heavy chain","Chain L, CR3022 light chain",2022-10-12
1082,2G12,2G12,6OZC_K,6OZC_N,unknown,Homo sapiens (human),evqlvesggglvkaggslilscgvsnfrisahtmnwvrrvpggglewvasistsstyrdyadavkgrftvsrddledfvylqmhkmrvedtaiyycarkgsdrlsdndpfdawgpgtvvtvspastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,dvvmtqspstlsasvgdtititcrasqsietwlawyqqkpgkapklliykastlktgvpsrfsgsgsgteftltisglqfddfatyhcqhyagysatfgqgtrveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Seabright,G.E. et al.; Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions; Structure 28 (8), 897-909 (2020); 2020.",10.1016/j.str.2020.04.022,"Chain K, 2G12 Fab Heavy chain","Chain N, 2G12 Fab light chain",2022-10-12
1088,10-1074,10-1074,6CCB_H,6CCB_L,unknown,Homo sapiens (human),gqvqlqesgpglvkpsetlsvtcsvsgdsmnnyywtwirqspgkglewigyisdresatynpslnsrvvisrdtsknqlslklnsvtpadtavyycatarrgqriygvvsfgeffyyysmdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscd,gsyvrplsvalgetariscgrqalgsravqwyqhrpgqapilliynnqdrpsgiperfsgtpdinfgtratltisgveagdeadyychmwdsrsgfswsfggatrltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Moyo,T. et al.; Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11; J Virol 92 (14), e02261-17 (2018); 2018.",10.1128/JVI.02261-17,"Chain H, 10-1074 FAB heavy chain","Chain L, 10-1074 Fab light chain",2022-10-12
1090,8ANC195,8ANC195,5CJX_H,5CJX_L,unknown,Homo sapiens (human),qihlvqsgtevkkpgssvtvsckaygvntfglyavnwvrqapgqsleyigqiwrwkssashhfrgrvlisavdltgssppissleiknltsddtavyfctttstydrwsglhhdgvmafsswgqgtlisvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsastgdtvriscrasqsitgnwvawyqqrpgkaprlliyrgaallggvpsrfrgsaagtdftltignlqaedfgtfycqqydtypgtfgqgtkvevkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scharf,L. et al.; Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env; Cell 162 (6), 1379-1390 (2015); 2015.",10.1016/j.cell.2015.08.035,"Chain H, 8ANC195 G52K5 heavy chain, IG gamma-1 chain","Chain L, 8ANC195 G52K5 light chain",2022-10-12
1093,8ANC195,8ANC195,5A8H_R,5A8H_Q,unknown,Homo sapiens (human),qihlvqsgtevkkpgssvtvsckaygvntfglyavnwvrqapgqsleyigqiwrwkssashhfrgrvlisavdltgssppissleiknltsddtavyfctttstydkwsglhhdgvmafsswgqgtlisvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsasigdtvriscrasqsitgnwvawyqqrpgkaprlliyrgaallggvpsrfsgsaagtdftltignlqaedfgtfycqqydtypgtfgqgtkvevkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scharf,L. et al.; Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env; Cell 162 (6), 1379-1390 (2015); 2015.",10.1016/j.cell.2015.08.035,"Chain R, Fab Of Broadly Neutralizing Antibody 8anc195 Variant G52k5","Chain Q, Fab Of Broadly Neutralizing Antibody 8anc195 Variant G52k5",2022-10-12
1094,17B,17B,5A8H_P,5A8H_O,unknown,Homo sapiens (human),evqlvesgaevkkpgssvkvsckasgdtfirysftwvrqapgqglewmgriitildvahyaphlqgrvtitadkststvylelrnlrsddtavyfcagvyegeadegeydnngflkhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,divmtqspatlsvspgeratlscrasesvssdlawyqqkpgqaprlliygastratgvparfsgsgsgaeftltisslqsedfavyycqqynnwpprytfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrg,"Scharf,L. et al.; Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env; Cell 162 (6), 1379-1390 (2015); 2015.",10.1016/j.cell.2015.08.035,"Chain P, Fab Of Broadly Neutralizing Antibody 17b","Chain O, Fab Of Broadly Neutralizing Antibody 17b",2022-10-12
1105,35O22,35O22,4TVP_D,4TVP_E,unknown,Homo sapiens (human),qgqlvqsgaelkkpgasvkiscktsgyrfnfyhinwirqtagrgpewmgwispysgdknlapafqdrvimttdtevpvtsftstgaaymeirnlkfddtgtyfcakgllrdgsstwlpylwgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkglevlfq,qsvltqsasvsgslgqsvtisctgpnsvccshksiswyqwppgraptliiyednerapgisprfsgyksywsayltisdlrpedettyyccsythnsgcvfgtgtkvsvlgqskanpsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Pancera,M. et al.; Structure and immune recognition of trimeric pre-fusion HIV-1 Env; Nature 514 (7523), 455-461 (2014); 2014.",10.1038/nature13808,"Chain D, 35O22 Heavy chain","Chain E, 35O22 Light chain",2022-10-12
1106,PGT122,PGT122,4TVP_H,4TVP_L,unknown,Homo sapiens (human),qvhlqesgpglvkpsetlsltcnvsgtlvrdnywswirqplgkqpewigyvhdsgdtnynpslksrvhlsldksknlvslrltgvtaadsaiyycattkhgrriygvvafkewftyfymdvwgkgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,aptfvsvapgqtaritcgeeslgsrsviwyqqrpgqapsliiynnndrpsgipdrfsgspgstfgttatltitsveagdeadyychiwdsrrptnwvfgegttlivlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshksyscqvthegstvektvaptecs,"Pancera,M. et al.; Structure and immune recognition of trimeric pre-fusion HIV-1 Env; Nature 514 (7523), 455-461 (2014); 2014.",10.1038/nature13808,"Chain H, PGT122 Heavy chain","Chain L, PGT122 Light chain",2022-10-12
1107,NaN,NaN,4P9H_H,4P9H_L,['Spike protein'],Homo sapiens (human),qihlvqsgtevkkpgssvtvsckaygvntfglyavnwvrqapgqsleyigqiwrwkssashhfrgrvlisavdltgssppissleiknltsddtavyfctttstydkwsglhhdgvmafsswgqgtlisvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsasigdtvriscrasqsitgnwvawyqqrpgkaprlliyrgaallggvpsrfsgsaagtdftltignlqaedfgtfycqqydtypgtfgqgtkvevkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scharf,L. et al.; Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike; Cell Rep 7 (3), 785-795 (2014); 2014.",10.1016/j.celrep.2014.04.001,"Chain H, Fab heavy chain","Chain L, Fab light chain",2022-10-12
1108,NNHTN-GN2,NNHTN-GN2,7O9S_H,7O9S_L,unknown,Oryctolagus cuniculus (rabbit),tgqsleesggrlvtpgtpltltctvsgfslsnynmqwvrqapgkglewigivytggvawyarwakgrftisrtsttvdlkitspttedtatyfcaraytsnsdivfdpwgpgtlvtvssgqpkapsvfplapccgdtpsstvtlgclvkgylpepvtvtwnsgtltngvrtfpsvrqssglyslssvvsvtsssqpvtcnvahpatntkvdktvapstcsgtkhhhhhh,tgqvltqtpasvsaavggtvtikcqasqsvstalawyqqkpgqrpklliylastltsgvpsrfkgsgsgteftltisgvecddaatyycqqgysysnvdnsfgggtevvvkgdpvapsvlifppaadqvatgtvtivcvankyfpdvtvtwevdgttqttgiensktpqnsadctynlsstltltstqynshkeytckvtqgttsvvqsfnrgdc,"Rissanen,I. et al.; Structural Basis for a Neutralizing Antibody Response Elicited by a Recombinant Hantaan Virus Gn Immunogen; mBio 12 (4), e0253120 (2021); 2021.",10.1128/mBio.02531-20,"Chain H, Fab nnHTN-Gn2 Heavy chain","Chain L, Fab nnHTN-Gn2 Light chain",2022-10-12
1109,HTN-GN1,HTN-GN1,7NKS_H,7NKS_L,unknown,Oryctolagus cuniculus (rabbit),tgqslvesggdlvkpegsltltctasgfsfssthwicwvrqapgkglewiaciyvgntydsyyanwakgrftisktssttvtlqmttltaadtatyfcarsgsvfgvvslwgpgtlvtvssgqpkapsvfplapccgdtpsstvtlgclvkgylpepvtvtwnsgtltngvrtfpsvrqssglyslssvvsvtsssqpvtcnvahpatntkvdktvapstcsgtkhhhhhh,tgqvltqtpasvsepvegtvtikcqasqsinnwlswyqqrpgqppklliydastvasgvssrfkgsgsgteftltisdlecadaatyacqsygygisitdnsafgggtevvvrgdpvapsvlifppaadqvatgtvtivcvankyfpdvtvtwevdgttqttgiensktpqnsadctynlsstltltstqynshkeytckvtqgttsvvqsfnrgdc,"Rissanen,I. et al.; Structural Basis for a Neutralizing Antibody Response Elicited by a Recombinant Hantaan Virus Gn Immunogen; mBio 12 (4), e0253120 (2021); 2021.",10.1128/mBio.02531-20,"Chain H, Fab HTN-Gn1 heavy chain","Chain L, Fab HTN-Gn1 light chain",2022-10-12
1111,NaN,NaN,QXP08760,QXP08759,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesggglvqpggslrlscaasgftfidyymnwvrqapgkglewvgfirnkandytteystsvkgrftisrdnskntlylqmnslraedtavyycarhmyddgfdfwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapefeggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcrasssvrymhwyqqkpgkapklliydtsklasgvpsrfsgsgsgtdytltisslqpedfatyycqqwsynpltfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Shi,R. et al.; A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants; Unpublished; 2021.",NaN,"humanized ACE2-targeting immunoglobulin heavy chain, partial [synthetic construct]","humanized ACE2-targeting immunoglobulin light chain, partial [synthetic construct]",2022-10-12
1112,NaN,NaN,4JDT_H,4JDT_L,unknown,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargkyctardyynwdfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkth,eivltqspatlslspgetaiiscrtsqsgslawyqqrpgqaprlviysgstraagipdrfsgsrwgadynlsisnlesgdfgvyycqqyeffgqgtkvqvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scharf,L. et al.; Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody; Proc Natl Acad Sci U S A 110 (15), 6049-6054 (2013); 2013.",10.1073/pnas.1303682110,"Chain H, Fab heavy chain","Chain L, Fab light chain",2022-10-12
1113,NaN,NaN,QVL61760,QVL61759,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigevnhsgstnynpslksrvtisvdtsknqlslklnsvtaadtavyycargntmvrgviipfeywdkgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslg,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Song,D. et al.; Structure and function analysis of a potent human neutralizing antibody CA521LALA against SARS-CoV-2; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12
1114,1C4,1C4,6XGC_I,6XGC_J,unknown,Macaca fascicularis (crab-eating macaque),evqlvesggglakpggslrlscaasgftfstyamhwvrqapgkglewisginsgggstwytasvkgrftisrdnskstlslqmnslrtedtavyycakdggnaifglvitnygldswgqgavvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgggskppthhhhhh,qsvltqppsasgapgqsvtiscsgsssnfgsnhvywyqqlsgkapklliynnnrrpsgvpdrfsgsksgtsaslaisglqsedeadyycsvwdsslnnvlfgggtrltvlgqpkaapsvtlfppsseelqankatlvclisdfypgvvkvawkadgnsvntgvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvapaecs,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.",10.1126/scitranslmed.abe5449,"Chain I, 1C4 Fab heavy chain","Chain J, 1C4 Fab light chain",2022-10-12
1117,PGT128,PGT128,5ACO_I,5ACO_L,unknown,Homo sapiens (human),epqlqesgptlveasetlsltcavsgdstaacnsfwgwvrqppgkglewvgslshcasywnrgwtyhnpslksrltlaldtpknlvflklnsvtaadtatyycarfggevlrytdwpkpawvdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscd,esaltqppsasgspgqsitisctgtsnnfvswyqqhagkapklviydvnkrpsgvpdrfsgsksgntasltvsglqtddeavyycgslvgnwdvifgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Lee,J.H. et al.; Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron Microscopy; Structure 23 (10), 1943-1951 (2015); 2015.",10.1016/j.str.2015.07.020,"Chain I, PGT128 FAB","Chain L, PGT128 FAB",2022-10-12
1120,4G2,4G2,6Z06_H,6Z06_L,unknown,Myodes glareolus (Bank vole),tgqvqmkesggglvqpgkslklscaasgftfsdfwmswvrqpsgkglewvarintngdtthytddmkgrftisrdnakttlylemsplksedtamyyctrdrlgpfdywgqgttvtvssattkgpsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsqtvtcnvahpasstkvdkkivprdcggtkhhhhhh,tgdivmtqspafppvslgdtvtitcqasqsvyknlawyqqkpgksprllifgmssladgvpsrfsasgsdkqyslkirglqpedaaiyycqqhyiapytfgagtrleikrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Rissanen,I. et al.; Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein; Elife 9, e58242 (2020); 2020.",10.7554/eLife.58242,"Chain H, Fab 4G2 Heavy chain","Chain L, Fab 4G2 Light chain",2022-10-12
1121,C05,C05,6D0U_H,6D0U_I,unknown,Homo sapiens (human),qvqlqesggglvqpgeslrlscvgsgssfgestlsyyavswvrqapgkglewlsiinagggdidyadsvegrftisrdnsketlylqmtnlrvedtgvyycakhmsmqqvpsagweredlvgdafdvwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkschhhhhh,diqltqspsslsasvgdrvtltcqasqdirkflnwyqqkpgkgpklliydasnlqrgvpsrfsgggsgtdftliisslqpedvgtyycqqydglpftfgggtkvvikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Sevy,A.M. et al.; Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses; Proc. Natl. Acad. Sci. U.S.A. 116 (5), 1597-1602 (2019); 2019.",10.1073/pnas.1806004116,"Chain H, Antibody C05 V110P/A117E mutant, heavy chain","Chain I, Antibody C05, light chain",2022-10-12
1125,CL40,CL40,5W0K_E,5W0K_F,unknown,Mus musculus (house mouse),evklqqsgaelvmpgasvkmsckasgytftdywmhwvkqrpgqglewigaidtsdsytsynqkfkgkatltvdessstaymqlssltsedsavyycargllpfdywgqgttltvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprd,divmtqsqkfmstsvgdrvsvtckasqnvgtnvawyqqkpgqspkaliysasyrysgvpdrftgsgsgtdftltisnvqsedlakyfcqqynsypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrne,"Sathiyamoorthy,K. et al.; Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies; Proc. Natl. Acad. Sci. U.S.A. 114 (41), E8703-E8710 (2017); 2017.",10.1073/pnas.1704661114,"Chain E, CL40 IgG heavy chain","Chain F, CL40 IgG light chain",2022-10-12
1127,37.7H,37.7H,5VK2_H,5VK2_L,unknown,Homo sapiens (human),devqlvqsggglvkaggslrlscaasgftfstysmnwirqapgkglewvasissrsgshinyvdsvkgrftisrdnardllylqmnslrvddsalyycardrrsgtsplpldvwgqgttvtvfsastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,dqsaltqpasvsgspgqsitisctgtgsdiggynfvswyqqypgkapkliiyevrirasgvsnrfsgsksgntasltisglqaedeadyycnsysihspwvfgggtkltvlrqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Hastie,K.M. et al.; Structural basis for antibody-mediated neutralization of Lassa virus; Science 356 (6341), 923-928 (2017); 2017.",10.1126/science.aam7260,"Chain H, Fab 37.7H heavy chain","Chain L, Fab 37.7H light chain",2022-10-12
1130,D12,D12,4ZPV_A,4ZPV_B,['MERS'],Mus musculus (house mouse),evklvesggglvkpggslklscaasgftfssyamswvrqtpekrlewvatissggtytyypdsvkgrftisrdnaentlylqmsslrsedtamyycvrdgnsmdywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiepr,diqmtqttsslsaslgdrvtiicrasqdinnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgsdysltisnleqediatyfcqqantlpptfgagtklelrradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Wang,L. et al.; Evaluation of candidate vaccine approaches for MERS-CoV; Nat Commun 6, 7712 (2015); 2015.",10.1038/ncomms8712,"Chain A, D12 Fab Heavy chain","Chain B, D12 Fab light chain",2022-10-12
1134,M336,M336,4XAK_D,4XAK_E,['MERS'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtasyaqkfqgrvtitadkststaymelsslrsedtavyycarvgycsstscnrgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsgqaghhhhhhgdykddddkg,diqltqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Ying,T. et al.; Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody; Nat Commun 6, 8223 (2015); 2015.",10.1038/ncomms9223,"Chain D, Heavy chain of neutralizing antibody m336","Chain E, Light chain of neutralizing antibody m336",2022-10-12
1136,1AF10,1AF10,4F2M_C,4F2M_D,['COVID'],Mus musculus (house mouse),qvqlqqsgpelvkpgasvkisckasgyafssswmnwvkqrpgqglewigriypgdgetnysekfkgkatltadkssstaymhlssltsvdsavyfcarggyrydpyyamdywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiep,dilltqspailsvspgervslscrasqsigtsihwyqqrtngsprplikyasesisgipsrfsgsgsgtdftlninsvesediadyfcqqtdswpttfgagtklelkradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Reguera,J. et al.; Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies; PLoS Pathog. 8 (8), E1002859 (2012); 2012.",10.1371/journal.ppat.1002859,"Chain C, monoclonal antibody 1AF10, heavy chain","Chain D, monoclonal antibody 1AF10, light chain",2022-10-12
1138,CHK-265,CHK-265,6W1C_L,6W1C_P,unknown,Homo sapiens (human),qiqlvqsgrevknpgetvkisckasgytfteypmlwvkqapgkgfrwmgliytntgeptyaeefkgrfvfsleisastaylqinnltnedtatyfcvrdyfisldywgqgttltvssakttapsvyplapvcggttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpallqsglytlsssvtvtsntwpsqtitcnvahpasstkvdkkiesrr,qavvtqesalttspgetvtltcrsnigavtssncanwvqekpdhfftgligdtnnrrsgvparfsgsligdkaaltitgaqtedeaiyfcalwynnlwvfgggtkltvlgqpksspsvtlfppsseeletnkatlvctitdfypgvvtvdwkvdgtpvtqgmettqpskqsnnkymassyltltarawerhssyscqvtheghtvekslsr,"Powell,L.A. et al.; Human mAbs Broadly Protect against Arthritogenic Alphaviruses by Recognizing Conserved Elements of the Mxra8 Receptor-Binding Site; Cell Host Microbe (2020) In press; 2020.",10.1016/j.chom.2020.07.008,"Chain L, Fab CHK-265 heavy chain","Chain P, Fab CHK-265 light chain",2022-10-12
1150,441D6,441D6,5TR8_H,5TR8_L,unknown,Mus musculus (house mouse),evqlvesggglmrpggslklscaasgfafsrfdmswvrqtpekrlewvayirngaddtyyadtekgrftisrdnakntlylqlsslkiedtamyycvrhsgysyvidywgqgtsvtvssasttapsvyplapvcggttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpallqsglytlsssvtvtsntwpsqtitcnvahpasstkvdkkieprvp,dikmtqspssmyaslgervtftckasqdiyssfswfqqrpgkspktliyranrlvdgvpsrfsgsgsgqdysltissleyedmgvyfclqheefpptfgggtklelkrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrn,"Kanekiyo,M. et al.; Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses; Nat. Immunol. 20 (3), 362-372 (2019); 2018.",10.1038/s41590-018-0305-x,"Chain H, 441D6 Fab Heavy chain","Chain L, 441D6 Fab Light chain",2022-10-12
1151,NaN,NaN,4UOM_H,4UOM_L,unknown,Homo sapiens (human),evqlqqsgpelvkpgasvkisckasgytftdyyinwmkqkpgqglewigriypgygntkyndkfkgkatltedtssntaymqlnsltsedtavyfcarsltffdvwgagttvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprd,phsasgppdqtvtiscsgsssniegntvnwyqqfpgkapqlliygkdqrpsgvpdrfsasksgtsasltisglqaedeadyycaawddslngwvfgggtkltvlgaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnr,"Porta,J. et al.; Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies; J. Virol. 88 (17), 9616-9623 (2014); 2014.",10.1128/JVI.01286-14,"Chain H, Fab Fragment Heavy Chain","Chain L, Fab Fragment Light Chain",2022-10-12
1152,S/RBD,S/RBD,QOQ45101,QOQ45102,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",synthetic construct,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,W. et al.; Phage display library derived human Fab against SARS-CoV-2 spike protein receptor binding domain; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 S/RBD immunoglobulin heavy chain, partial [synthetic construct]","anti-SARS-CoV-2 S/RBD immunoglobulin light chain, partial [synthetic construct]",2022-10-12
1153,NaN,NaN,AAC53258,AAC53259,['COVID'],Mus musculus (house mouse),mkcswvifflmavviginsevqlqqsgaelvrsgasvklsctasgfnikdyymhwvkqrpeqglewigwidpengyteyapkfqgkatvtadtssntaylqlssltsedtavyycnafyyrydafdywgqgttltvss,mesqiqvfvfvflwlsgvdgdivmtqshkfmstsvgdrvsitckasqdvstavawyqqkpgqspklliysasyrytgvpvrftgsgsgtdftftissvqaedlavyycqqhystpytfgggtkleik,"Castilla,J. et al.; Interference of coronavirus infection by expression of immunoglobulin G (IgG) or IgA virus-neutralizing antibodies; J. Virol. 71 (7), 5251-5258 (1997); 1997.",NaN,"monoclonal antibody gamma one chain variable region, partial [Mus musculus]","monoclonal antibody kappa chain variable region, partial [Mus musculus]",2022-10-12
1154,NaN,NaN,7XCP_H,7XCP_L,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhao,Z. et al.; Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape; Nat Commun 13 (1), 4958 (2022); 2022.",10.1038/s41467-022-32665-7,"Chain H, Heavy chain of 304 Fab","Chain L, Lignt chain of 304 Fab",2022-10-12
1155,NaN,NaN,7V5J_I,7V5J_H,['MERS'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsiyaiswvrqapgqglewmggiipifgtanyaqqfqgrvtitadestttaymelsrltsedtavyycarqmtaydywnpsfdywgqgtlvtvssawstkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrv,divmtqtpsslsasvgdrvtitcraseditsylnwyqlkpgkapmfliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrg,"Wang,X. et al.; MERS S ectodomain trimer in complex with neutralizing antibody 0722(state 2); Unpublished; 2022.",NaN,"Chain I, H","Chain H, L",2022-10-12
1158,NaN,NaN,7V6N_I,7V6N_H,['MERS'],Homo sapiens (human),evqlvesgggvvqpgrslrlscaasaftfsnygmhwvrqapgkglewvaviwsagslkyyadsvkgrfiisrdnskntlylqmdslrpedtavyycarenttyyyetsgswgasyyfdfwgqgtlvtvssstkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrv,diqmtqtpaslsasvgdrvtitcrasqnissylnwyqqkpgkapkvliydtsrlqsgvpsrfsgsasgtdftltisslqpedfatyycqqscttlrcwtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,X. et al.; MERS S ectodomain trimer in complex with neutralizing antibody 111 state1; Unpublished; 2022.",NaN,"Chain I, H","Chain H, L",2022-10-12
1164,NaN,NaN,7V3L_H,7V3L_I,['MERS'],Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfssyaicwvrqapgqglewmggiipffgtvnyaqkfqgrvtitadeststvymelsslrsedtavyycansycsstncyryyqngldvwgqgttvtvssawstkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrv,airmtqspvtlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykastlqsgvpsrfsgsgsgteftltisslqpddfatyycqqydnysqltfgpgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,X. et al.; MERS S ectodomain trimer in complex with neutralizing antibody 6516; Unpublished; 2022.",NaN,"Chain H, antibody H","Chain I, antibody L",2022-10-12
1167,002-S21F2,002_S21F2,7U0P_D,7U0P_F,['COVID'],Homo sapiens (human),evqlvqsgaevkkpgeslkisckasgynfayywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargemtavfgdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftltisslqpediatyycqqykilltwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Patel,A. et al.; SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-S21F2; Unpublished; 2022.",NaN,"Chain D, mAb 002-S21F2 Heavy chain","Chain F, mAb 002_S21F2 light chain",2022-10-12
1169,VACW-209,C335_LIGHT_IGLV1-40_IGLJ3,7WON_H,7WP0_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssiamhwvrqapgkglewvavmsfdgsikyygdsvkgrftisrdnskstlylqmnslraedtavyycargvqgyydrsgyynldynygmdvwgqgttvtvss,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Ju,B. et al.; Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209; Cell Res. 32, 491 (2022); 2022.",NaN,"Chain H, VacW-209 heavy chain","Chain L, IG c335_light_IGLV1-40_IGLJ3",2022-10-12
1170,XMA09,C1437_LIGHT_IGLV1-40_IGLJ1,7WI0_H,7WI0_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssfaiswvrqapgqglewmggiipiygtanyaqkfqgrvtitadeststaymdlsslrsedtavyycardgsstyyphnwfdpwgqgtlvtvss,qsvltqppsvsgapgqrvtisctgsssnigsgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgvfgtgtkvtvl,"Wang,S. et al.; Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron; Cell Rep 39 (8), 110862 (2022); 2022.",10.1016/j.celrep.2022.110862,"Chain H, XMA09 heavy chain variable domain","Chain L, IG c1437_light_IGLV1-40_IGLJ1",2022-10-12
1171,XMA01,C934_LIGHT_IGKV1-5_IGKJ1,7WI0_C,7WI0_E,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvssissnggstyyadsvkgrftisrdnskntlylqmsslrvedaavyycvkhyqqqllwggpdvwgqgttvtvss,diqmtqspvslsasvgdrvtitcrasqsistwlawyqqkpgkapklliyetsslesgvpsrfsgsgsgteftltisslqpddfatyycqqfnsypwtfgqgtkveik,"Wang,S. et al.; Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron; Cell Rep 39 (8), 110862 (2022); 2022.",10.1016/j.celrep.2022.110862,"Chain C, XMA01 heavy chain variable domain","Chain E, IG c934_light_IGKV1-5_IGKJ1",2022-10-12
1172,XMA04,C4029_LIGHT_IGKV1-39_IGKJ2,7WI0_B,7WI0_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfrtyamhwvrqapgkglewvavmwndgsnkyyadsvkgrftisrdnskntlylemnslraedtavyycaregvaaagsssdafdiwgqgtmvtvss,diqmtqspsslsasvgdrvtitcrasqsisnflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlysfgqgtkleik,"Wang,S. et al.; Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron; Cell Rep 39 (8), 110862 (2022); 2022.",10.1016/j.celrep.2022.110862,"Chain B, XMA04 heavy chain variable domain","Chain D, IGL c4029_light_IGKV1-39_IGKJ2",2022-10-12
1176,NaN,NaN,7WE8_H,7WE8_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltcnfsgfslntygvgvgwirqppgkalewlaliywdgderygpffknkvtiakdtsknqvvltmtnmdpvdtatyycarhliptifdywgqgtlvtvss,saltqpasvsgspgqsitisctgtssdvggsnyvswyqhhpdrapklliyevtnrpsgvsnrfsgsksantasltisglqaedeadyycssytttsthilfgggtkltv,"Wang,K. et al.; Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants; Nature 603 (7903), 919-925 (2022); 2022.",10.1038/s41586-022-04466-x,"Chain H, Heavy chain of Fab 265","Chain L, Light chain of Fab 265",2022-10-12
1177,NaN,NaN,7WE7_K,7WE7_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vqlvqsgaevkkpgssvkvsckasgdtfssytfswvrqapgqglewmgrsipivgkaiyaqefqgrvtisadrstttvymelsslrsddtavyycardqsgfdffyydhwgqgtlvav,qsvltqppsasgtpgqrvtiscsgsgsnigsntinwyqqlpgtapkvliyrnnerpsgvpdrfsgsksgtsasltisglqsedeayyhcaawddslngpvfgggtkltvlg,"Wang,K. et al.; Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants; Nature 603 (7903), 919-925 (2022); 2022.",10.1038/s41586-022-04466-x,"Chain K, Heavy chain of Fab 282","Chain N, The light chain of Fab 282",2022-10-12
1180,NaN,NaN,7MW5_D,7MW5_E,"['COVID', 'SARS-COV-2']",Homo sapiens (human),mgwnwifililsvttgvhsevqlqqsgpelvkpgasvkisckasgysftgysmnwmkqspekslewigeinpstggttdnqkfkakatltvdkssstaymqlksltsedsavyycarsrgdywgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,mesdtlllwvlllwvpgstgdivltqspaslavslgqratiscrasesveyygtslmqwyqqkpgqppkvliyaasnvesgvparfsgsgsgtdfslnihpveeddiamyfcqqsrkvpwtfgggtkleikradaaptvsifppsseqltsggasvvcftvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgea,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,"Chain D, Fab of antibody clone 2, heavy chain","Chain E, Fab of antibody clone 2, light chain",2022-10-12
1183,ANTI-H5N1,8D3,7W9E_D,7W9E_E,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgkslewigginpnigdtsynqnfkgkatltvdrssstaymelrsltsedsavyycardgypyyyaldhwgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgckpcictvpevssvfifppkpkdvltitltpkvtcvvvdiskddpevqfswfvddvevhtaqtqpreeqfnstfrsvselpimhqdwlngkefkcrvnsaafpapiektisktkgrpkapqvytipppkeqmakdkvsltcmitdffpeditvewqwngqpaenykntqpimdtdgsyfvysklnvqksnweagntftcsvlheglhnhhtekslshspgk,divmtqsqkfmstsvgdrvsvtckasqnvgtnvawyqqkpgqspkaliystsyrysgvpdrftgsgsgtdftltisnvqsedlaeyfcqqynsypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Wang,Y. et al.; Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies; Nat Commun 13 (1), 871 (2022); 2022.",10.1038/s41467-022-28528-w,"Chain D, Anti-H5N1 hemagglutinin monoclonal anitbody H5M9 heavy chain","Chain E, The light chain of 8D3 fab",2022-10-12
1184,NaN,812L,7EZV_H,7EZV_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),mgwslillflvavatrvlsevqlvqsgaevkkpgeslkiscqfseyklisfwiawvrqrpgkglewmgiiypddsdtkyspssqgqvtisadksirtaylqwsslmasdtamyyctsgsyygtldfwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,mgwsciilflvatatgvhsdieitqspsslsasvgdrvtiscrasqdirtyvawyqqrpgkvprlliyaastlqsgvpsrfsgrgsgtdftltisslqpedvatyycqqynsapltfgggakveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain H, H","Chain L, 812L",2022-10-12
1185,NaN,NaN,7PHG_H,7PHG_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqqfqervtitrdmststaymelsslgsedtavyycaapncsggscydgfdlwgqgtmvtvss,eivltqspgtlslspgeratlscrgsqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Fenwick,C. et al.; A highly potent antibody effective against SARS-CoV-2 variants of concern; Cell Rep 37 (2), 109814 (2021); 2021.",10.1016/j.celrep.2021.109814,"Chain H, Heavy ChaIn variable","Chain L, Light ChaIn",2022-10-12
1186,NaN,NaN,7RR0_B,7RR0_C,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgsgnanyaprfqervtitrdmstntaymelsslrsedtavyycaapncsrtlcydgfnmwgqgtmvtv,eivltqspgslslspgeratlscrasqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsetdftltisrlepedfavyycqqydsspwtfgqgtkvei,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain B, PDI 222 Fab Heavy Chain","Chain C, PDI 222 Fab Light Chain",2022-10-12
1187,NaN,NaN,7MZN_H,7MZN_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesgggliqpggslrlscvasgltvssnymnwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslraedtavyycarvggycssancvsdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapkimiydasiletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtqleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, PDI 231 heavy chain","Chain L, PDI 231 light chain",2022-10-12
1188,NaN,NaN,7E8F_D,7E8F_E,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdkskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsdlytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain D, H","Chain E, L",2022-10-12
1189,NaN,NaN,7E8C_O,7E8C_Q,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdkskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscd,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsdlytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain O, H","Chain Q, L",2022-10-12
1192,NaN,NaN,7DZY_O,7DZY_P,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvaninqdggekyyvdsvrgrftisrdnaknslylqmnslraedtavyycardpydlygdyggtfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtdftltisslqsedfalyycqqynnwwrtfgqgtkveinrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.",10.1016/j.cell.2021.05.032,"Chain O, Fab Heavy chain of enhancing antibody 2490","Chain P, Fab light chain of enhancing antibody 2490",2022-10-12
1195,NaN,NaN,7DZX_H,7DZX_L,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvaninqdgsekyyvdsvkgrftisrdnaknslylqvnslraedtavyycardwdydiltgswfgafdiwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.",10.1016/j.cell.2021.05.032,"Chain H, Fab Heavy chain of enhancing antibody","Chain L, Fab light chain of enhancing antibody",2022-10-12
1196,NaN,NaN,7KLG_I,7KLG_M,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfdlggysmhwvrqapgkglewvagiyasggatayadsvkgrftisadtskntaylqmnslraedtavyycarsyyyggfgmdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcrasqsvssavawyqqkpgkapklliysasdlysgvpsrfsgsrsgtdftltisslqpedfatyycqqsyrypitfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Miersch,S. et al.; Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations; bioRxiv (2020); 2021.",10.1101/2020.10.31.362848,"Chain I, Fab 15033 heavy chain","Chain M, Fab 15033 light chain",2022-10-12
1198,NaN,NaN,5YY5_C,5YY5_D,"['MERS', 'Spike protein']",Homo sapiens (human),gvqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyyctntyywgqgtlvt,ltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqlt,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.",10.1016/j.celrep.2018.06.041,"Chain C, Heavy chain","Chain D, Light chain",2022-10-12
1199,NaN,NaN,5YY5_H,5YY5_L,"['MERS', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyyctntyywgqgtlvtvs,gsqpvltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqltvl,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.",10.1016/j.celrep.2018.06.041,"Chain H, Heavy chain","Chain L, Light chain",2022-10-12
1200,4-61CHAIN,C2312_LIGHT_IGLV2-14_IGLJ2IGL@,7D03_H,7D03_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsvssgsyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarercyygsgraprcvwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain H, Immunoglobulin heavy variable 4-61,chain H of FabP5A-2G7,Epididymis luminal protein 214","Chain L, IGL c2312_light_IGLV2-14_IGLJ2,IGL@ protein",2022-10-12
1201,C642_HEAVY_IGHV3-53_IGHD1-26_IGHJ6CHAIN,C4203_LIGHT_IGKV1-9_IGKJ4UNCHARACTERIZED,7D00_J,7D00_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaretlafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, IG c642_heavy_IGHV3-53_IGHD1-26_IGHJ6,chain H of FabP5A-1B8,IGH@ protein","Chain N, IGL c4203_light_IGKV1-9_IGKJ4,Uncharacterized protein",2022-10-12
1203,1-8IMMUNOGLOBULIN,C168_LIGHT_IGKV4-1_IGKJ4IMMUNOGLOBULIN,7CZZ_J,7CZZ_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycaryivvvpaakgfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, Immunoglobulin heavy variable 1-8,Immunoglobulin heavy variable 1-8,chain H of P5A-2F11_3B,Epididymis luminal protein 214,Epididymis luminal protein 214","Chain N, IG c168_light_IGKV4-1_IGKJ4,Immunoglobulin kappa constant",2022-10-12
1210,3-30-3CHAIN,1-33UNCHARACTERIZED,7CZV_J,7CZV_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgqaitmvqgvigppfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, Immunoglobulin heavy variable 3-30-3,chain H of P5A-1B6_3B,Immunoglobulin gamma-1 heavy chain","Chain N, Immunoglobulin kappa variable 1-33,Uncharacterized protein",2022-10-12
1213,3-30-3IMMUNOGLOBULIN,1-33IMMUNOGLOBULIN,7CZU_H,7CZU_K,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgqaitmvqgvigppfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain H, Immunoglobulin heavy variable 3-30-3,Immunoglobulin heavy variable 3-30-3,Chain H of P5A-1B6_2B,Immunoglobulin gamma-1 heavy chain,Immunoglobulin gamma-1 heavy chain","Chain K, Immunoglobulin kappa variable 1-33,Immunoglobulin kappa variable 1-33,Uncharacterized protein",2022-10-12
1215,3-33CHAINH,C689_LIGHT_IGLV5-37_IGLJ3IGL@,7CZT_I,7CZT_M,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarwfhtggyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,qpvltqppsssaspgesarltctlpsdinvssyniywyqqkpgsppryllyyysdsdkgqgsgvpsrfsgskdasantgillisglqsedeadyycmiwpsnalyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain I, Immunoglobulin heavy variable 3-33,chainH of P5A-2G9,Immunoglobulin gamma-1 heavy chain","Chain M, IG c689_light_IGLV5-37_IGLJ3,IGL@ protein",2022-10-12
1217,C542_HEAVY_IGHV3-53_IGHD3-10_IGHJ6IGH@,C4203_LIGHT_IGKV1-9_IGKJ4UNCHARACTERIZED,7CZS_J,7CZS_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaretlafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, IG c542_heavy_IGHV3-53_IGHD3-10_IGHJ6,IGH@ protein","Chain N, IGL c4203_light_IGKV1-9_IGKJ4,Uncharacterized protein",2022-10-12
1220,C542_HEAVY_IGHV3-53_IGHD3-10_IGHJ6IGH@,C4203_LIGHT_IGKV1-9_IGKJ4IGL,7CZR_J,7CZR_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaretlafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, IG c542_heavy_IGHV3-53_IGHD3-10_IGHJ6,IGH@ protein","Chain N, IGL c4203_light_IGKV1-9_IGKJ4,IGL c4203_light_IGKV1-9_IGKJ4,Uncharacterized protein",2022-10-12
1222,C642_HEAVY_IGHV3-53_IGHD1-26_IGHJ6CHAIN,1-33UNCHARACTERIZED,7CZQ_J,7CZQ_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaregpksitgtafdiwgqgtivtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqdisnyfnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, IG c642_heavy_IGHV3-53_IGHD1-26_IGHJ6,Chain H of P2B-1A10,Immunoglobulin gamma-1 heavy chain","Chain N, Immunoglobulin kappa variable 1-33,Uncharacterized protein",2022-10-12
1224,4-59CHAIN,C181_LIGHT_IGLV2-14_IGLJ3IGL@,7CZP_J,7CZP_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtskkqfslklssvtaadtavyycarlerdwpldafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapkfmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytsnntfafgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, Immunoglobulin heavy variable 4-59,Chain H of P2B-1A1,Anti-RhD monoclonal T125 gamma1 heavy chain","Chain N, IG c181_light_IGLV2-14_IGLJ3,IGL@ protein",2022-10-12
1226,NaN,NaN,6XPY_B,6XPY_C,unknown,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggslsiyywswvrqspgkglewigyisnsgsptyhpslksrvtisldtsksqfslkltsvtaadtalyfcargvleqlapdfdsyyygmnvwgqgttvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,diqmtqspssvsaslgdrvtltcrasqpirsylnwyqhkpglapkllvyavsnlqsgvpsrfsgsgsgtdftltvsslqpedfatyycqqsystpytfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCarthy,K.R. et al.; A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface; mBio 12 (3), e0114421 (2021); 2021.",10.1128/mBio.01144-21,"Chain B, Fab heavy chain","Chain C, Fab light chain",2022-10-12
1227,NaN,NaN,6WZT_G,6WZT_F,unknown,Macaca fascicularis (crab-eating macaque),qvqlqesgpglvkpsetlsltcavsggtfsayywgwirqppgkglewigsisggsgstdyspslksratisrdtsknqfslkltsvtaadtavyycvrkywgdyyanwfdvwgpgvlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgggskppt,diqmtqspsslsasvgdtvtitcrasqsisswlawyqqkpgkapklliykasslqggvpsrfsgsgsgsdftltisslqsedfatyycqqysgrpptfgqgtkveikravaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlsstdyqshnvyacevthqglsspvtksfnrgec,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.",10.1126/scitranslmed.abe5449,"Chain G, Cyno antibody heavy chain","Chain F, Cyno antibody light chain",2022-10-12
1230,NaN,NaN,5ZXV_C,NaN,"['MERS', 'Spike protein']",Homo sapiens (human),gvqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyycagndywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,NaN,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.",10.1016/j.celrep.2018.06.041,"Chain C, heavy chain",NaN,2022-10-12
1232,4-59CHAIN,NaN,7CZX_J,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyisysgstnynpslksrvtisldtsknqfslklssvtaadtavyycasngqyydiltgqppdywyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, Immunoglobulin heavy variable 4-59,chain H of P5A-1B9,IGH@ protein",NaN,2022-10-12
1235,NaN,NaN,NaN,7WCD_B,NaN,NaN,NaN,saltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstphvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvapt,NaN,NaN,NaN,"Chain B, Light chain",2022-10-12
1238,NaN,NaN,NaN,7TTX_L,NaN,NaN,NaN,nfmltqphsmsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssswvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,NaN,NaN,NaN,"Chain L, light chain",2022-10-12
1239,NaN,NaN,NaN,7TTY_L,NaN,NaN,NaN,nfmltqphsmsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssswvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvapt,NaN,NaN,NaN,"Chain L, light chain",2022-10-12
1240,NaN,NaN,NaN,6YOR_C,NaN,NaN,NaN,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,NaN,NaN,NaN,"Chain C, IgG L chain",2022-10-12
1242,NaN,NaN,NaN,7MW4_G,NaN,NaN,NaN,mekdtlllwvlllwvpgstgdivltqspaslavslgqratiscrasesvdnygisfmnwfqqtpgqppklliygssnqgsgvparfsgsgsgtdfslnihpmeeddtamyfcqqskevpytfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgea,NaN,NaN,NaN,"Chain G, Fab of antibody clone 6, light chain",2022-10-12
1251,NaN,NaN,NaN,7MZL_L,NaN,NaN,NaN,esvltqspvslslspgeratlscrasqsvgtylawyqhrpgqaprlliynaskratgiparfsgsgsgtdftltisslepedlavyfcqqrsnwltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,NaN,NaN,NaN,"Chain L, PDI 210 light chain",2022-10-12
1252,NaN,NaN,NaN,7K9Z_A,NaN,NaN,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,NaN,NaN,NaN,"Chain A, Fab Light Chain",2022-10-12
1253,NaN,NaN,NaN,7K9Z_L,NaN,NaN,NaN,sdiqmtqspsslsasvgdrvtitcrasqgisnnlnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqgngfpltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,NaN,NaN,NaN,"Chain L, Fab Light Chain",2022-10-12
1254,NaN,C168_LIGHT_IGKV4-1_IGKJ4UNCHARACTERIZED,NaN,7CZX_N,NaN,NaN,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,NaN,NaN,NaN,"Chain N, IG c168_light_IGKV4-1_IGKJ4,Uncharacterized protein",2022-10-12
1257,NaN,IGK@,NaN,7CHC_L,NaN,NaN,NaN,eivltqspgtlslspgeratlscrasqgvssflawyqqkpgqaprllihgassratgipdrfsgsgsgtdftltitrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,NaN,NaN,NaN,"Chain L, IGK@ protein",2022-10-12
1258,C5G2,NaN,7XRP_B,NaN,"['COVID', 'SARS-COV-2']",Camelus dromedarius (Arabian camel),dvqlvesgggsvqaggslrlscaasgkfshlvflgwfrqapgkeregvaaglgayesgyyadsvkgrftvsldnaentvylqmnslkpedtalyycaalvvlsrdntefiahnywgqgtqvtvss,NaN,"Zhao,D. et al.; A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode; J Nanobiotechnology 20 (1), 411 (2022); 2022.",10.1186/s12951-022-01619-y,"Chain B, C5G2 nanobody",NaN,2022-10-12
1259,H11-H4,NaN,7Z9R_Z,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycarteyvsyllsdyatwpydywgqgtqvtvss,NaN,"Mikolajek,H. et al.; Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes; Proc Natl Acad Sci U S A 119 (31), e2205412119 (2022); 2022.",10.1073/pnas.2205412119,"Chain Z, Nanobody H11-H4 Q98R H100E",NaN,2022-10-12
1262,H11-A10,NaN,7Z9Q_F,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycagfsatrsllsdyatwpydywgqgtqvtvsskhhhhhh,NaN,"Mikolajek,H. et al.; Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes; Proc Natl Acad Sci U S A 119 (31), e2205412119 (2022); 2022.",10.1073/pnas.2205412119,"Chain F, Nanobody H11-A10",NaN,2022-10-12
1268,H11-B5,NaN,7Z85_E,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycasyqatrsllsdyatwpydywgqgtqvtvsskhhhhhh,NaN,"Mikolajek,H. et al.; Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes; Proc Natl Acad Sci U S A 119 (31), e2205412119 (2022); 2022.",10.1073/pnas.2205412119,"Chain E, Nanobody H11-B5",NaN,2022-10-12
1271,H11-H6,NaN,7Z7X_E,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycagskitrsllsdyatwpydywgqgtqvtvsskhhhhhh,NaN,"Mikolajek,H. et al.; Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes; Proc Natl Acad Sci U S A 119 (31), e2205412119 (2022); 2022.",10.1073/pnas.2205412119,"Chain E, Nanobody H11-H6",NaN,2022-10-12
1274,H11,NaN,7Z6V_Z,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycaqtrvtrsllsdyatwpydywgqgtqvtvsskhhhhhh,NaN,"Mikolajek,H. et al.; Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes; Proc Natl Acad Sci U S A 119 (31), e2205412119 (2022); 2022.",10.1073/pnas.2205412119,"Chain Z, Nanobody H11",NaN,2022-10-12
1277,C144,NaN,8DCE_H,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),etevqlvesgggliqpggslrlscaasgftvsnnymswvrqapgkglewvsviysggstyyadsvkgrftisrdkskntlylqmnrlraedtavyycaregevegyndfwsgysrdryyfdywgqgtlvtvssggggsggggsggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstrvfgtgtkvtvlgthhhhhh,NaN,"Dickey,T.H. et al.; Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response; Sci Adv 8 (37), eabq8276 (2022); 2022.",10.1126/sciadv.abq8276,"Chain H, C144 scFv",NaN,2022-10-12
1279,B5,NaN,7Z1C_E,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycasyqatrsllsdyatwpydywgqgtqvtvsskhhhhhh,NaN,"Mikolajek,H. et al.; Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes; Proc Natl Acad Sci U S A 119 (31), e2205412119 (2022); 2022.",10.1073/pnas.2205412119,"Chain E, Nanobody B5",NaN,2022-10-12
1280,F2,NaN,7Z1C_D,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Lama glama (llama),qvqlvesggglvqaggslrlaciasgrtfhsyvmawfrqapgkerefvaaiswsstptyygesvkgrftisrdnakntvylqmnrlkpedtavyfcaadrgesyyytrpteyefwgqgtqvtvsshhhhhh,NaN,"Mikolajek,H. et al.; Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes; Proc Natl Acad Sci U S A 119 (31), e2205412119 (2022); 2022.",10.1073/pnas.2205412119,"Chain D, Nanobody F2",NaN,2022-10-12
1283,A10,NaN,7Z1B_E,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycagfsatrsllsdyatwpydywgqgtqvtvsskhhhhhh,NaN,"Mikolajek,H. et al.; Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes; Proc Natl Acad Sci U S A 119 (31), e2205412119 (2022); 2022.",10.1073/pnas.2205412119,"Chain E, Nanobody A10",NaN,2022-10-12
1291,NaN,NaN,7VOA_A,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),qvqlvesggglvqpggtlrlscaasgftldyyaigwfrqapgkeregvscisgsggitnytdsvkgrftisrdnakntvylqmnslkpedtavyycapvshtvvagcafeawtdfgswgqgtqvtvss,NaN,"Ma,H. et al.; Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron; Cell Res 32 (9), 831-842 (2022); 2022.",10.1038/s41422-022-00700-3,"Chain A, alpaca nanobody",NaN,2022-10-12
1292,P86,NaN,7VQ0_F,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Vicugna pacos (alpaca),qvqlqesggglvqaggslrlscvasgrtfsslnivwfrqapgkerkfvaaindrntayaesvkgrftisrdnakntvhlqmnslkpedtavyychsadvnggmdywgkgtqvtvsshhhhhh,NaN,"Maeda,R. et al.; A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron; Commun Biol 5 (1), 669 (2022); 2022.",10.1038/s42003-022-03630-3,"Chain F, Neutralizing nanobody P86",NaN,2022-10-12
1295,NaN,NaN,7VPY_B,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Vicugna pacos (alpaca),mkyllptaaagllllaaqpamaqvqlqesggglvqaggslrlscvasgrtfsslnivwfrqapgkerkfvaaindrntayaesvkgrftisrdnakntvhlqmnslkpedtavyychsadvnggmdywgkgtqvtvsshhhhhh,NaN,"Maeda,R. et al.; A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron; Commun Biol 5 (1), 669 (2022); 2022.",10.1038/s42003-022-03630-3,"Chain B, Nanobody",NaN,2022-10-12
1297,PAN-SARBECOVIRUS,NaN,8CYJ_D,NaN,unknown,Lama glama (llama),qvqlvesggglvqaggslrlscaasgrtfstyamawfrqapgkerefvagvarsadttyygdsvkgrftisrdnaknevnlqmsslkpedtavyycaarsviqygivpgndfhyeywgqgtqvtvss,NaN,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain D, pan-sarbecovirus nanobody 2-62",NaN,2022-10-12
1298,PAN-SARBECOVIRUS,NaN,8CYJ_C,NaN,unknown,Lama glama (llama),qvqlvesggglvqpggslrlscaasgftfnryamswvrqapgkgrewvsgiysdgsetyytesvkgrftisrdnaknmlylqmnslkpedtalyycakdenahedyfnsgfdrkydywgqgtqvtvss,NaN,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain C, pan-sarbecovirus nanobody 2-10",NaN,2022-10-12
1299,PAN-SARBECOVIRUS,NaN,8CYJ_B,NaN,unknown,Lama glama (llama),hvqlvesggglvqaggslrlscatsgrtfstyrmswfrqapgkerefvatiiwsvgsthyadsvkgrftisrdnaknmvylqmnslkpedtavyycaaqrsdssswgyeddydywgqgtqvtvss,NaN,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain B, pan-sarbecovirus nanobody 1-25",NaN,2022-10-12
1300,PAN-SARBECOVIRUS,NaN,8CYJ_A,NaN,unknown,Lama glama (llama),evqlvesggglvqtggslrlscalsgytfsifptawfrqapgkerefvagirwngstrdyteyadfvkgrftisrdnaknmvylqmislkpedtalyycaasdgvidgtnanayrywgqgtqvtvss,NaN,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain A, pan-sarbecovirus nanobody 2-67",NaN,2022-10-12
1301,PAN-SARBECOVIRUS,NaN,8CYD_F,NaN,unknown,Lama glama (llama),qvqlvesggglvqaggslrlsctasgydfsilaiawyrqapgkerelvaaisrvgstdyadsvkgrftisrdntkntvslqmdslkpedtavyycnagipmttvlsglgfwgqgtqvtvss,NaN,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain F, pan-sarbecovirus nanobody 2-45",NaN,2022-10-12
1304,PAN-SARBECOVIRUS,NaN,8CYC_F,NaN,unknown,Lama glama (llama),hvqlvesggglvqaggslrlscaasgrtfsryaagwfrqapgkerefvaviewdgdsayyadpvkgrftisrdnakntvylqmnrlkpedtavyicavggnhysrskyynldeyddwgqgtqvtvss,NaN,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain F, pan-sarbecovirus nanobody 2-34",NaN,2022-10-12
1307,PAN-SARBECOVIRUS,NaN,8CYB_D,NaN,unknown,Lama glama (llama),nsqvqlvesggglvqtggslrlscaasgrtfsnyvmgwfrqapgkerefvssiewnsentfyansvkgrftisrdnakntvylqmnslkaedtavyycaadrgssyyytraseytywgqgtqvtvss,NaN,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain D, pan-sarbecovirus nanobody 1-8",NaN,2022-10-12
1311,PAN-SARBECOVIRUS,NaN,8CY9_F,NaN,unknown,Lama glama (llama),qvqlvesggglvqaggslrlscaasgrtdsisdmgwfrqapgkerefvavvgwsgggtdyahsvkgrftisrdnakntvylqmnslkpedtavyycavgslrvgsfsveywgqgtqvtvss,NaN,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain F, pan-sarbecovirus nanobody 1-23",NaN,2022-10-12
1314,PAN-SARBECOVIRUS,NaN,8CY7_F,NaN,unknown,Lama glama (llama),qvqlvesggglvqaggslrlscaaaarfstsamgwfrqapgkerefvaaiswsntnthyadtvkgrftisadtaketvdlqmnslkpedtavyycvqggwgirqpiivdywgkgtqvtvss,NaN,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain F, pan-sarbecovirus nanobody 2-38",NaN,2022-10-12
1317,PAN-SARBECOVIRUS,NaN,8CY6_F,NaN,unknown,Lama glama (llama),nshvqlvesggglvqaggslrlscaasgtistlnamgwyrqapgkqrellasisnlgttyhadsvagrftisrgsakntvnlqmnslkpddtavyycntrvleggtqirdywgqgtqvtvss,NaN,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain F, pan-sarbecovirus nanobody 2-65",NaN,2022-10-12
1320,PAN-SARBECOVIRUS,NaN,8CXQ_F,NaN,unknown,Lama glama (llama),hvqlvesggglvqpggslrlscaasgrsfnsylmgwfrqapgkerefvawisgsphdiiryrdsvkdrftisrdnakntvylqmnslkpvdtavyycavgslrvgsfspdywgqgtqvtvss,NaN,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain F, pan-sarbecovirus nanobody 1-22",NaN,2022-10-12
1323,PAN-SARBECOVIRUS,NaN,8CXN_E,NaN,unknown,Lama glama (llama),qvqlvesggglvqaggslrlscavsgrtistfgmgwfrqapgkerefvatitrdedmllyadsvkgrftisrdtaknmvflqmnslkiedtalyycavrrdsswgysrqsteydywgqgtqvtvss,NaN,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain E, pan-sarbecovirus nanobody 2-57",NaN,2022-10-12
1326,2-31,NaN,8CWV_B,NaN,unknown,Lama glama (llama),masmtggqqmgrdpnsqvqlvesggglvqageslrlscaaskptfrnfaagwfrqtpgkdrefvavieydgdsayyadsvkgrftisrdnakntvylqmnrlkpgdtavyicaiggnhydpskyytadeydywgqgtqvtvssklaaalehhhhhh,NaN,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain B, VHH 2-31",NaN,2022-10-12
1327,1-21,NaN,8CWU_B,NaN,unknown,Lama glama (llama),masmtggqqmgrdpnshvqlvesggglvqaggslrlscaapgrtfstsamgwfrqapgkerefvaaidwsntnihyadtvkgrftistdtakntvylqmnnlkpedtavyycaqggwgltqpisvdywgkgtqvtvssklaaalehhhhhh,NaN,"Xiang,Y. et al.; Superimmunity by pan-sarbecovirus nanobodies; Cell Rep 39 (13), 111004 (2022); 2022.",10.1016/j.celrep.2022.111004,"Chain B, VHH 1-21",NaN,2022-10-12
1328,NaN,NaN,7XOD_T,NaN,unknown,Lama glama (llama),mgsqvqlqesggglvqpggslrlscaasgrtisryamswfrqapgkerefvavarrsgdgafyadsvqgrftvsrddakntvylqmnslkpedtavyycaidsdtfysgsydywgqgtqvtvss,NaN,"Xu,Y. et al.; Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins; Cell Res 32 (7), 609-620 (2022); 2022.",10.1038/s41422-022-00672-4,"Chain T, Nanobody",NaN,2022-10-12
1331,NB-007,NaN,7W1S_B,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Vicugna pacos (alpaca),qlqlvesggglvqaggsmrlscaasisfssfpmgwhrqapgkqrelvaktgiggtayddsvkgrftisrdntkntvylqmnslkvedtavyycwgwrmndywgqgtqvtvsshhhhhh,NaN,"Yang,J. et al.; A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding; Front Immunol 13, 820336 (2022); 2022.",10.3389/fimmu.2022.820336,"Chain B, Nanobody Nb-007",NaN,2022-10-12
1332,DL28,NaN,7F5H_D,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),gsssqvqlqesggglvqaggslrlscaasgsdfssstmgwyrqapgkqrefvaissegstsyagsvkgrftisrdnakntvylqmnslepedtavyycnvvdrwydywgqgtqvtvsagrageqkliseedlnsavdhhhhhh,NaN,"Li,D.F. et al.; Discovery of nanobodies against SARS-CoV-2 and an uncommon neutralizing mechanism; Unpublished; 2022.",NaN,"Chain D, Nanobody DL28",NaN,2022-10-12
1334,C1,NaN,7ZFB_N,NaN,unknown,Lama glama (llama),qvqlvesggglvqpggslrlscaasgftndfysiawfrqapgkeregvswlsvsdntptyvdsvkdrftisrhnanntvylqmnmlkpedtaiyycaagrfagrdtwpssydywgqgtqvtvsskhhhhhh,NaN,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain N, Nanobody C1",NaN,2022-10-12
1340,F2,NaN,7ZF4_F,NaN,unknown,Lama glama (llama),qvqlvesggglvqaggslrlaciasgrtfhsyvmawfrqapgkerefvaaiswsstptyygesvkgrftisrdnakntvylqmnrlkpedtavyfcaadrgesyyytrpteyefwgqgtqvtvsskhhhhhh,NaN,"Nutalai,R. et al.; Potent cross-reactive antibodies following Omicron breakthrough in vaccinees; Cell 185 (12), 2116-2131 (2022); 2022.",10.1016/j.cell.2022.05.014,"Chain F, Nanobody F2",NaN,2022-10-12
1342,CAMEL-DERIVED,NaN,7R4R_D,NaN,"['COVID', 'SARS-COV-2']",Camelus dromedarius (Arabian camel),qvqlvesgggsvqaggslrlscaasgytystcrkgwyrqapgkerelvasitadgatyyldsvkgrltisqdnakntvylqmnslkpedtavyycaasvkdftctfnswgqgtqvtvssalvpr,NaN,"Casasnovas,J.M. et al.; Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron; Front Immunol 13, 863831 (2022); 2022.",10.3389/fimmu.2022.863831,"Chain D, Camel-derived nanobody 1.10",NaN,2022-10-12
1343,CAMEL-DERIVED,NaN,7R4Q_E,NaN,"['COVID', 'SARS-COV-2']",Camelus dromedarius (Arabian camel),qvqlvesgggsvqaggslrlscaasgytintdavawfrqapgkgdervaviytgsgntnyadsvkgrftisqdnakntvylqmnslkpedtalyycasgyygasgydfnnwgqgtqvtvssalvpr,NaN,"Casasnovas,J.M. et al.; Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron; Front Immunol 13, 863831 (2022); 2022.",10.3389/fimmu.2022.863831,"Chain E, Camel-derived nanobody 1.29",NaN,2022-10-12
1345,CAMEL-DERIVED,NaN,7R4I_E,NaN,"['COVID', 'SARS-COV-2']",Camelus dromedarius (Arabian camel),qvqlvesgggsvqaggslklscaasgyaswarkcigwfrqapgqeregvaaifdfdgstyysdsvkgrftisgdnakntvslqmnsllpkdtavyyctvafgtcdnwyrgrgdywgqgtqvtvssalvpr,NaN,"Casasnovas,J.M. et al.; Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron; Front Immunol 13, 863831 (2022); 2022.",10.3389/fimmu.2022.863831,"Chain E, Camel-derived nanobody 2.15",NaN,2022-10-12
1347,DL4,NaN,7F5G_D,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),gsssqvqlqesggglvqpggslrlscaasgsffefgtvgwfrqapgkqrelvsritgndhryyadsvkgrftisrdndettvylqmdslkpedtaiyhcnilegqrwsnywgqgtqvtvsagrageqkliseedlnsavdhhhhhh,NaN,"Li,T. et al.; Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2; Int J Biol Macromol 209 (Pt A), 1379-1388 (2022); 2022.",10.1016/j.ijbiomac.2022.04.096,"Chain D, Nanobody DL4",NaN,2022-10-12
1349,ILAMA-ISOLATED,NaN,7RBY_D,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Lama glama (llama),dvqlqesggglvqpggslrlscaasgltldyyaigwfrqapgkeregvscisssdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgtyyytchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19; MAbs 14 (1), 2047144 (2022); 2022.",10.1080/19420862.2022.2047144,"Chain D, Ilama-isolated nanobody NIH-CoV nb-112 specific to SARS-CoV-2 RBD",NaN,2022-10-12
1351,FD20THE,NaN,7CYV_H,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),gsssqqvqlqqsgaevkkpgssvkvsckasggtfssyafswvrqapgqglewmgriipilgianyaqkfqgrvtitadiststaymalsslrsedtavyycakvevnigmddyyyyygmdvwgqgttvtvssgggsggggsggggssyvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvlsagrageqkliseedlnsavdhhhhhh,NaN,"Li,T. et al.; Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody; EMBO Mol Med 13 (12), e14544 (2021); 2021.",10.15252/emmm.202114544,"Chain H, The heavy chain variable region of the scFv FD20,The light chain variable region of the scFv FD20",NaN,2022-10-12
1352,SYBODY#68,NaN,7P7A_D,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesgggsvqaggslrlscaasgsissitylgwfrqapgkeregvaalitvnghtyyadsvkgrftvsldnakntvylqmnslkpedtalyycaaaawgyawplhqddywywgqgtqvtvs,NaN,"Walter,J.D. et al.; Bispecific sybody constructs neutralize SARS-CoV-2 variants of concern and mitigate emergence of drug-resistance; bioRxiv (2020); 2021.",NaN,"Chain D, sybody#68",NaN,2022-10-12
1354,SYBODY#15,NaN,7P79_H,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasgfpvknfemewyrkapgkerewvaaiqsggvetyyadsvkgrftisrdnakntvylqmnslkpedtavyycfvyvgrsyigqgtqvtvs,NaN,"Walter,J.D. et al.; Bispecific sybody constructs neutralize SARS-CoV-2 variants of concern and mitigate emergence of drug-resistance; bioRxiv (2020); 2021.",NaN,"Chain H, sybody#15",NaN,2022-10-12
1368,7A3,NaN,7TPR_H,NaN,"['COVID', 'SARS-COV-2']",Camelus dromedarius (Arabian camel),qvqlvesgggsvqpggslrlscvvsgytsssrymgwfrqvpgkglewvsgikrdgtntyyadsvkgrftisqdnakntvylqmnslkpedtamyycaagswynqwgysmdywgkgtqvtvsssgq,NaN,"Hong,J. et al.; Camel nanobodies broadly neutralize SARS-CoV-2 variants; bioRxiv (2021); 2022.",10.1101/2021.10.27.465996,"Chain H, Nanobody 7A3",NaN,2022-10-12
1371,8A2,NaN,7TPR_E,NaN,"['COVID', 'SARS-COV-2']",Camelus dromedarius (Arabian camel),avqlvdsgggsvqaggslrlscaasgytysictmgwyrqapgeglewvsginadgsnthytdsvkgrftisrdnakktlylqmnslkpedtaiyycaahgtydkyapcggfagtytywgqgtqvtvsssgqa,NaN,"Hong,J. et al.; Camel nanobodies broadly neutralize SARS-CoV-2 variants; bioRxiv (2021); 2022.",10.1101/2021.10.27.465996,"Chain E, Nanobody 8A2",NaN,2022-10-12
1373,ANTI-FAB,NaN,7WPE_W,NaN,['Spike protein'],Lama glama (llama),gsqvqlqesggglvqpggslrlscaasgrtisryamswfrqapgkerefvavarrsgdgafyadsvqgrftvsrddakntvylqmnslkpedtavyycaidsdtfysgsydywgqgtqvtvsshhhhhhepea,NaN,"Yin,W. et al.; Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody; Science 375 (6584), 1048-1053 (2022); 2022.",10.1126/science.abn8863,"Chain W, Anti-Fab nanobody",NaN,2022-10-12
1375,4B6,NaN,6H3U_I,NaN,['Spike protein'],Mus musculus (house mouse),qmqlqesgpglvkpsqslsltctvtgysitsdsawnwirqfpgnklewmgyisysgstsynpslksrisitrdtsknqfflqlnsvttedtatyyctrwgdgyylywyfdvwgagttvtvssggggsggggsggggsggggg,NaN,"Hellert,J. et al.; Orthobunyavirus spike architecture and recognition by neutralizing antibodies; Nat Commun 10 (1), 879 (2019); 2019.",10.1038/s41467-019-08832-8,"Chain I, scFv 4B6 VH",NaN,2022-10-12
1376,NaN,4B6,NaN,6H3U_M,['Spike protein'],Mus musculus (house mouse),NaN,diqmtqttsslsaslgdrvtiscsasqgisyylnwyqqkpdgtvklliyytsslhsgvpsrfsgsgsgtdysltisnlepediatyycqqysklpwtfgggtkleikggwshpqfek,"Hellert,J. et al.; Orthobunyavirus spike architecture and recognition by neutralizing antibodies; Nat Commun 10 (1), 879 (2019); 2019.",10.1038/s41467-019-08832-8,NaN,"Chain M, scFv 4B6 VL",2022-10-12
1379,NaN,1C11,NaN,6H3T_M,['Spike protein'],Mus musculus (house mouse),NaN,divmtqaasslavsvgekvtmsckssqsllyssnqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvkaedlavyycqqyysfpptfgggtkleikggwshpqfek,"Hellert,J. et al.; Orthobunyavirus spike architecture and recognition by neutralizing antibodies; Nat Commun 10 (1), 879 (2019); 2019.",10.1038/s41467-019-08832-8,NaN,"Chain M, scFv 1C11 VL",2022-10-12
1380,1C11,NaN,6H3T_I,NaN,['Spike protein'],Mus musculus (house mouse),evqlqqsgpelvkpgasvkvsckasgysftdynmcwvkqshgkslewigyidpyngltsynpkfkgkatltvdkssstafmhlnsltsedsavyycarnyygrsyamdywgqgtsvtvssggggsggggsggggsggggg,NaN,"Hellert,J. et al.; Orthobunyavirus spike architecture and recognition by neutralizing antibodies; Nat Commun 10 (1), 879 (2019); 2019.",10.1038/s41467-019-08832-8,"Chain I, scFv 1C11 VH",NaN,2022-10-12
1387,B6,NaN,7R98_F,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),maevqlqasggglvqagdslrlscvavsgrtistfamgwfrqapgkerefvatinwsgssaryadpvegrftisrddakntvylemsslkpgdsavyycasgrylggitsysqgdfapwgqgtqvtvssaaalehhhhhh,NaN,"Ye,Q. et al.; Structural basis for SARS-CoV-2 Nucleocapsid protein recognition by single-domain antibodies; bioRxiv (2021); 2021.",10.1101/2021.06.01.446591,"Chain F, Nanobody B6",NaN,2022-10-12
1390,E2,NaN,7N0I_L,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),maevqlqasggglvqaggslrlscaasgrtdstqhmawfrqapgkerefvtaiqwrgggtsytdsvkgrftisrdnakntvylemnslkpedtavyycatntrwtyfsptvpdrydywgqgtqvtvssaaalehhhhhh,NaN,"Ye,Q. et al.; Structural basis for SARS-CoV-2 Nucleocapsid protein recognition by single-domain antibodies; bioRxiv (2021); 2021.",10.1101/2021.06.01.446591,"Chain L, Single-domain antibody E2",NaN,2022-10-12
1394,C2,NaN,7N0R_D,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),maevqlqasggglvrpggslrlscaasgftfssyammwvrqapgkglewvsainggggstsyadsvkgrftisrdnakntlylqmnslkpedtavyycakyqaavhqekedywgqgtqvtvssaaalehhhhhh,NaN,"Ye,Q. et al.; Structural basis for SARS-CoV-2 Nucleocapsid protein recognition by single-domain antibodies; bioRxiv (2021); 2021.",10.1101/2021.06.01.446591,"Chain D, Single-domain antibody C2",NaN,2022-10-12
1396,NaN,NaN,6ZCZ_F,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycaqthyvsyllsdyatwpydywgqgtqvtvssgpggqhhhhhhgaeqkliseedls,NaN,"Zhou,D. et al.; Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient; Nat Struct Mol Biol 27 (10), 950-958 (2020); 2020.",10.1038/s41594-020-0480-y,"Chain F, Nanobody",NaN,2022-10-12
1397,E4,NaN,7VMU_A,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgggliqpggslrlscaasgvtvssnymswvrqapgrglewvsliypggstyyadsvkgrftisrdnsrntlylqmnslraedtavyycardlsekggmdvwgqgttvtvssggggsggggsggggsggggasdivmtqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsyprfgpgtkveik,NaN,"Li,L. et al.; Antibody engineering improves neutralization activity against K417 spike mutant variants of SARS-CoV-2; Unpublished; 2021.",NaN,"Chain A, scFv E4",NaN,2022-10-12
1398,RE9F06,NaN,7OLZ_B,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),gsqvqlvesggglvqaggslrlscaasgrtfsndalgwfrqaprkerefvaainwnsgtyyadsvkgrftisrdnakntvylqmnslkpedtavyscaaasdyglpredflydywgqgtqvtvssts,NaN,"Guttler,T. et al.; Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies; EMBO J 40 (19), e107985 (2021); 2021.",10.15252/embj.2021107985,"Chain B, Nanobody Re9F06",NaN,2022-10-12
1399,RE5D06,NaN,7OLZ_C,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),gsqvqlvesggglvqpggslrlscaasgitldyyaigwfrqapgkeregvsrirssdgstnyadsvkgrftmsrdnakntvylqmnslkpedtavyycaygpltkygsswywpyeydywgqgtqvtvssts,NaN,"Guttler,T. et al.; Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies; EMBO J 40 (19), e107985 (2021); 2021.",10.15252/embj.2021107985,"Chain C, Nanobody Re5D06",NaN,2022-10-12
1400,F2,NaN,7OAY_LLL,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),qvqlvesggglvqaggslrlaciasgrtfhsyvmawfrqapgkerefvaaiswsstptyygesvkgrftisrdnakntvylqmnrlkpedtavyfcaadrgesyyytrpteyefwgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain LLL, F2 nanobody",NaN,2022-10-12
1406,H3,NaN,7OAP_FFF,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),maqvqlvesggglvktggslrlscaasgrtfstysmgwfrqapgkerefvagmrwtgsstfysdsvkgrftvsrnnakdtvylhmnslkpedtavyycaittivrayyteyteadfgswgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain FFF, H3 nanobody",NaN,2022-10-12
1407,C1,NaN,7OAP_AAA,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),qvqlvesggglvqpggslrlscaasgftndfysiawfrqapgkeregvswlsvsdntptyvdsvkdrftisrhnanntvylqmnmlkpedtaiyycaagrfagrdtwpssydywgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain AAA, C1 nanobody",NaN,2022-10-12
1408,C5,NaN,7OAO_FFF,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),qvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain FFF, C5 nanobody",NaN,2022-10-12
1409,NB17,NaN,7N9T_F,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),hvqlvesggglvqaggslrlscaasgsifssnamswyrqapgkqrelvasitsggnadyadsvkgrftisrdkntvypemsslkpadtavyychavgqeasayapraywgqgtqvtvss,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain F, Nanobody Nb17",NaN,2022-10-12
1412,NB36,NaN,7MEJ_B,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),vqlvesggglvqaggsltltcaasgrtfssetmdmgwfrqapgkerefvaadswndgstyyadsvkgrftisrdsakntlylqmnslkpedtavyycaaetysiyekddswgywgqgtqvtvs,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain B, Nanobody Nb36",NaN,2022-10-12
1413,NB21,NaN,7MEJ_A,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),qvqlvesggglvqaggslrlscavsglgahrvgwfrrapgkerefvaaiganggntnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeytywgqgtqvtvss,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain A, Nanobody Nb21",NaN,2022-10-12
1414,NB105,NaN,7ME7_B,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),vqlvesggglvqaggslrlscavsgrtfstygmawfrqapgkerdfvatitrsgettlyadsvkgrftisrdnakntvylqmnslkiedtavyycavrrdsswgysrdlfeydywgqgtqvtvs,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain B, Nanobody Nb105",NaN,2022-10-12
1417,NB34,NaN,7N9E_D,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),masmtggqqmgrdpnsdvqlvesggglvqaggslrlscaasgftfsnyvmywgrqapgkgrewvsgidsdgsdtayassvkgrftisrdnakntlylqmnnlkpedtalyycvkskdpygspwtrsefddywgqgtqvtvssklaaalehhhhhh,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain D, Nb34 nanobody",NaN,2022-10-12
1418,NB95,NaN,7N9C_E,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),masmtggqqmgrdpnsqvqlvesggglvqaggslrlscaasgrtfssysmgwfrqaqgkerefvatingngrdtyytnsvkgrftisrddatntvylqmnslkpedtaiyycaadkdvyygytsfpneyeywgqgtqvtvssklaaalehhhhhh,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain E, Nanobody NB95",NaN,2022-10-12
1420,NB21,NaN,7N9B_F,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),masmtggqqmgrdpnsqvqlvesggglvqaggslrlscavsglgahrvgwfrrapgkerefvaaiganggntnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeytywgqgtqvtvssklaaalehhhhhh,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain F, NB21 Nanobody",NaN,2022-10-12
1423,NB12,NaN,7MY3_D,NaN,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),qvkleesgggsvqaggslrlictapglthnncgldwyrrapgkerefvssisadgttsyadsvkgrftiskdkvedtvylqmnslkpedtaiyscktafpyfgnscvldywgqgtsvtvsshhhhhh,NaN,"Xu,J. et al.; Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants; Nature 595 (7866), 278-282 (2021); 2021.",10.1038/s41586-021-03676-z,"Chain D, Nanobody Nb12",NaN,2022-10-12
1426,NB30,NaN,7MY2_D,NaN,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),qvqlvesggglvqaggslrlscaasgltfskyamgwfrqapgkerkfvatiswsgdsafyadsvkgrftisrdnarntvylqmnslkpedtavyycaadrgmgygdfmdywgqgtsvtassasgahhhhhh,NaN,"Xu,J. et al.; Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants; Nature 595 (7866), 278-282 (2021); 2021.",10.1038/s41586-021-03676-z,"Chain D, Nanobody Nb30",NaN,2022-10-12
1429,SB45,NaN,7N0H_Z,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasgfpvyrdrmawyrqapgkerewvaaiysagqqtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkdvghhyeyydywgqgtqvtvsa,NaN,"Ahmad,J. et al.; Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction; J Biol Chem 297 (4), 101202 (2021); 2021.",10.1016/j.jbc.2021.101202,"Chain Z, Synthetic nanobody (Sb45)",NaN,2022-10-12
1434,#68,NaN,7MFU_F,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,ssqvqlvesgggsvqaggslrlscaasgsissitylgwfrqapgkeregvaalitvnghtyyadsvkgrftvsldnakntvylqmnslkpedtalyycaaaawgyawplhqddywywgqgtqvtvsa,NaN,"Ahmad,J. et al.; Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction; J Biol Chem 297 (4), 101202 (2021); 2021.",10.1016/j.jbc.2021.101202,"Chain F, Synthetic nanobody #68 (Sb68)",NaN,2022-10-12
1435,#14,NaN,7MFU_E,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasgfpvqaremewyrqapgkerewvaaikstgtytayaysvkgrftisrdnakntvylqmnslkpedtavyycyvyvgssyigqgtqvtvsa,NaN,"Ahmad,J. et al.; Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction; J Biol Chem 297 (4), 101202 (2021); 2021.",10.1016/j.jbc.2021.101202,"Chain E, Synthetic Nanobody #14 (Sb14)",NaN,2022-10-12
1438,NaN,NaN,7B14_D,NaN,"['COVID', 'SARS-COV-2']",Camelus bactrianus (Bactrian camel),qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain D, Nanobody against SARS-CoV-2",NaN,2022-10-12
1439,NaN,NaN,7DEU_B,NaN,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmhwvkqshgkslewigginpnngdntynqklkgkatltvhkssstaymelrsltsedsavyycardgypyyyaldywgqgtsvtvssggggsggggsggggsdivmtqsqkfmstsvgdrvsvtckasqnvgtnvawyqqkpgqspkpliysassrysgvpdrftgsgsgtdftltisnvqsedlaeyfcqqynnypwtfgggtkleikaaahhhhhhhh,NaN,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.",10.1371/journal.pbio.3001209,"Chain B, antibody scFv",NaN,2022-10-12
1440,NaN,NaN,7DET_D,NaN,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),mkflvnvalvfmvvyisyiyadgsqvqlvqsgaevkkpgasvklsckasgysftsywvnwvrqapgqglewigmihpsdsetrlnqkfkdrvtitvdkststaymelsslrsedtavyycaradgyewyfdvwgrgtlvtvssggggsggggsggggsdivltqspaslavspgqratitcrasesvdsygnsfmhwyqqkpgqppklliyrasnlesgiparfsgsgsgtdftltinpveandvanyycqqsnedpwtfgqgtkveikaaahhhhhhhh,NaN,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.",10.1371/journal.pbio.3001209,"Chain D, antibody scFv",NaN,2022-10-12
1442,NaN,NaN,7DEO_C,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),gsevqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnrfyadsvkgrftisrdnskstlylqmnslraedtavyycatdppglrfrfdywgqgtlvtvssggggsggggsggggsdivmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqtpltfgggtkveikgggshhhhhh,NaN,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.",10.1371/journal.pbio.3001209,"Chain C, antibody scFv",NaN,2022-10-12
1444,MR17-SR31,NaN,7D30_A,NaN,"['COVID', 'SARS-COV-2', 'RBD']",synthetic construct,gsssqvqlvesggglvqaggslrlscaasgfpvevwrmewyrqapgkeregvaaiesyghgtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkddgqlayhydywgqgtqvtvsggggsggggsggggsggggsggggsggggsgsssqvqlvesggglvqaggslrlscaasgfpvwqgemawyrqapgkerewvaaissmgyktyyadsvkgrftisrdnakntvylqmnslkpedtavyycavmvgfwyagqgtqvtvsagrageqkliseedlnsavdhhhhhh,NaN,"Yao,H. et al.; A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2; PLoS Pathog 17 (3), e1009328 (2021); 2021.",10.1371/journal.ppat.1009328,"Chain A, sybody fusion of MR17-SR31 with a GS linker",NaN,2022-10-12
1445,GLAMASARS-COV-2,NaN,7B17_B,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvssggggsggggsggggsqvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvssggypydvpdyaghhhhhh,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain B, SARS-CoV-2 neutralizing biparatopic nanobody VE,nanobody E from Lama glama,SARS-CoV-2 neutralizing biparatopic nanobody VE,nanobody E from Lama glama",NaN,2022-10-12
1446,SB68,NaN,7KLW_C,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,sssqvqlvesgggsvqaggslrlscaasgsissitylgwfrqapgkeregvaalitvnghtyyadsvkgrftvsldnakntvylqmnslkpedtalyycaaaawgyawplhqddywywgqgtqvtvs,NaN,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.",10.1101/2021.01.27.428466,"Chain C, SB68, Synthetic nanobody",NaN,2022-10-12
1447,SB45,NaN,7KLW_B,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasgfpvyrdrmawyrqapgkerewvaaiysagqqtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkdvghhyeyydywgqgtqvtvs,NaN,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.",10.1101/2021.01.27.428466,"Chain B, SB45, Synthetic Nanobody",NaN,2022-10-12
1448,SB16,NaN,7KGK_B,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasgfpvayktmwwyrqapgkerewvaaiesygikwtryadsvkgrftisrdnakntvylqmnslkpedtavyycivwvgaqyhgqgtqvtvsagra,NaN,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.",10.1101/2021.01.27.428466,"Chain B, Sb16, Sybody-16, Synthetic Nanobody",NaN,2022-10-12
1450,NaN,NaN,7KSG_F,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvssgglpetgghhhhhh,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain F, Nanobody against SARS-CoV-2 glycoprotein",NaN,2022-10-12
1453,NM1230,NaN,7B27_DDD,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),qvqlvesggglvrpggslrlscvgsgftfsgyamnwyrqapgkalelvagisnagdlthyeepmkgrvaisrandkntvylqmddlkpedtavyrchapgvrvgtgerkdvwgqgaqvtvsseqkliseedlkkkhhhhhh,NaN,"Wagner,T.R. et al.; NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies; EMBO Rep 22 (5), e52325 (2021); 2021.",10.15252/embr.202052325,"Chain DDD, neutralizing nanobody NM1230",NaN,2022-10-12
1455,NM1226,NaN,7NKT_BBB,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),qvqlvesgggsvqpggslrlsclgsgsldyyaigwfrqapgkeregvsciassgdrtiyadsvkgrftisrdygkntvylqmnslkpedtamyycaalqgsyyytgfvaneydywgqgapvtvsseqkliseedlkkkhhhhhh,NaN,"Wagner,T.R. et al.; NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies; EMBO Rep 22 (5), e52325 (2021); 2021.",10.15252/embr.202052325,"Chain BBB, neutralizing nanobody NM1226",NaN,2022-10-12
1456,NaN,NaN,7B18_I,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Vicugna pacos (alpaca),qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvss,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain I, Nanobody against spike glycoprotein VHH V",NaN,2022-10-12
1457,NaN,NaN,7B18_H,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),sqvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain H, Nanobody against SARS-CoV-2 VHH E",NaN,2022-10-12
1462,H11-H4,NaN,6ZH9_FFF,NaN,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycaqthyvsyllsdyatwpydywgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2; Nat Struct Mol Biol 27 (9), 846-854 (2020); 2021.",10.1038/s41594-020-0469-6,"Chain FFF, Nanobody H11-H4",NaN,2022-10-12
1463,NaN,NaN,7KN7_B,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),qvqlvesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssgdsthyvdsvkgrftisrdnakntvylqmnslkpedtavyycaaqsgsyywcgsdwheydyrgqgtqvtvssgglpetgghhhhhh,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain B, VHH W",NaN,2022-10-12
1464,NaN,NaN,7KN6_C,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvssgglpetgghhhhhh,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain C, VHH V",NaN,2022-10-12
1465,NaN,NaN,7KN5_F,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),qvqlvesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssggsthfadsvkgrftisrdnakntvylqmnslipedtavyycaaqsgsyywcgsdwheyeywgqgtqvtvss,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain F, VHH U",NaN,2022-10-12
1469,NB20,NaN,7JVB_D,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),qvqlvesggglvqaggslrlscavsgagahrvgwfrrapgkerefvaaigasggmtnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeyiywgqgtqvtvss,NaN,"Xiang,Y. et al.; Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2; Science 370 (6523), 1479-1484 (2020); 2020.",10.1126/science.abe4747,"Chain D, Nanobody Nb20",NaN,2022-10-12
1471,NaN,NaN,7A25_F,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasgfpvesenmhwyrqapgkerewvaaiystggwtlyadsvkgrftisrdnakntvylqmnslkpedtavyycavqvgywyegqgtqvtvs,NaN,"Custodio,T.F. et al.; Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2; BiorXiv (2020); 2020.",NaN,"Chain F, Sybody 23",NaN,2022-10-12
1474,MNB6,NaN,7KKL_F,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvagitrrgsityyadsvkgrftisrdnakntvylqmnslkpedtavyycaadpaspaygdywgqgtqvtvsshhhhhh,NaN,"Schoof,M. et al.; An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike; Science 370 (6523), 1473-1479 (2020); 2020.",10.1126/science.abe3255,"Chain F, Synthetic nanobody mNb6",NaN,2022-10-12
1477,NB6,NaN,7KKK_F,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",synthetic construct,qvqlvesggglvqaggslrlscaasgiifgrnamgwyrqapgkerelvagitrrgsityyadsvkgrftisrdnakntvylqmnslkpedtavyycaadpaspapgdywgqgtqvtvss,NaN,"Schoof,M. et al.; An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike; Science 370 (6523), 1473-1479 (2020); 2020.",10.1126/science.abe3255,"Chain F, Synthetic nanobody Nb6",NaN,2022-10-12
1480,SB23,NaN,7A29_F,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasgfpvesenmhwyrqapgkerewvaaiystggwtlyadsvkgrftisrdnakntvylqmnslkpedtavyycavqvgywyegqgtqvtvs,NaN,"Custodio,T.F. et al.; Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2; BiorXiv (2020); 2020.",NaN,"Chain F, Neutralising sybody (Sb23)",NaN,2022-10-12
1483,TY1,NaN,6ZXN_F,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),maqvqlvetggglvqpggslrlscaasgftfssvymnwvrqapgkgpewvsrispnsgnigytdsvkgrftisrdnakntlylqmnnlkpedtalyycaiglnlssssvrgqgtqvtvssgglpetgghhhhhh,NaN,"Hanke,L. et al.; An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction; BioRxiv (2020); 2020.",NaN,"Chain F, Nanobody Ty1",NaN,2022-10-12
1486,VHH-55,NaN,6WAR_P,NaN,"['COVID', 'MERS']",Lama glama (llama),qvqlqesgggsvqaggslrlscvasgsifsinamdwyrqapgkqrelvagitsggstnygdfvkgrftisrdnakntvylqmdslkpedtavyycaaevggwgpprpdywghgtqvtvssgslevlfq,NaN,"Wrapp,D. et al.; Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies; Cell 181 (5), 1004-1015 (2020); 2020.",10.1016/j.cell.2020.04.031,"Chain P, nanobody MERS VHH-55",NaN,2022-10-12
1494,B39,NaN,4NC2_B,NaN,unknown,Lama glama (llama),qvqlvesggglvqaggslrlscaasgltfsryvmgwfrqapgkerefvaaitwggtpnyadsvkgrftisrdnskntqylqmnslkpedtavyycaaglgwdsrysqsynywgqgtqvtvssgseqkliseedlnhhhhhh,NaN,"Murase,T. et al.; Structural Basis for Antibody Recognition in the Receptor-binding Domains of Toxins A and B from Clostridium difficile; J. Biol. Chem. 289 (4), 2331-2343 (2014); 2013.",10.1074/jbc.M113.505917,"Chain B, B39 Vhh",NaN,2022-10-12
1495,A26.8,NaN,4NC1_F,NaN,unknown,Lama glama (llama),qvkleesggglvqaggslrlscaasertfsrypvawfrqapgaerefvavisstgtstyyadsvkgrftisrdnakvtvylqmnnlkredtavyfcavnsqrtrlqdpneydywgqgtqvtvsshhhhhh,NaN,"Murase,T. et al.; Structural Basis for Antibody Recognition in the Receptor-binding Domains of Toxins A and B from Clostridium difficile; J. Biol. Chem. 289 (4), 2331-2343 (2014); 2013.",10.1074/jbc.M113.505917,"Chain F, A26.8 Vhh",NaN,2022-10-12
1496,A20.1,NaN,4NC1_D,NaN,unknown,Lama glama (llama),qpamaqaqvqlvesggglaqaggslrlscaasgrtfsmdpmawfrqppgkerefvaagsstgrttyyadsvkgrftisrdnakntvylqmnslkpedtavyycaaapyganwyrdeyaywgqgtqvtvssgqagqgseqkliseedlnhhhhhh,NaN,"Murase,T. et al.; Structural Basis for Antibody Recognition in the Receptor-binding Domains of Toxins A and B from Clostridium difficile; J. Biol. Chem. 289 (4), 2331-2343 (2014); 2013.",10.1074/jbc.M113.505917,"Chain D, A20.1 Vhh",NaN,2022-10-12
1500,A26.8,NaN,4NBZ_D,NaN,unknown,Lama glama (llama),qvkleesggglvqaggslrlscaasertfsrypvawfrqapgaerefvavisstgtstyyadsvkgrftisrdnakvtvylqmnnlkredtavyfcavnsqrtrlqdpneydywgqgtqvtvssgseqklisegseqkliseedlnhhhhhh,NaN,"Murase,T. et al.; Structural Basis for Antibody Recognition in the Receptor-binding Domains of Toxins A and B from Clostridium difficile; J. Biol. Chem. 289 (4), 2331-2343 (2014); 2013.",10.1074/jbc.M113.505917,"Chain D, A26.8 Vhh",NaN,2022-10-12
1505,MR17-K99Y,NaN,7CAN_A,NaN,"['COVID', 'SARS-COV-2', 'RBD']",synthetic construct,gsssqvqlvesggglvqaggslrlscaasgfpvevwrmewyrqapgkeregvaaiesyghgtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvyddgqlayhydywgqgtqvtvsagrageqkliseedlnsavdhhhhhh,NaN,"Li,T. et al.; A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection; Nat Commun 12 (1), 4635 (2021); 2020.",10.1038/s41467-021-24905-z,"Chain A, sybody MR17-K99Y",NaN,2022-10-12
1506,MR17,NaN,7C8W_A,NaN,"['COVID', 'SARS-COV-2', 'RBD']",synthetic construct,qvqlvesggglvqaggslrlscaasgfpvevwrmewyrqapgkeregvaaiesyghgtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkddgqlayhydywgqgtqvtvsag,NaN,"Li,T. et al.; A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection; Nat Commun 12 (1), 4635 (2021); 2020.",10.1038/s41467-021-24905-z,"Chain A, Synthetic nanobody MR17",NaN,2022-10-12
1507,SR4,NaN,7C8V_A,NaN,"['COVID', 'SARS-COV-2', 'RBD']",synthetic construct,gsssqvqlvesggglvqaggslrlscaasgfpvyswnmwwyrqapgkerewvaaieshgdstryadsvkgrftisrdnakntvylqmnslkpedtavyycyvwvghtyygqgtqvtvsagrageqkliseedlnsavdhhhhhh,NaN,"Li,T. et al.; A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection; Nat Commun 12 (1), 4635 (2021); 2020.",10.1038/s41467-021-24905-z,"Chain A, Synthetic nanobody SR4",NaN,2022-10-12
1508,NaN,NaN,7KM5_D,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),qvqlvesggglvqpggslrlscaasgftfknadmnwyrqvpgqglewvtsiysdgrtvyadsvkgrftvsrdnpkstvslqmnslkpedtgvyycmagsksgheldhwgqgtqvtvsshhhhhh,NaN,"Ye,G. et al.; The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates; Elife 10, e64815 (2021); 2021.",10.7554/eLife.64815,"Chain D, nanobody",NaN,2022-10-12
1510,S1,NaN,UGN74788,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,sggglqtpggglglvckapgfsiggyimhwvrqtpgkgleyvagidagggvtwygaavkgratisrdngqstvrlqlndlraedtgiyycarstgsdyydwnyageigawghgtevivssggggsggggsggggsaltqpssvsanpgetvkitcsgggsssyygwyqqkspggapvtviysntgrpsdipsrfsgsksgsthtltitgvqvddeavyycgsedssthdgifgagttltvlg,NaN,"Ge,S. et al.; Specific anti-SARS-CoV-2 S1 IgY-scFv is promising tools for COVID-19 diagnosis and treatment; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 S1 scFv antibody, partial [synthetic construct]",NaN,2022-10-12
1511,80R,NaN,2GHW_D,NaN,"['COVID', 'Spike protein']",Homo sapiens (human),maevqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvssggggsggggsggggsettltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevksglvpr,NaN,"Hwang,W.C. et al.; Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R; J. Biol. Chem. 281 (45), 34610-34616 (2006); 2006.",10.1074/jbc.M603275200,"Chain D, anti-sars scFv antibody, 80R",NaN,2022-10-12
1513,#16,NaN,7MFV_B,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasgfpvayktmwwyrqapgkerewvaaiesygikwtryadsvkgrftisrdnakntvylqmnslkpedtavyycivwvgaqyhgqgtqvtvsa,NaN,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.",10.1101/2021.01.27.428466,"Chain B, Synthetic Nanobody #16 (Sb16)",NaN,2022-10-12
1514,RE5D06,NaN,7ON5_A,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),egsqvqlvesggglvqpggslrlscaasgitldyyaigwfrqapgkeregvsrirssdgstnyadsvkgrftmsrdnakntvylqmnslkpedtavyycaygpltkygsswywpyeydywgqgtqvtvss,NaN,"Guttler,T. et al.; Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies; EMBO J 40 (19), e107985 (2021); 2021.",10.15252/embj.2021107985,"Chain A, Nanobody Re5D06",NaN,2022-10-12
1515,2D9,NaN,7RK2_D,NaN,['Spike protein'],Mus musculus (house mouse),rsqvqlkqsgpglvqpsqslsitctvsgfsltsygvhwvrqspgkglewlgviwsggstdynaafisrlsiskdnsksqvffkmnslqandtaiyycarnslldamdywgqgtsvtvssggsggggsggggsggggssivmtqtpkfllvsagdrvtitckasqsvsnavawyqqkpgqspklliyyasnrytgvpdrftgsgygtdftftistvqaedlavyfcqqdysspltfgagtklelkraslvpr,NaN,"Meyer,L. et al.; Crystal structure of the human astrovirus serotype 8 capsid spike in complex with scFv 2D9, an astrovirus-neutralizing antibody, at 2.65-A resolution; Unpublished; 2021.",NaN,"Chain D, scFv 2D9",NaN,2022-10-12
1517,3E8,NaN,7RK1_D,NaN,['Spike protein'],Mus musculus (house mouse),dvqlqesgpglvkpsqslsltcsvtgysitsgyywnwirqfpgnklewmgyisydgsnnynpslknrisitrdtsknqfflklnsvttedtatyycatfydgydywgqgttltvssggsggggsggggsggggsdivmtqshkfmstsvgdrvsitckasqdvstavawyqqkpgqspklliywastrhtgvpdrftgsgsgtdytltissvqaedlalyycqqhystpftfgsgtkleikraslvpr,NaN,"Meyer,L. et al.; Crystal structure of the human astrovirus serotype 8 capsid spike in complex with scFv 3E8, an astrovirus-neutralizing antibody, at 2.05-A resolution; Unpublished; 2021.",NaN,"Chain D, scFv 3E8",NaN,2022-10-12
1519,NaN,NaN,QZW25479,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",synthetic construct,qvqlvesggglvqaggslrlscavsgagahrvgwfrrapgkerefvaaigasggmtnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeyiywgqgtqvtvss,NaN,"Zhang,J. et al.; Recombinant expression of a SARS-CoV-2 neutralizing nanobody in Trichoderma reesei; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 spike protein receptor-binding domain nanobody, partial [synthetic construct]",NaN,2022-10-12
1520,NaN,NaN,QYK30720,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdywgqgtqvtvsseqkliseedl,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-10-12
1521,NaN,NaN,QYK30719,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycntdpapgnpllrypdfdywgqgtqvtvsseqkliseedl,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-10-12
1522,NaN,NaN,QYK30718,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpgdtavyycnadpylwefdswgqgtqvtvsseqklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-10-12
1523,NaN,NaN,QYK30717,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesggglvqaggslrlscaasgfifgrnamgwyrqapgkerelvagitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvsseqklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-10-12
1524,NaN,NaN,QYK30716,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvsseqklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-10-12
1525,NaN,NaN,QYK30715,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasggifignamgwyrqapgkerelvatirniggttyyadsvkgrftisrdnakntvylqmnslkpedtavyycntdpapgnpllrypdfdywgqgtqvtvsseqkliseedl,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-10-12
1526,NaN,NaN,QYK30714,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasgfifgrnamgwyrqapgkerelvaginwggdntyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvssklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-10-12
1527,NaN,NaN,QYK30713,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycaadpgdvgsdfdywgqgtqvtvssklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-10-12
1528,RBD-SPECIFIC,NaN,QYF06674,NaN,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Vicugna pacos (alpaca),qlqlvesggglvqaggslrlscaasertfsggvmgwfrqrpgkerefvaairwngastfyadsvkgrftcsrdnakntgylqmnsltpedtavyycaravrtyassdyyfqertydywgqgtqvtvss,NaN,Ma H et al.; Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain; J Virol (2021) In press; 2021.,10.1128/JVI.02438-20,"anti-SARS-CoV-2 RBD-specific nanobody, partial [Vicugna pacos]",NaN,2022-10-12
1529,RBD-SPECIFIC,NaN,QYF06673,NaN,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Vicugna pacos (alpaca),qvqlvesggglvqpggtlrlscaasgftldyyaigwfrqapgkeregvscisgsggitnytdsvkgrftisrdnakntvylqmnslkpedtavyycapvshtvvagcafeawtdfgswgqgtqvtvss,NaN,Ma H et al.; Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain; J Virol (2021) In press; 2021.,10.1128/JVI.02438-20,"anti-SARS-CoV-2 RBD-specific nanobody, partial [Vicugna pacos]",NaN,2022-10-12
1530,RBD-SPECIFIC,NaN,QYF06672,NaN,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Vicugna pacos (alpaca),qvqlvesggglvqaggslrlscaasgrtytmgwfrqapgkerefvaamrwsdtdyadslkgrftisrdnannamylqmnslgpedtavyycaageawlarsthhydywgqgtqvtvss,NaN,Ma H et al.; Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain; J Virol (2021) In press; 2021.,10.1128/JVI.02438-20,"anti-SARS-CoV-2 RBD-specific nanobody, partial [Vicugna pacos]",NaN,2022-10-12
1533,PL-2,NaN,5KOV_U,NaN,unknown,Mus musculus (house mouse),rsdvqlkqsgpglvqpsqslsitctvsgfslidygvhwvrqspgkglewlgviwtggstdynaafisrltiskdnsksqvffkmnslqandtgiyycgrpyygnvmdywgqgtsvtvssgtggsggggsggggsgggasdiqmtqttsslsaslgdrvtiscrasqdisnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgtdysltisnleqediatyfcqqgntfpptfgggtkleikrlvpr,NaN,"Bogdanoff,W.A. et al.; Structure of a Human Astrovirus Capsid-Antibody Complex and Mechanistic Insights into Virus Neutralization; J. Virol. 91 (2), e01859-16 (2017); 2016.",10.1128/JVI.01859-16,"Chain U, PL-2 scFv chain",NaN,2022-10-12
1541,ANTI-F4+ETEC,NaN,4P2C_K,NaN,unknown,Lama glama (llama),qvqlqesggglvqaggslrlscavsgsifrlstmgwyrqapgkqrefvasitsygdtnyrdsvkgrftisrdnakntvylqmnslkpedtavyycnanieagtyygpgrdywgqgtqvtvsshhhhhh,NaN,"Lo,A.W. et al.; The molecular mechanism of Shiga toxin Stx2e neutralization by a single-domain antibody targeting the cell receptor-binding domain; J. Biol. Chem. 289 (36), 25374-25381 (2014); 2014.",10.1074/jbc.M114.566257,"Chain K, Nanobody 1, Anti-F4+ETEC bacteria VHH variable region",NaN,2022-10-12
1546,VHH-72,NaN,6WAQ_C,NaN,['COVID'],Lama glama (llama),qvqlqesggglvqaggslrlscaasgrtfseyamgwfrqapgkerefvatiswsggstyytdsvkgrftisrdnakntvylqmnslkpddtavyycaaaglgtvvsewdydydywgqgtqvtvssgs,NaN,"Wrapp,D. et al.; Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies; Cell 181 (5), 1004-1015 (2020); 2020.",10.1016/j.cell.2020.04.031,"Chain C, nanobody SARS VHH-72",NaN,2022-10-12
1548,JLO-G11,NaN,6UL4_B,NaN,unknown,Vicugna pacos (alpaca),mhhhhhhmasmtggqqmgrgsqvqlaesggglvqpggslrlsceasgfhlehfavgwfrqapgkeregvscisasgdsttyadsvkgrstiskdnaknavylqmdslrpedtgdyycaashfsvcgknirkieyrywgqgtpvtvssepktpkpq,NaN,"Lam,K.H. et al.; Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins; Cell Rep 30 (8), 2526-2539 (2020); 2020.",10.1016/j.celrep.2020.01.107,"Chain B, VHH JLO-G11",NaN,2022-10-12
1549,VHH-C2,NaN,5L21_B,NaN,unknown,Vicugna pacos (alpaca),qvqlvesggglaqpggslrlsceasgfgtwfrfdentvnwyrqppgksrefdelvarypksgivtyldsvkgrftisrdnakkmaflqmdnlkpedtavyycnvgefwgqgtqvtisse,NaN,"Yao,G. et al.; A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding; Sci Rep 7 (1), 7438 (2017); 2017.",10.1038/s41598-017-07457-5,"Chain B, VHH-C2",NaN,2022-10-12
1550,SDAB-5F8,NaN,QNA42481,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",synthetic construct,qvqlvesggglvqpggslrlscaasgrqavvfgwfrqapgkgleavaaihvpaknryyadsvkgrftisrdnskntlylqmnslraedtavyycaahyefndfvwqgyssdywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 nanobody sdAb-5F8, partial [synthetic construct]",NaN,2022-10-12
1551,SDAB-4D8,NaN,QNA42480,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",synthetic construct,qvqlvesggglvqpggslrlscaasgnidstryhgwfrqapgkgleavaaikgvwpedyyadsvkgrftisrdnskntlylqmnslraedtavyycaadqyewwvpgevgpylywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 nanobody sdAb-4D8, partial [synthetic construct]",NaN,2022-10-12
1552,SDAB-3F11,NaN,QNA42479,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",synthetic construct,qvqlvesggglvqpggslrlscaasggnaaermagwfrqapgkgleavaaiyyakfgpyyadsvkgrftisrdnskntlylqmnslraedtavyycaaeafvqspysgshttkywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 nanobody sdAb-3F11, partial [synthetic construct]",NaN,2022-10-12
1553,SDAB-2F2,NaN,QNA42478,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",synthetic construct,qvqlvesggglvqpggslrlscaasglaqskwaygwfrqapgkgleavaaidvatgpwyyadsvkgrftisrdnskntlylqmnslraedtavyycaahhiptkhpafpdfrdywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 nanobody sdAb-2F2, partial [synthetic construct]",NaN,2022-10-12
1554,SDAB-1E2,NaN,QNA42477,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",synthetic construct,qvqlvesggglvqpggslrlscaasgadafviiggwfrqapgkgleavaaiawtdqheyyadsvkgrftisrdnskntlylqmnslraedtavyycaaqdsayikskgsrayeywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 nanobody sdAb-1E2, partial [synthetic construct]",NaN,2022-10-12
